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CHAPTER I 
INTRODUCTION 
 
It is estimated that 35 million cases of significant skin loss occur in the United 
States each year, of which 7 million become chronic [1]. Furthermore, the aging of the 
population and the rising incidence of diabetes and vascular disease have resulted in a 
higher prevalence of chronic wounds. In addition, approximately one million burns 
require hospital visits each year [2]. These and other cutaneous defects create a need for 
cost-effective wound care products that restore tissue function. The gold standard for 
treatment of skin wounds is autograft skin, but it is in limited supply and introduces 
complications of a second surgery and potential for donor site morbidity [1-3]. Natural 
and synthetic scaffolds that are currently available, such as Alloderm
TM
 and Integra
TM
, 
are thin sheets that provide a temporary wound covering but do not fill deep tissue 
defects [1-4]. Other biomaterials such as hydrogels and nanofibrous scaffolds are 
biocompatible and biodegradable; however, hydrogels lack sufficient pore structure and 
mechanical properties, and nanofibrous scaffolds must be pre-formed and cannot 
conform to irregular defects [3, 5, 6].  
Lysine-derived polyurethane (PUR) scaffolds have been used in a variety of tissue 
engineering applications including bone regeneration and skin wound healing [7-13]. 
These scaffolds have previously been shown to be biocompatible and biodegradable, and 
they have tunable physical and mechanical properties. Furthermore, PUR scaffolds have 
potential for injectability [7, 8]. Injectable scaffolds are advantageous because they allow 
for site-specific customization, require minimally invasive surgical techniques, and can 
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conform to fill irregularly shaped wounds [5]. In addition, PUR scaffolds have been used 
to deliver biologics such as antibiotics and growth factors in animal wound models [9, 
10]. 
In a previous study, implantable PUR scaffolds with delivery of platelet-derived 
growth factor accelerated tissue infiltration and scaffold degradation in a mouse 
subcutaneous model [9]. However, injectable PUR scaffolds have not been investigated 
previously in skin wound healing applications. In addition, PUR scaffolds delivering 
biologics other than drugs and proteins, such as nucleic acids, have not been studied. 
Therapeutic proteins are often expensive and difficult to manufacture, but plasmid DNA 
can be produced more cheaply and efficiently than proteins [14]. Therefore, delivery of 
plasmid DNA encoding genes for regenerative factors from PUR scaffolds is a promising 
approach for regenerative medicine applications. In addition, a PUR delivery system for 
plasmid DNA has potential for use as a screening tool to test the ability of newly 
discovered regenerative factors to facilitate wound healing.  
The goal of this dissertation was to develop an injectable PUR delivery system for 
biologics such as plasmid DNA. In order to accomplish this goal, the research was 
focused on two main objectives: developing an injectable PUR scaffold for skin wound 
healing applications, and delivering plasmid DNA from PUR scaffolds. Chapters III – V 
discuss the investigation of the effects of injectable and implantable polyurethane 
scaffolds on skin wound healing in rats and pigs. Chapter VI describes the development 
of a PUR plasmid delivery system that can be used for local gene therapy applications. 
In Chapter III, the development of injectable PUR scaffolds for use in skin wound 
healing applications is described. Injectable scaffolds are a promising approach for 
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healing skin defects because they can conform to irregularly shaped defects, allow for 
patient-specific customization, and be applied with minimally invasive surgical 
techniques [5]. However, there are many challenges associated with injectable 
biomaterials. They must be flowable for a sufficient time (the working time) to enable 
injection and cure within minutes of injection (the setting time) to avoid long surgical 
procedures. The injected material should not have adverse effects on surrounding host 
tissue due to the reactivity of specific components or to the release of heat through a 
reaction exotherm [15]. Porous biomaterials must have suitable pore structure and 
mechanical properties for cell migration, nutrient exchange, and tissue ingrowth [16].  
In this study, the properties of injectable PUR biocomposite scaffolds were 
characterized in vitro, and their capacity to facilitate wound healing was investigated 
using a rat excisional model. Carboxymethylcellulose or hyaluronic acid was added to the 
injectable scaffolds as a filler to control the foaming reaction and absorb excess moisture 
in the wound bed. The scaffolds had a minimal reaction exotherm and clinically relevant 
working and setting times. Moreover, the mechanical and thermal properties of the 
scaffolds were consistent with rubbery elastomers. In the rat excisional wound model, 
injection of settable biocomposite scaffolds stented the wounds at early time points, 
resulting in a regenerative rather than a scarring phenotype at later time points. 
Measurements of wound length and thickness revealed that the scaffold-treated wounds 
were significantly less contracted at day 7 compared to blank wounds. Analysis of cell 
proliferation and apoptosis showed that the scaffolds were biocompatible and supported 
tissue ingrowth. Myofibroblast formation and collagen fiber organization provided 
evidence that the scaffolds had a positive effect on extracellular matrix remodeling by 
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disrupting the formation of an aligned matrix under elevated tension. In summary, an 
injectable biodegradable PUR biocomposite scaffold that enhances cutaneous wound 
healing in a rat model was developed. 
Although PUR scaffolds successfully promoted wound healing in a small animal 
model, large animal models with similarities to human skin needed to be tested to prove 
scaffold compatibility in a clinically relevant model. Chapter IV describes the 
investigation of the capacity of implantable lysine-derived PUR scaffolds to support 
wound healing in a porcine excisional wound model. This model was chosen because pig 
skin is physiologically and anatomically similar to human skin [17]. To improve cellular 
infiltration into and attachment to the scaffolds, carboxymethylcellulose was added as a 
porogen to increase interconnectivity (CMC), and plasma treatment was applied to 
decrease surface hydrophobicity (Plasma). All three types of PUR scaffolds supported 
cellular infiltration and were biodegradable. Scaffolds stented the wounds hence reducing 
unwanted wound contraction compared to untreated wounds at day 15. Wounds treated 
with CMC and Plasma scaffolds for 15 days showed higher macrophage presence than 
untreated wounds, a finding that was consistent with macrophage-mediated scaffold 
degradation via an oxidative mechanism. Cell proliferation decreased from day 8 to day 
15 in untreated and scaffold-treated wounds, and scaffolds had no significant effects on 
apoptosis or blood vessel area density compared to untreated wounds. These results 
provide further evidence that PUR scaffolds had no adverse effects on the wound healing 
process. To summarize, PUR scaffolds in porcine excisional wounds supported tissue 
infiltration, underwent biodegradation, and stented wounds to prevent unwanted 
contraction.  
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Chapter V describes the use of injectable PUR scaffolds in a porcine excisional 
wound model. As described above, injectable scaffolds are advantageous compared to 
preformed implants due to their abilities to fill the contours of irregularly shaped defects 
and allow for patient-specific customization [5]. In this study, sucrose was added as a 
filler to control the PUR foaming reaction through absorption of excess moisture from the 
wound bed. The physical, mechanical, and rheological properties of the scaffolds were 
characterized in vitro, and injectable and implantable PUR scaffolds were applied in a 
porcine excisional wound model. Scaffolds had working and setting times of 4.8 ± 1.2 
min and 16 ± 3 min, respectively, which are appropriate for the clinical environment. The 
permeability of the scaffolds ranged from 10
-10
 to 10
-9
 m
2
 and was comparable to the 
permeability of rigid open-cell foams reported elsewhere [18].  
In porcine excisional wounds, implantable and injectable scaffolds stented 
wounds and reduced unwanted contraction at early time points. Although 
epithelialization was delayed at early time points in scaffold-treated wounds, there were 
no differences in epithelialization between untreated and scaffold-treated wounds by day 
30. The amount of PUR remaining in the wounds decreased over time with only a few 
fragments remaining after 30 days, providing evidence that the scaffolds underwent 
biodegradation. There were no differences in fractional area of PUR remaining in the 
wounds between implantable and injectable treatment groups. The number of 
proliferating cells decreased from day 9 to day 13 in all treatment groups, and there were 
no significant differences in apoptosis among scaffold treatment groups. Although the 
injectable group had fewer macrophages at day 9 and more blood vessels at day 13 
compared to the implant group, blood vessel density and macrophage presence decreased 
 6 
 
from day 9 to day 13 in all treatment groups. Overall, these results provide evidence that 
applying PUR scaffolds by injection rather than implantation did not adversely affect the 
wound healing process or scaffold persistence. In this study, injectable and implantable 
PUR scaffolds were shown to be biocompatible and biodegradable, reduce wound 
contraction, and support wound healing in a porcine excisional model. 
In Chapter VI, the research focus shifts from the development and testing of 
injectable PUR scaffolds to the delivery of plasmid DNA from PUR scaffolds. Nonviral 
gene therapy has potential for safely promoting tissue restoration and treating diseases 
[14]. One current limitation is that conventional transfection reagents such as 
polyethylenimine (PEI) form polyplexes with plasmid DNA that suffer from colloidal 
instability during storage or incorporation into biomaterial scaffolds [19-21]. In this 
study, a library of poly(ethylene glycol-b-(dimethylaminoethyl methacrylate-co-butyl 
methacrylate)) [poly(EG-b-(DMAEMA-co-BMA))] polymers were synthesized and 
screened for improved stability and nucleic acid transfection following lyophilization and 
incorporation into PUR scaffolds. When added to plasmid DNA, the DMAEMA moieties 
initiate formation of electrostatic polyplexes that are further stabilized by both 
hydrophobic interactions of the core BMA and steric shielding from the PEG corona. The 
BMA content in the second block of the copolymer was varied from 0 mol% to 60 mol% 
in order to optimally tune the balance of electrostatic and hydrophobic interactions in the 
polyplex core. Polymers with 40% and 50% BMA achieved the highest transfection 
efficiency.  
Diblock copolymers aggregated more slowly than PEI in physiologic buffers, 
leading to slower aggregation that was reaction-controlled rather than diffusion-
 7 
 
controlled. Polymers with 40% BMA did not aggregate significantly after lyophilization 
and had higher transfection efficiency than PEI polyplexes both before and after 
lyophilization. Furthermore, poly(EG-b-(DMAEMA-co-BMA)) polyplexes exhibited pH-
dependent membrane disruption in a red blood cell hemolysis assay and endosomal 
escape as observed by confocal microscopy. When incorporated into PUR scaffolds as a 
lyophilized powder, poly(EG-b-(DMAEMA-co-BMA))-pDNA polyplexes achieved 
higher transfection than fresh polyplexes injected into the scaffold pores for up to three 
days. In summary, poly(EG-b-(DMAEMA-co-BMA))-pDNA polyplexes have the 
potential to be incorporated into PUR scaffolds for local gene therapy applications due to 
their colloidal stability, endosomal escape, and resultant high transfection efficiency. 
In conclusion, Chapter VII summarizes the results of this dissertation, and 
Chapter VIII presents suggestions for future studies to build on this work. Overall, this 
dissertation shows that the use of injectable PUR scaffolds with delivery of biologics is a 
promising approach for treatment of skin wounds. 
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CHAPTER II 
BACKGROUND 
 
Wound Healing   
Skin functions as a barrier against infectious agents, prevents dehydration, and 
performs immune surveillance and self-healing [1]. When skin is wounded, healing 
progresses through several stages to restore tissue function: (1) hemostasis and 
inflammation, (2) proliferation and granulation tissue formation, and (3) remodeling. 
Hemostasis, characterized by vasoconstriction and fibrin clot formation, occurs within 
minutes of injury to restrict blood loss. Neutrophils and later macrophages infiltrate the 
wound site to phagocytose microorganisms and secrete growth factors. In the 
proliferative phase, granulation tissue containing fibroblasts, macrophages, new blood 
vessels, and extracellular matrix (ECM) components is formed within days after injury. 
After migrating to the wound site in response to growth factor signals, fibroblasts 
proliferate and produce ECM components such as collagen. Tensile forces and growth 
factors stimulate fibroblasts to differentiate into myofibroblasts, which have a highly 
contractile and synthetic phenotype. Angiogenesis, the sprouting of new blood vessels 
from existing ones, occurs in order to supply oxygen and nutrients to the wound site. 
Keratinocytes in adjacent skin proliferate and begin migrating over the wound site. 
During the remodeling phase, which occurs from weeks to months after injury, the 
cellular granulation tissue is replaced by relatively acellular scar tissue. The number of 
fibroblasts and myofibroblasts decreases due to apoptosis. Angiogenesis ceases, and the 
number of blood vessels declines. Fibroblasts remodel the ECM, rearranging collagen 
fibers so that they support the tensile strength of skin. The healing process restores the 
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functions of the skin, but it does not result in regeneration.  Rather, scarring occurs, and 
the tensile strength of healed skin never reaches that of native skin [1-7]. 
 
Abnormal Healing   
Wound healing is a complex process involving coordinated interactions among 
different cell types, growth factors, and ECM components. When this process is 
disrupted, abnormal healing can result. Estimates suggest that 35 million cases of 
significant skin loss occur in the United States each year, of which 7 million become 
chronic and infected [8]. Over 2 million Americans suffer from chronic ulcers, requiring 
treatment costs of approximately $8 billion per year [8]. Chronic wounds are 
characterized by prolongation of the inflammatory phase, abnormal levels of growth 
factors, increased levels of proteases, and decreased ECM production [2-4]. Moreover, 
approximately one million burns require hospital visits each year, and hypertrophic 
scarring occurs in 90% of these injuries [9]. Hypertrophic scars result from increased 
myofibroblast formation, decreased protease levels, and excessive production of collagen 
[2-4]. These and other cutaneous defects create a need for cost-effective wound care 
products that restore skin function. 
 
Current Standard of Care   
Autograft skin, which is transplanted from an uninjured location on the patient’s 
body, is the current gold standard for treatment of burns and traumatic injuries [8]. 
However, autografts are in limited supply. Autograft transplantation requires additional 
surgery to harvest the skin, which causes pain and can result in donor site morbidity [8]. 
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Allograft skin (usually taken from cadavers) avoids the complications of a second 
surgery, but it introduces the risk of immune rejection and is also in limited supply [8, 9]. 
Alloskin
TM
 is a cellular graft containing both epidermis and dermis that is used for acute 
and chronic wound therapy [10]. In order to retain the benefits of autografts and 
allografts while avoiding some of the risks, cellular skin substitute products that 
incorporate autologous keratinocytes in a natural or synthetic matrix, such as EpiCel
®
 and 
Bioseed
TM
, have been developed [8, 9, 11]. A small punch biopsy is used to obtain the 
cells, so expensive and invasive surgery is not needed [9]. Since the cells are autologous, 
immune rejection is avoided. EpiCel
®
 has served as a permanent wound coverage that 
reduced the appearance of scarring in burns and diabetic ulcers [2, 8, 9]. However, 
disadvantages of these treatments include high costs, long time needed to culture cells (2-
3 weeks), labor intensive procedures, and scaffold fragility [2, 9].   
 
Natural and Synthetic Scaffolds   
A variety of acellular scaffolds comprising natural and/or synthetic polymers have 
been developed in order to overcome the challenges associated with autograft and 
allograft skin. Alloderm
TM
 is a scaffold comprising decellularized allograft tissue that has 
been used to treat chronic wounds and burns [1, 8, 9, 11]. Integra
TM
, a scaffold composed 
of both natural (bovine collagen-glycosaminoglycan) and synthetic (silicone) 
components, has been used to treat burns [1, 8, 9, 11]. Oasis
TM
, a skin substitute derived 
from porcine small intestinal submucosa, has accelerated healing in chronic leg ulcers [8, 
12]. Although over 200,000 people have been treated with tissue-engineered skin 
substitutes, none of these products fully restores the functions of native skin [8]. Skin 
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substitutes currently only lead to a 25% increase in healing of chronic leg ulcers 
compared to standard of care [8]. These scaffolds are thin sheets that do not function as 
void fillers for deep tissue defects. They often serve as temporary skin substitutes that 
require additional treatments such as autografts [1]. 
Research on other tissue engineered scaffolds, such as hydrogels and nanofibrous 
scaffolds, focuses on providing molecular cues for tissue repair. Hydrogels composed of 
natural or synthetic polymers such as polyethylene glycol, alginate, hyaluronic acid, and 
chitosan have been used successfully in drug and growth factor delivery applications in a 
variety of tissues, including skin and bone [1, 13-18]. Hydrogels are advantageous due to 
their biodegradability and injectability. Furthermore, many hydrogels are “smart” 
biomaterials that undergo a phase transition in response to environmental stimuli such as 
temperature, pH, or ionic strength. However, their small pore size and low porosity can 
result in delayed infiltration and vascularization, and their low strength and stiffness do 
not provide mechanical support for tissue infiltration and matrix remodeling [1, 14, 16, 
18].  
Nanofibrous meshes have been used as wound dressings and as three-dimensional 
tissue engineering scaffolds. They mimic the structure and function of natural ECM, and 
their high surface area to volume ratio and high porosity (up to 90%) result in excellent 
permeability for oxygen and nutrients [1, 14]. A study by Scherer et al. showed that poly-
N-acetyl-glucosamine nanofibrous membranes enhanced keratinocyte migration, cell 
proliferation, and angiogenesis in cutaneous wounds in diabetic mice [19]. In another 
study, nanofibrous meshes used as wound dressings were shown to promote hemostasis 
and cell respiration while preventing infection [20]. However, nanofibrous scaffolds must 
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be pre-formed using techniques such as electrospinning [1, 14]. Thus, they must be 
implanted rather than injected, and they cannot conform to large irregularly shaped 
wounds. 
 
Injectable Scaffolds   
Injectable scaffolds are advantageous due to their abilities to incorporate and 
deliver biologics at the point of care, allow for patient specific customization, conform to 
fill irregular tissue defects, and be applied with minimally invasive surgical techniques.  
Several techniques are being investigated for fabrication of injectable scaffolds, including 
ionic crosslinking, self-assembly, thermogelling, and in situ polymerization and 
crosslinking [18]. Examples of each of these systems are discussed below. 
Alginate and chitosan are naturally derived biomaterials that can undergo ionic 
crosslinking with divalent cations such as calcium [11, 18, 21]. These biomaterials are 
beneficial for use in drug delivery due to their biocompatibility, tunable degradation rate, 
stabilizing effects on drugs, and ability to target specific tissues. One approach to creating 
injectable drug delivery systems using ionic crosslinking systems involves mixing a 
solution of alginate or chitosan, an anionic drug, and lipid vesicles containing calcium 
ions into the targeted tissue [21]. The vesicles are disrupted upon the temperature 
increase to 37˚C, resulting in rapid release of calcium and formation of an alginate or 
chitosan gel incorporating the drug. The drug is encapsulated and stabilized in the 
biomaterial matrix due to electrostatic interactions. 
Self-assembling systems are commonly used for drug delivery applications. They 
are advantageous because they do not involve potentially cytotoxic compounds such as 
  
15 
 
catalysts and initiators, but they have weak mechanical properties due to the absence of 
covalent crosslinking [18, 22]. One approach to creating self-assembling systems is phase 
separation. In these systems, a water insoluble polymer is dissolved in a biocompatible 
organic solvent such as dimethyl sulfoxide. When injected in a physiologic environment, 
the polymer precipitates to form a gel. A study by Tae et al. demonstrated that a 
fluorocarbon-functionalized poly(ethylene glycol) phase separation system delivered 
therapeutic proteins with diffusion-controlled release kinetics [22].  
Poly(N-isopropylacrylamide) (pNIPAAM) is a synthetic thermogelling polymer. 
It is advantageous for use as an injectable drug delivery system due to its lower critical 
solution temperature (LCST) of 32˚C, which is between room temperature and 
physiologic temperature.  An aqueous solution containing pNIPAAM can be mixed with 
the drug and injected into the targeted tissue, where it forms a gel. However, pNIPAAM 
exhibits cytotoxicity and has a slow degradation rate. Therefore, it is incorporated into a 
copolymer or blended with a biocompatible polymer when used in drug delivery 
applications. Liposomes and nanoparticles incorporating pNIPAAM have been used to 
deliver doxorubicin, a drug for cancer therapy [23, 24]. When the temperature is 
increased above pNIPAAM’s LCST, pNIPAAM disrupts the liposomal membrane [23] 
or collapses the nanoparticles [24], resulting in a burst release of the drug. Sustained 
delivery of the drugs dexamethasone and ascorbate from pNIPAAM hydrogels 
successfully promoted chondrocyte differentiation when injected in mice subcutaneous 
wounds. Furthermore, copolymers of pNIPAAM are widely used due to their 
thermosensitivity. An injectable poly(NIPAAM-co-propylacrylic acid (PAA)) copolymer 
has been developed for use as a delivery vehicle for angiogenic factors to sites of 
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ischemia, such as diabetic ulcers [25]. The copolymer is temperature-sensitive (due to 
NIPAAM) and pH-sensitive (due to PAA). It forms a gel at physiologic temperature and 
low pH, which are the conditions present in an ischemic site. The gel has been shown to 
release the encapsulated angiogenic drug in a sustained manner [25]. When ischemia is 
eliminated and the tissue returns to physiologic pH, the polymer quickly degrades due to 
the phase transition of the PAA component from a gel to a solution [25]. 
Although they are beneficial for drug delivery systems, self-assembling and 
thermogelling systems are not well-suited for tissue engineering applications due to their 
weak mechanical properties (low modulus, low strength, and high fragility). In situ 
polymerizable scaffolds can achieve robust mechanical properties due to polymerization 
and crosslinking. However, they must meet several requirements in order to be used in 
biomedical applications: they must have nontoxic reactants and intermediates, minimal 
reaction exotherm, reproducible and robust mechanical properties, and clinically relevant 
working and setting times (on the order of minutes) [18]. Two biocompatible and 
biodegradable polymers that meet these requirements are polypropylene fumarate and 
polyurethane. 
Polypropylene fumarate (PPF) is a viscous liquid with unsaturated carbon-carbon 
double bonds that can be crosslinked to form a solid polymeric network. Due to its high 
strength and stiffness, PPF is well-suited for use in hard tissue applications such as bone 
regeneration [26]. PPF is biodegradable to noncytotoxic degradation products (fumaric 
acid and propylene glycol) via hydrolysis of its ester bonds [26]. Furthermore, PPF can 
be combined with crosslinking agents such as diethyl fumarate, poly(ethylene glycol), 
polycaprolactone, or N-vinyl pyrrolidinone to form a copolymer with tunable physical 
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and mechanical properties [27]. In several injectable delivery systems, PPF is mixed with 
an initiator and crosslinking agent and injected into the targeted tissue. The polymer is 
then crosslinked in situ to form a solid polymeric network. Injectable scaffolds 
incorporating PPF have been used to deliver osteogenic peptides and transforming 
growth factor-1 in bone tissue engineering applications and the drugs acetazolamide, 
dichlorphenamide, and timolol maleate in ophthalmic applications [26-28]. 
 
Polyurethane Scaffolds   
Polyurethane (PUR) has been used in biodegradable medical devices since the 
1980s [29]. It is advantageous for the field of tissue engineering due to its 
biocompatibility, biodegradability to nontoxic decomposition products, tunable 
mechanical and degradation properties, reproducible pore structure, and potential for 
injectability and use as a delivery vehicle [30-33]. Polyurethane is synthesized from the 
reaction of a polyol and an isocyanate.  Hydroxyl groups from the polyol react with 
isocyanates to form urethane bonds.  In addition, water can be added to the reaction. 
Water reacts with isocyanates to from carbamic acid, an unstable compound that quickly 
decomposes to an amine and carbon dioxide. The amine can further react with an 
isocyanate to form a disubstituted urea. In the Guelcher lab, we use polyols comprising 
glycolide, lactide and caprolactone [30, 32, 33]. These compounds have been commonly 
used in tissue engineering and drug delivery applications [18, 34-37]. We use lysine-
derived aliphatic polyisocyanates such as lysine triisocyanate (LTI) because they are 
biocompatible and degrade to nontoxic decomposition products [30, 31]. By adjusting the 
composition and molecular weight of the polyol and isocyanate and the amount of water, 
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the physical, mechanical, and degradation properties of PUR can be tuned [30-32]. As a 
result, PUR is a versatile biomaterial that is suitable for use with both soft tissues (such as 
skin) and hard tissues (such as bone).  
Our lab has used PUR scaffolds to enhance bone regeneration and skin wound 
healing in several animal models. One study demonstrated that injectable allograft 
bone/PUR composite scaffolds supported tissue infiltration and new bone formation in 
femoral plug defects in rats [38]. Another study showed that compression-molded 
mineralized bone particle/PUR composites exhibited cellular infiltration, resorption, and 
new bone formation in femoral plug defects in rabbits [39]. Injectable allograft bone/PUR 
composite scaffolds supported ingrowth of new bone in a critical-size rabbit calvarial 
defect model, and delivery of bone morphogenetic protein-2 from the biocomposites 
enhanced new bone formation [40].  
Furthermore, PUR scaffolds have been tested in several studies investigating skin 
wound healing. Pre-formed PUR implants developed for cutaneous healing supported 
cellular infiltration and ECM synthesis in both subcutaneous and excisional wounds in 
rats [41, 42]. Although they serve as a provisional ECM and support cellular infiltration 
and remodeling, PUR scaffolds alone are not enough to accelerate wound healing. PUR 
scaffolds also have the potential to serve as delivery vehicles for growth factors, nucleic 
acids, and small molecule drugs to enhance wound healing. For example, a study by Li et 
al. showed that delivery of platelet-derived growth factor from PUR implants resulted in 
increased fibroblast infiltration and accelerated granulation tissue formation and scaffold 
degradation compared to blank PUR scaffolds in rat excisional wounds [42].   
 
  
19 
 
Porcine Wound Model 
Animal models are advantageous for studying wound healing because there is less 
variation than in the clinical setting, there are few limits to obtaining tissue samples, and 
different treatments can be compared in the same animal [43]. Small animal models are 
useful when a large number of animals or certain characteristics (such as a compromised 
immune system or transgenic animals) are required [43]. Several previous studies on the 
use of PUR scaffolds in wound healing applications have used rat wound models [31, 41, 
42]. However, rat skin differs from human skin physiologically and anatomically. The 
dermis and epidermis are thinner in rats than in humans, rat skin has lower vascular 
density than human skin, and rats heal primarily through contraction rather than through 
epithelialization and production of granulation tissue [44]. In contrast, pig skin is 
physiologically and anatomically similar to human skin [44]. Pig skin and human skin 
have similar density and distribution of blood vessels, sweat glands, and hair follicles 
[44]. Furthermore, pigs and humans have similar epidermal thickness and close primarily 
through epithelialization rather than contraction [44]. In addition, the porcine wound 
model is advantageous because each animal has a large area of skin available for 
experimentation. Therefore, several treatments can be applied on the same animal, which 
reduces variability [43]. 
Previous studies have investigated the use of void-filling scaffolds in porcine 
wound models, but this research has been limited to preformed implants and does not 
include injectable scaffolds [45-48]. A study by Huang et al. treated full-thickness 
porcine wounds with a bilayer dressing comprising an external PUR layer and an internal 
gelatin sponge layer incorporating basic fibroblast growth factor-loaded microspheres 
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[45]. After 21 days, wounds treated with these dressings had smaller areas, thicker 
epidermis, and better collagen organization than control wounds treated with Vaseline 
gauze. Studies by Greenwood and Dearman investigated the use of biodegradable PUR 
foams and spun mats as a temporizing matrix prior to skin graft surgery [46, 47]. Porcine 
excisional wounds treated with a PUR foam sealed with a microporous PUR membrane 
had no signs of infection and delayed contraction compared to wounds treated with 
Integra after 28 days. However, wounds treated with unsealed foams exhibited significant 
contraction and had thick scar layers above the implants. No studies have shown that 
single-layer void filling scaffolds without the use of protective membranes facilitate 
dermal wound healing in a full-thickness porcine excisional wound model. Furthermore, 
the use of injectable scaffolds in porcine cutaneous wound models has not been 
investigated. 
 
Gene Therapy   
One advantage of PUR scaffolds is their ability to incorporate and deliver 
biologics. A promising strategy for delivering regenerative factors from PUR scaffolds is 
to release plasmid DNA (pDNA) encoding genes for growth factors that enhance wound 
healing. Proteins are often expensive and difficult to manufacture, and gene therapy is an 
alternative to conventional protein therapy that avoids these problems [49]. Nonviral gene 
therapy has potential for use in accelerating restoration of tissue defects and treatment of 
myriad diseases. Plasmid production is efficient and relatively inexpensive, and DNA 
therapy avoids the immunogenic risk associated with viral vectors.  
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Naked pDNA uptake and utilization is inefficient; however, synthetic polymer- 
and lipid-based carriers face several in vivo challenges, and there has been limited 
translation of efficient and nontoxic nonviral options for pDNA delivery. An ideal 
transfection reagent for pDNA delivery in vivo should condense pDNA into stable 
nanoparticles, minimize aggregation in physiological conditions (i.e., presence of 
proteins and salts), and protect the plasmid from nuclease degradation in the extracellular 
environment. After endocytosis, the vectors must escape the endo-lysosomal pathways to 
avoid degradation or exocytosis, and the plasmid must be unpackaged and trafficked to 
the nucleus.  
Electrostatic condensation of plasmids into nanoparticles using cationic polymers 
or lipids is a promising approach for overcoming in vivo barriers to nonviral gene 
therapy. Lipofectamine2000 is a cationic lipid that achieves high transfection efficiency 
in a wide range of cell lines in vitro, but several studies have reported high cytotoxicity 
[50, 51]. Polyethylenimine (PEI) is one of the most commonly used polymeric vectors for 
DNA delivery due to its low immunogenicity, high transfection efficiency, and low 
manufacturing cost [49, 52-55]. After entering cells through endocytosis, polyplexes 
made from amine-containing polymers with pKa in the range 5.0 – 7.4 (such as PEI) are 
presumed to buffer the acidification of the vesicles of the endo-lysosomal trafficking 
pathways. This “proton sponge” behavior increases proton and counterion influx and 
causes osmotic swelling and rupture of endosomes, enabling pDNA cytoplasmic entry 
[56]. While direct injection of PEI-pDNA polyplexes has been used successfully in vivo 
for a number of tissue types, effective delivery of polyplexes from tissue engineering 
scaffolds has been challenging due to aggregation of the polyplex nanoparticles [52, 53, 
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57-59]. Recently, lyophilization of PEI-pDNA polyplexes with excipients such as sucrose 
has reduced polyplex aggregation and increased transfection efficiency [53, 60]. 
However, approaches to improve the inherent stability of the polymer-pDNA polyplexes 
and studies on the contribution of colloidal stability to transfection efficiency have not 
been extensively investigated. 
Block copolymers are a promising strategy to improve colloidal stability, increase 
transfection efficiency, and decrease cytotoxicity of nonviral carriers. Complexation of 
pDNA with block copolymers comprising polycations and polyethylene glycol (PEG) has 
been reported to enhance steric stability of the resulting polyplexes by formation of a 
PEG corona [61-63]. Furthermore, adding hydrophobic components into the cationic, 
pDNA-condensing polymer block has also been investigated as a strategy for reducing 
charge density, increasing stability, decreasing toxicity, and enhancing endosomal escape 
of polycations. For example, increasing hydrophobicity and decreasing charge density 
through the modification of poly(amido amines) with benzoyl groups was found to 
increase polyplex stability, decrease cytotoxicity, and increase transfection efficiency [64, 
65]. In other studies, the ratio of cationic DMAEMA to hydrophobic butyl methacrylate 
(BMA) or propylacrylic acid (PPAA) has been optimized to achieve pH-dependent 
membrane disruptive properties ideally tuned for endosomal escape [66-68]. Recently, 
Nelson et al. investigated a PEG-stabilized polyplex system in which siRNA cargo was 
loaded into the poly(BMA-co-DMAEMA) particle core and yielded enhanced 
performance following intravenous injection in vivo [69]. Due to their high transfection 
efficiency and stability in vivo, these polymers have potential for use as transfection 
reagents in PUR nucleic acid delivery systems for wound healing applications. 
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Conclusion 
In summary, the research on skin wound healing and tissue engineering scaffolds 
supports the need for an injectable, biodegradable polyurethane scaffold that serves as a 
delivery system for biologics such as nucleic acids. My research is divided into aims that 
address different aspects of developing this scaffold: (1) creating an injectable PUR 
scaffold and applying it in a rat wound model, (2) investigating the effects of implantable 
PUR scaffolds on porcine wound healing, (3) testing the use of injectable PUR scaffolds 
in porcine wounds, and (4) developing a PUR delivery system for nucleic acids.  
Chapters III – VI discuss each of these aims. 
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CHAPTER III 
 
INJECTABLE POLYURETHANE COMPOSITE SCAFFOLDS DELAY WOUND 
CONTRACTION AND SUPPORT CELLULAR INFILTRATION AND 
REMODELING IN RAT EXCISIONAL WOUNDS 
 
Introduction 
The increases in immobile aging, diabetic amputee, and paralyzed patients 
afflicted with large, chronic wounds and fistulas as well as trauma victims with large 
cutaneous defects create a need for development of injectable biomaterials to promote 
restoration of tissue integrity. Such scaffolds could offer new options for both cutaneous 
and fascial indications while adding options for site-specific customization [1]. 
Furthermore, a biomaterial that is applied as a liquid and cures in situ can flow to fill the 
contours of irregularly shaped defects that may not conform to a preformed implant. 
Maximizing the contact surface area between the material and surrounding tissue should 
enhance cellular infiltration and integration of the scaffold.   
 Several requirements are critical to the success of injectable biomaterials, such as 
flowability for a sufficient time (the working time) to enable injection and curing within 
minutes of injection (the setting time) thus avoiding long surgical procedures. The 
injected material should not have adverse effects on surrounding host tissue due to the 
reactivity of specific components or to the release of heat through a reaction exotherm 
[2]. The viscosity of the injected material should be high enough to be retained at the 
injection site and to minimize extravasation into surrounding tissues where it may have 
an adverse effect [3]. The reproducibility of properties such as porosity, degradation, and 
setting time in the clinical environment is also a significant challenge. Injectable porous 
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biomaterials must have a suitable pore structure for cell migration, nutrient exchange, and 
tissue ingrowth [4]. 
Injectable hydrogels, such as poly(ethylene glycol) (PEG), collagen, fibrin, 
chitosan, alginate, and hyaluronan, have been shown to support bone ingrowth in vivo, 
particularly when combined with angiogenic or osteogenic growth factors [5-11]. 
However, hydrogels lack the tough, elastomeric properties of thermoplastic polymers that 
are appropriate for cutaneous applications. Furthermore, the microstructure of synthetic 
hydrogels is typically smaller than the average size of cellular populations (5-15 m) 
[12], thus requiring resorption or displacement of the matrix by cells that results in slow 
infiltration of the scaffold. We have recently developed injectable, allograft 
bone/polyurethane (PUR) composite scaffolds for bone regeneration with tunable 
working and setting times of 5 and 15 minutes [13]. Materials were prepared by mixing 
allograft bone particles, a flowable lysine triisocyanate (LTI)-PEG prepolymer, a 
flowable polyester triol, and triethylene diamine catalyst.  An LTI-PEG prepolymer was 
used in the scaffold synthesis rather than monomeric LTI because it has been shown 
previously that injection of LTI in vivo could be toxic [13]. The porosity of the cured 
scaffolds varied from 30 – 70%, and the pore size ranged from 177 – 700 m. When 
injected into 3-mm femoral condylar plug defects in rats, the composites exhibited 
cellular infiltration and new bone formation at 3 weeks. While these composites are not 
suitable for cutaneous wound healing due to the allograft bone component, our previous 
studies have shown that pre-formed PUR scaffolds implanted in both subcutaneous [14] 
and excisional [15] wounds in Sprague-Dawley rats supported cellular infiltration and 
ingrowth of new tissue.  
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In the present study, we have synthesized injectable PUR composite scaffolds 
incorporating polysaccharide particles and evaluated their performance in vitro and in 
vivo. We hypothesized that the degradable scaffolds would function as an initial 
temporary matrix that both provides a surface for attachment and proliferation of cells 
and also stents the wound to minimize the undesirable outcomes of contraction and 
scarring. Either hyaluronic acid (HA), a 1,500 – 2,200 kDa glycosaminoglycan found in 
the extracellular matrix, or carboxymethylcellulose (CMC), a plant-derived 90 kDa 
polysaccharide, was added to the reactive PUR to control the foaming reaction through 
absorption of excess moisture from the wound bed. Rheological and physical properties 
of the scaffolds were measured in vitro, and their potential to support cellular infiltration 
and new tissue ingrowth were evaluated in excisional wounds in Sprague-Dawley rats. 
 
Methods 
Materials 
Glycolide and D,L-lactide were purchased from Polysciences (Warrington, PA).  
TEGOAMIN33, a tertiary amine catalyst composed of 33 wt% triethylene diamine 
(TEDA) in dipropylene glycol, was obtained from Goldschmidt (Hopewell, VA).  
Polyethylene glycol (PEG, 200 Da) was supplied by Alfa Aesar (Ward Hill, MA).  
Glycerol and the sodium salts of carboxymethylcellulose (CMC; 90 kDa) and hyaluronic 
acid (HA; 1,500 – 2,200 kDa) were purchased from Acros Organics (Morris Plains, NJ).  
Lysine triisocyanate (LTI) was obtained from Kyowa Hakko USA (New York), and 
stannous octoate catalyst was obtained from Nusil technology (Overland Park, KS).  All 
other reagents were purchased from Sigma-Aldrich (St. Louis, MO). Prior to use, 
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glycerol and PEG were dried at 10 mm Hg for 3 h at 80ºC, and -caprolactone was dried 
over anhydrous magnesium sulfate. All other materials were used as received. 
 
Synthesis of PUR scaffolds and reactive intermediates 
PEG (200 Da) was reacted with an excess of LTI (NCO:OH equivalent ratio = 
3:1) to form an LTI-PEG prepolymer (21,000 cP) in which the PEG molecules were end-
capped with LTI [13]. PEG with molecular weight > 200 Da did not yield a flowable 
prepolymer, and thus could not be injected.  PEG was added dropwise to LTI in a 100 
mL reaction flask with stirring under argon for 24 h at 45°C.  The prepolymer was then 
dried under vacuum at 80°C for 14 h. A polyester triol (900 Da) with a backbone 
comprising 60% caprolactone, 30% glycolide, and 10% lactide was synthesized by 
reacting the monomers (-caprolactone, glycolide, and D,L-lactide) with a glycerol starter 
in the presence of stannous octoate catalyst [16]. This polyester triol composition and 
molecular weight were chosen to maintain both good flowability of the reactive mixture 
as well as a favorable degradation rate of the cured PUR scaffold in vivo [17]. The 
reaction was carried out under dry argon at 140ºC for 48 h, and the resulting polyester 
triol was dried under vacuum at 80ºC for 24 h. 
PUR scaffolds were synthesized by reactive liquid molding of the LTI-PEG 
prepolymer with a hardener component [13, 14] and a polysaccharide filler (CMC or 
HA). The hardener comprised 100 parts polyester triol (polyol), 1.5 parts per hundred 
parts polyol (pphp) water, 0.625 pphp TEGOAMIN33 catalyst, 0.375 pphp 30% bis(2-
dimethylaminoethyl)ether (DMAEE) blowing catalyst in poly(propylene glycol), and 4.0 
pphp calcium stearate pore opener. The polysaccharide was combined with the hardener 
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and mixed by hand for 30 s. The prepolymer was added to the hardener and 
polysaccharide and mixed by hand for 1 min. The resulting mixture then rose freely for 
10 – 20 min and cured. The targeted index (the ratio of NCO to OH equivalents times 
100) was 115. 
 
Scaffold characterization 
Core densities and porosities were determined from mass and volume 
measurements of triplicate cylindrical foam cores [14, 18]. The scaffold pore size 
distribution was assessed by scanning electron microscopy (Hitachi S-4200 SEM, 
Finchampstead, UK) after gold sputter coating with a Cressington Sputter Coater.  
Temperature profiles of the reactive mixtures during foaming were measured using a 
digital thermocouple at the centers of the rising foams. Scaffold degradation was 
evaluated by incubating triplicate 20 mg samples in 1 ml phosphate buffered saline (PBS) 
(pH 7.4) at 37°C for up to 24 weeks. At various time points, the samples were rinsed in 
deionized water, dried under vacuum for 48 h at room temperature, and weighed.  
 
Reactivity of scaffold components 
 The reactivities of the LTI-PEG prepolymer with the polyester triol, HA, and 
CMC were measured using attenuated total reflectance fourier transform infrared 
spectroscopy (ATR-FTIR; Bruker Tensor 27 FTIR, Billerica, MA). Prepolymer; 
TEGOAMIN33 and DMAEE catalyst; and either polyol, HA, or CMC were mixed 
together for 1 min and then placed in contact with the ATR crystal. The area of the 
isocyanate peak (wavelength 2150 – 2350 cm) was monitored as a function of time.   
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Mechanical properties 
Mechanical properties were measured using a TA Instruments Q800 Dynamic 
Mechanical Analyzer (DMA) in compression mode (New Castle, DE). Samples were 
soaked in water for a few minutes or 7 days prior to mechanical testing. Stress-strain 
curves were generated by compressing wet cylindrical 7 x 6 mm samples at 37°C at a rate 
of 0.1 N/min until they reached 50% strain. The Young’s modulus was determined from 
the slope of the initial linear region of each stress-strain curve. The scaffolds could not be 
compressed to failure due to their elasticity, so the compressive stress was measured one 
minute after the application of 50% strain [14].   
 
Rheological properties during cure 
The cure profiles of the HA and CMC scaffolds were measured using a TA 
Instruments parallel plate AR 2000ex rheometer operating in dynamic mode with 25 mm 
disposable aluminum plates (New Castle, DE). LTI-PEG prepolymer was added to a 
mixture of hardener and polysaccharide (0, 15, or 30 wt%) and mixed by hand using a 
spatula for 1 min. The sample was then loaded onto the bottom plate of the rheometer.  
An oscillation time sweep was run with a controlled strain of 1% and a frequency of 6.28 
rad/s in order to obtain the cure profile of each PUR scaffold. The storage modulus (G’) 
and loss modulus (G”) were determined as a function of time. The working time was 
determined to be the G-crossover point. To measure the setting time, the surface of the 
foam was contacted with a spatula at regular intervals of 30 sec. The tack-free time, 
which approximates the setting time, was determined to be the time at which the foam did 
not stick to the spatula. 
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In vivo cutaneous repair in rats 
All surgical procedures were reviewed and approved by the local Institutional 
Animal Care and Use Committee. NIH guidelines for the care and use of laboratory 
animals (NIH Publication #85-23 Rev. 1985) have been observed. The capacity of the 
scaffolds to facilitate dermal wound healing was evaluated in an excisional wound model 
(6.25cm
2
 square wounds) in adult male Sprague-Dawley rats. All materials were 
sterilized by gamma irradiation at 5 kGy prior to surgery. The treatment groups 
investigated were untreated wounds (negative control) and PUR scaffolds with 15 wt% 
HA or CMC polysaccharide. We have previously observed that PUR scaffolds without 
polysaccharide fillers over-expanded and formed large voids in vivo, so this treatment 
group was not investigated in the rat study. Preliminary experiments showed that 15% 
polysaccharide was sufficient to control foaming, and no additional benefits were 
observed at 30%. To investigate the effects of the bioactivity of the polysaccharide on 
healing, both HA (which was anticipated to possibly have biological effects and enhance 
healing) and CMC (which was considered a relatively inert material) were tested. For the 
HA and CMC treatment groups, the materials were applied as a reactive liquid 
immediately after mixing the LTI-PEG prepolymer with the hardener and polysaccharide.  
The polyurethane expanded by gas foaming to fill the defects and cured in situ. When the 
scaffolds expanded beyond the wound dimensions, they were trimmed to be flush with 
the skin surface. Each wound and scaffold was covered with nonadherent, absorbent, 
Release gauze (Johnson & Johnson) and covered with a Tegaderm outer dressing (3M, 
St. Paul, MN). Wounds were harvested at days 7, 17, 26, and 35 after surgery.  Four 
replicates of each treatment group were harvested at each time point.  The wounds were 
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fixed in neutral buffered formalin for 24 h, transferred into 70% ethanol for 48 h, 
embedded in paraffin, and sectioned at 5 µm. Hematoxylin & eosin (H&E), Gomori’s 
trichrome, picrosirius red, TUNEL, myeloperoxidase, Ki67, -SMA, and procollagen I 
immunostaining were performed on the tissue sections.   
 
Statistical analysis 
Single factor analysis of variance (ANOVA) was used to evaluate the statistical 
significance of results. P values less than 0.05 were considered statistically significant. 
Data are plotted as mean ± standard error unless otherwise indicated. 
 
Results 
Setting properties of PUR foams 
 The specific reaction rates for the second order reactions between LTI-PEG 
prepolymer and water, polyol, HA, and CMC were determined using ATR-FTIR (Figure 
3.1B). Water was the most reactive, with a rate constant of 600 g mol
-1
 min
-1
 (data not 
shown). The rate constant measured for the polyester triol (9.14 g mol
-1
 min
-1
) was 21 
times larger than that measured for CMC (0.438 g mol
-1
 min
-1
) and 7 times larger than 
that measured for HA (1.29 g mol
-1
 min
-1
). These data show that the water and polyester 
triol components are the most reactive in the system and considerably more reactive than 
the polysaccharides. The higher reactivity of HA compared to CMC is consistent with the 
structures shown in Figure 3.1A.  Each repeat unit of HA has one primary OH group, 
while CMC has only carboxylic acids and secondary OH groups, which are at least 2 – 4 
times less reactive than primary OH groups [19].   
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The rheological properties of PUR, PUR + 15% CMC, and PUR + 15% HA 
scaffolds are shown in Figure 3.2A-C. The G-crossover point was considered to be the 
gel point and thus the working time of the foam. The working time was 5.8 ± 0.7 min for 
the PUR foam, 6.2 ± 0.5 min for the PUR + 15% CMC foam, and 5.5 ± 0.6 min for the 
PUR + 15% HA foam. Although the working time can be adjusted by altering the 
concentrations of the catalysts, it was maintained constant in the present study. The tack-
free time was 16 ± 3 min for the PUR foam, 19 ± 3 min for the PUR + 15% CMC foam, 
 
 
Figure 3.1. Reactivities of polyester triol, HA, and CMC with LTI-PEG prepolymer.  
(A) Chemical structures of HA and CMC.  HA contains one primary hydroxyl group per 
repeat unit while CMC has no primary hydroxyl groups. (B) Determination of second-
order rate constants for the reactions of polyester triol, HA, and CMC with LTI-PEG 
prepolymer.   
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and 15 ± 4 min for the PUR + 15% HA foam. The addition of the polysaccharide had no 
significant effect on either the working or tack-free time.   
 
 
The temperature profiles of PUR, PUR + 15% CMC, and PUR + 15% HA foams 
are shown in Figure 3.2D. The temperature within the reactive mixture was recorded with 
a digital thermocouple at the center of the rising foams, which were insulated to minimize 
the effects of heat loss from the exterior surface. Starting at room temperature, the 
maximum increase in temperature was 7.3 ± 1.7 °C for the PUR foam, 7.1 ± 1.4 °C for 
 
Figure 3.2. Rheological properties of injectable PUR scaffolds. (A) PUR, (B) PUR + 
15% CMC, (C) PUR + 15% HA. (D) Temperature profile during cure. 
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the PUR + 15% CMC foam, and 6.7 ± 1.1 °C for the PUR + 15% HA foam. The addition 
of the polysaccharide did not significantly affect the temperature profile.   
 
Physical properties of PUR scaffolds 
 Physical properties of the PUR scaffolds before and after incubating in an 
aqueous environment for 7 days are shown in Table 3.1. On day 0, the properties of PUR 
+ 15% HA and PUR + 15% CMC scaffolds were not significantly different from each 
other, but both had significantly higher densities (45%), lower porosities (4%), and 
smaller pore sizes (13%) than the blank PUR scaffolds. However, by day 7 there were no 
significant differences in porosity or density between the three groups, presumably due to 
dissolution of the polysaccharides. 
 
Table 3.1. Physical properties of PUR scaffolds. 
PUR Sample 
Day 0 Day 7 
Density 
(kg/m
3
) 
Porosity 
(vol %) 
Pore Size 
(μm) 
Density 
(kg/m
3
) 
Porosity 
(vol %) 
Pore Size 
(μm) 
Blank 110 ± 2 90.9 ± 0.1 370 ± 90 105 ± 2 91.4 ± 0.1 320 ± 70 
PUR + HA 158 ± 9 87.0 ± 0.7 330 ± 70 100 ± 7 91.8 ± 0.6 330 ± 80 
PUR + CMC 161 ± 8 86.7 ± 0.6 320 ± 80 116 ± 18 90.4 ± 1.5 340 ± 90 
 
Degradation of PUR scaffolds 
A representative SEM image of a PUR + HA scaffold is shown in Figure 3.3A.1. 
The interconnected pores of the scaffolds permit cellular infiltration [14]. Panels A.2 and 
A.3 show images of 100 – 200 m particles embedded in a PUR + HA scaffold at low 
and high magnification, respectively. As shown in Panel A.4, the particles were almost 
completely dissolved after 24 h in vitro incubation time in buffer, resulting in the 
formation of additional pores. Alcian blue staining was used to confirm the presence of 
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HA particles embedded in the scaffolds. PUR (negative control) and PUR + HA scaffolds 
were stained with Alcian blue at pH 2.5 and pH 1.0. At pH 1.0, Alcian blue only stains 
highly sulfated glycosaminoglycans, while at pH 2.5 the dye stains HA blue. While PUR 
scaffolds did not stain at either pH and PUR + HA scaffolds did not stain at pH 1.0, PUR 
+ HA scaffolds stained blue at pH 2.5, thereby confirming the presence of HA in the 
scaffolds. Taken together, these data suggest that dissolution of HA (or CMC) can create 
additional pores in the scaffold in vivo. To investigate the effects of polysaccharide 
loading on scaffold degradation, the degradation rates of the PUR and PUR + CMC (15 
and 30%) scaffolds in PBS at 37°C were recorded for up to 24 weeks (Figure 3.3B). 
Under in vitro conditions, the primary mechanism of degradation was hydrolysis of the 
ester bonds within the polyester soft segment [17]. The polysaccharides caused a high 
initial mass loss within the first few days, which is consistent with the SEM data in 
Figure 3.3A. After this time period, the rates of polymer degradation were similar. 
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Mechanical properties of PUR scaffolds 
The compressive Young’s modulus and compressive stress of the scaffolds under 
physiological conditions (wet at 37
o
C) before and after incubation for 7 days are 
summarized in Table 3.2. When compressed for extended periods of time, the scaffolds 
exhibited less than 5% permanent deformation, which is consistent with the properties of 
rubbery elastomers. Furthermore, the materials did not fail under compression, so 
compressive stress-strain tests were carried out to 50% strain, where the compressive 
stress was measured as reported previously [20]. The initial modulus and strength of 
scaffolds containing filler were higher (but not significantly) than those of blank 
scaffolds. After incubating 7 days, the modulus and strength of all three scaffolds 
 
Figure 3.3. (A) SEM images of injectable LTI-PEG PUR scaffolds with no additive 
(top left) and 30 wt% HA (top right). The HA (or CMC) granules rise with the foam 
and become bridged in the pore walls, as indicated by the arrows and magnified at 
bottom left.  Some of the HA dissolved (arrows) when the PUR was foamed in a high-
moisture environment, as would occur in vivo (bottom right). (B) Degradation of 
injectable PUR scaffolds in PBS at 37 °C. The wt% polysaccharide affects the rate of 
degradation due to the rapid rate of dissolution of the polysaccharide (n = 3). 
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decreased, but only the changes in the modulus of the polysaccharide-filled scaffolds 
were significant (p < 0.005 for PUR + HA and p < 0.02 for PUR + CMC). 
 
Table 3.2. Mechanical properties of PUR scaffolds. 
PUR Sample 
Day 0 Day 7 
Young's 
Modulus (kPa) 
Compressive 
Stress (kPa) 
Young's 
Modulus (kPa) 
Compressive 
Stress (kPa) 
Blank 30 ± 4 7.7 ± 1.0 19 ± 8 6.8 ± 0.6 
PUR + HA 50 ± 20 10 ± 2 11 ± 4 8 ± 3 
PUR + CMC 60 ± 30 10 ± 7 14 ± 4 9 ± 3 
 
Measurements of excisional wounds 
Injectable PUR scaffolds with 15% CMC or HA were tested for their effects upon 
dermal wound healing in a rat excisional wound model. No frank necrosis of the 
surrounding tissue was seen at the early time points, suggesting that the mild exotherm 
resulting from the PUR reaction did not adversely affect the host tissue. In addition, the 
level of apoptosis in the scaffold-treated groups was not greater than in the blank wounds 
at any of the time points (Figure 3.5B). The average length of the wound gap, granulation 
tissue thickness, and percent re-epithelialization of the wounds in the three treatment 
groups at each time point are summarized in Figure 3.4. At days 7 and 17, the thickness 
of the wounds in the HA and CMC treatment groups was less than the thickness of the 
blank wounds; however, only the thickness of the wounds in the HA group at day 17 was 
significantly less than the blank (p < 0.015). At day 7, the length of the blank wounds 
was significantly less than those of the HA and CMC groups (p < 0.045, p < 0.015, 
respectively), providing evidence that the PUR scaffolds stented the wound. Blank 
(contracted) wounds were fully epithelialized by day 26, while HA and CMC treatment 
groups (stented) were not fully epithelialized by day 35.   
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Analysis of proliferating and apoptotic cells in an excisional wound model 
Ki67 staining was performed to assess the level of cell proliferation within the 
wound bed (Figure 3.5A). After 7 days, we found no difference in the number of Ki67
+
 
cells in the blank wounds compared to the scaffold treatment groups. From day 7 to day 
17, the number of proliferating cells remained constant in the CMC and HA treatment 
groups but decreased by 67% in the blank treatment group. Thus at day 17, the number of 
 
Figure 3.4. Measurements of wounds from the blank, HA, and CMC treatment groups 
at days 7, 17, 26, and 35. (A) Schematic summarizing measured dimensions using a 
representative image of PUR + HA at day 26 as an example. Line 1 represents wound 
gap length and line 2 represents wound thickness. Percent reepithelialization was 
calculated by dividing the length of the epidermis on either side of the wound (sum of 
lines 3 and 4) by the total length of the wound surface (sum of lines 3, 4, and 5). (B) 
Wound thickness. (C) Wound length. (D) Percentage of reepithelialization. Asterisks 
indicate statistically significant differences from the blank treatment group. 
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Ki67
+
 cells was significantly higher in the scaffold treatment groups than in the blanks. 
The number of Ki67
+
 cells decreased slightly from day 17 to day 26, but the level of 
proliferation in the scaffold treatment groups remained significantly higher than in the 
blank wounds. From day 26 to day 35, the number of Ki67
+
 cells decreased by 40% in 
the scaffold treatment groups and remained constant in the blank treatment group. At day 
35, the number of Ki67
+
 cells in the scaffold treatment groups was comparable to that 
observed for the blank wounds. 
 
 
TUNEL staining was used to measure cell apoptosis in the wound site (Figure 
3.5B). At day 7, the number of cells stained with TUNEL was higher in the blank wounds 
than in the wounds with scaffolds, but the difference was not statistically significant. 
From day 7 to day 17, the number of cells stained with TUNEL decreased by 40% in the 
blank wounds and remained relatively constant in the scaffold treatment groups. The 
 
Figure 3.5. Immunohistochemical staining for Ki67 tissue sections from the blank, 
HA, and CMC treatment groups.  (A) Ki67 staining at days 7, 17, 26, and 35. (B) 
TUNEL staining at days 17, 26, and 35. Asterisks indicate statistically significant 
differences from the blank treatment group. 
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level of apoptosis did not change in any of the treatment groups from day 17 to day 26. 
There were no significant differences in the number of cells stained with TUNEL among 
the three treatment groups at any of the time points.  
 
Analysis of contraction in an excisional wound model 
Staining for -smooth muscle actin (-SMA) was performed in order to examine 
the formation of myofibroblasts in the wound site. Representative images of sections 
stained for -SMA are displayed in Figure 3.6. In the blank wounds, the number of 
myofibroblasts was greatest at days 17 and 26 and decreased almost completely by day 
35. In contrast, fewer myofibroblasts were present at days 17 and 26 in the HA and CMC 
treatment groups. Myofibroblast formation in these groups was delayed and remained 
higher at the day 35 interval than in the blank group. Myofibroblasts were oriented 
parallel to the epidermis in the blank wounds, forming lines of tension in the skin as is 
characteristic of wounds undergoing scarring and contraction. In contrast, myofibroblasts 
were randomly oriented around pieces of PUR in the HA and CMC groups. These results 
show that myofibroblast formation was delayed in the HA and CMC groups and that 
fragments of PUR scaffolds disrupted the linear alignment of myofibroblasts.   
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During the nascent phases of cutaneous wound repair, the provisional loose 
connective tissue matrix develops a very robust capillary network, which causes the 
healing wound to appear red due to the fragile capillaries that bleed easily. If healing 
progresses through its expected phases, the number of new capillaries peaks and 
subsequently begins to decline. By days 26 and 35 in the life of the wound, the capillary 
density is regressing, which is consistent with the histological sections in Figure 3.6. The 
remodeling phase is underway and is converting the newly formed tissue within the 
 
Figure 3.6. Representative images of tissue sections from the blank, HA, and CMC 
treatment groups at days 17, 26, and 35 stained for SMA (scale bar = 100 m).   
Remnants of polyurethane foam (F), blood vessels (B), and myofibroblasts (M) are 
indicated by arrows. Blood vessels, which exhibit immunoreactivity for SMA, were 
ignored in the analysis. Myofibroblast formation in blank wounds was highest at days 
17 and 26 and decreased by day 35.  In the HA and CMC treatment groups, 
myofibroblast formation was low at days 17 and 26 and increased at day 35.   
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wound bed into a dense irregular connective tissue that is characterized by a higher 
density of matrix proteins (predominantly collagens) and a lower number of capillaries.  
Taken together, the histological sections in Figure 3.6 are consistent with a maturing 
wound that is progressing past the granulation tissue stage that is typical of chronically 
impaired wound healing settings. 
 
Analysis of collagen production in the excisional wound model 
Picrosirius red staining and procollagen I immunostaining were performed in 
order to analyze the temporal and spatial production, accumulation, and organization of 
collagen in the rat excisional wounds. Representative images of sections stained with 
picrosirius red are shown in Figure 3.7. Picrosirius red staining supports the observation 
that collagen fiber formation in the HA and CMC treatment groups was more randomly 
oriented than in the blank wounds. At days 17, 26, and 35, collagen fibers in blank 
wounds were organized and aligned parallel to the epidermis. In contrast, collagen fibers 
surrounding polymer remnants in the HA and CMC scaffolds were randomly oriented.  
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Representative images of sections stained for procollagen I are displayed in 
Figure 3.8A, and the number of procollagen I-producing cells is quantified in Figure 
3.8B. At day 17, there were significantly more procollagen I-producing cells in the HA 
group than in the blanks (p < 0.02). At day 26, there were significantly fewer procollagen 
I-producing cells in the HA group than in the blanks (p < 0.02).  At day 35, there were 
significantly fewer procollagen I-producing cells in the CMC group than in the blanks (p 
< 0.045).   
 
Figure 3.7. Representative images of tissue sections from the blank, HA, and CMC 
treatment groups at days 17, 26, and 35 stained with picrosirius red and observed with 
polarized light microscopy (scale bar = 200 m).  Remnants of polyurethane foam are 
labeled (F).  Collagen surrounding pieces of PUR foam in the HA and CMC treatment 
groups appears less organized and more randomly oriented than collagen in the blank 
wounds. 
  
49 
 
 
 
 
Figure 3.8. (A) Representative images of tissue sections from the blank, HA, and CMC 
treatment groups at days 17, 26, and 35 stained for procollagen I (scale bar = 100 m).  
Remnants of polyurethane foam are labeled (F). (B) Number of procollagen I-producing 
cells in the three treatment groups.  At day 17, HA and CMC treatment groups exhibited 
modest staining while the blank group had very few procollagen I-producing cells.  The 
staining in the blank group increased at day 26 and day 35.   In contrast, minimal 
immunostaining was seen in the HA and CMC groups at days 26 and 35. Asterisks 
indicate statistically significant differences from the blank treatment group. 
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The presence of the scaffold had a modifying impact on collagen I production and 
deposition.  Blank wounds developed a linear pattern of contraction and scarring and 
were highly cellular. By comparison, scaffold-treated wounds at day 35 revealed reduced 
cellularity and fewer collagen I-secreting cells.  Furthermore, the orientation of the cells 
and collagen fibers was more random in the presence of scaffolds. These data support the 
hypothesis that the scaffold hinders or alters the expected scarring and contraction pattern 
observed in blank wounds. 
 
Discussion 
In this study, we have shown that the physical, mechanical, and rheological 
properties of polyurethane composites render them suitable for use as injectable scaffolds 
in the setting of cutaneous wound repair. The materials exhibited working and cure times 
of 5 – 7 and 15 – 19 min, respectively, which are compatible with the temporal 
practicalities imposed by the clinical setting.  Due to their compressive properties, which 
approach those of intact skin, the scaffolds stented the wounds at early time points and 
promoted granulation tissue formation while preventing wound contraction. As a result of 
wound contraction, unstented wounds resurfaced more rapidly.  Collagen synthesis and 
organization, as well as myofibroblast formation, were altered by the presence of the 
scaffolds with a net positive impact. 
Injectable scaffolds are advantageous because they can fill large, irregularly 
shaped wounds and cavities.  Moreover, scaffolds have the added potential to serve as 
delivery vehicles for additives such as antibacterial and growth factors. Nevertheless, 
several challenges associated with injectable biomaterials have been described in recent 
reviews [21]. The reactants and catalyst must not be cytotoxic, and the reaction exotherm 
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must be minimal to avoid necrosis of surrounding tissues. Achieving interconnected 
pores while retaining robust mechanical properties presents an additional challenge. In a 
recent study, injectable poly(propylene fumarate) (PPF) scaffolds with pores ranging 
from 50 - 500 m, <61% porosity, and elastic modulus of 20 – 40 MPa were fabricated 
via a gas-foaming process using an NVP crosslinker and benzoyl peroxide initiator [22]. 
However, the effects of the solvents and initiator on in vivo biocompatibility remain 
untested to date.  
Natural and synthetic polymers including collagen, chitosan, fibrin, and 
poly(lactic-co-glycolic acid) are currently used in cutaneous wound healing in the form of 
hydrogels, sheets, sponges, and electrospun scaffolds [4, 23]. These polymers are 
advantageous due to their biocompatibility and biodegradability, but they present 
potential drawbacks such as low mechanical properties, small pore size, and low porosity 
[12]. Low mechanical properties result in undesirable outcomes such as contraction and 
scarring, and small pores and low porosity lead to slow infiltration and delayed 
vascularization [23].  Scaffolds with >90% porosity are desirable because they can easily 
support infiltration of new tissue and transport of nutrients and waste [24]. A previous 
study has reported optimal pore sizes for fibroblast infiltration and new tissue ingrowth 
ranging from 90 – 360 m [25], while another study has shown that the viability of 
seeded fibroblasts was highest for pore size <160 m [26, 27]. Another study resulted in 
low viability of fibroblasts in scaffolds with pores ranging from 50 – 80 m compared to 
scaffolds with larger pores [24]. 
Nanofibrous scaffolds have potential for use in cutaneous wound healing because 
they mimic the structure and function of natural ECM [23].  Despite their small pores, 
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their high surface area to volume ratio results in excellent permeability for oxygen and 
nutrients [23].  Delivery of recombinant human platelet-derived growth factor (rhPDGF) 
from nanofibrous PLGA scaffolds has been reported to enhance wound healing in rats 
[28], and another study has examined the use of bioactive poly-N-acetyl-glucosamine 
nanofibrous membranes in cutaneous wounds in diabetic mice [29]. The nanofibers 
enhanced keratinocyte migration, cell proliferation, and angiogenesis compared to a 
cellulose control [29].  However, pre-formed implants such as nanofibrous scaffolds 
cannot be injected, and thus cannot fill and conform to deep tissue defects. 
We have previously reported an injectable polyurethane scaffold for use in bone 
tissue engineering applications, wherein a matrix comprising allograft bone particles and 
a two-component reactive polyurethane supported cellular infiltration, extracellular 
matrix synthesis, and new bone formation in femoral plug defects in rats [13]. In this 
study, we have applied the findings from our previous work on injectable allograft bone 
biocomposites to create injectable scaffolds for use in cutaneous wound repair and 
regeneration.  With a working time of <7 min and a setting time of <19 min, the scaffolds 
can be mixed and injected in a clinically relevant period of time. The pore size ranged 
from 320 – 370 m, which is consistent with values reported previously for polyurethane 
scaffolds [13, 14, 30], and are comparable to those known to facilitate infiltration of cells 
such as fibroblasts (90 – 360 m [25]) and osteoblasts [31].  While blank, HA-, and 
CMC-filled scaffolds showed no significant differences in pore size, the polysaccharide-
filled scaffolds exhibited higher density and modulus and lower porosity than the blank 
scaffolds.  However, by day 7 the density, modulus, and porosity of the polysaccharide-
filled scaffolds were not significantly different than those properties measured for the 
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blank scaffolds.  These data are consistent with the SEM images in Figure 3.3A and the 
degradation data in Figure 3.3B suggesting that the polysaccharide had leached from the 
scaffolds by day 7, resulting in lower modulus and density.  They are also in agreement 
with a previous study showing a reduction in the modulus of PUR scaffolds incorporating 
7 – 8% tobramycin after 7 days due to leaching of the tobramycin from the scaffolds [32]. 
An abundance of fibroblasts was observed in our histological sections. 
Proliferative assays were performed to demonstrate that the scaffolds supported cellular 
attachment and proliferation, which provides compelling evidence that the scaffold was 
non-toxic and biocompatible as it degraded and was replaced by new matrix.  In the in 
vivo experiment, there were no significant differences in the level of apoptosis among the 
three treatment groups, suggesting that the polyurethane scaffolds and their degradation 
products are noncytotoxic and do not harm the surrounding tissue, which is consistent 
with previous studies [14, 33-35]. In addition to its role as an initial temporary matrix that 
provides a surface for cell attachment, the scaffolds also stented the wounds by providing 
resistance to the contractile forces exerted by the cells.  The Young’s modulus of the 
scaffolds measured under compressive deformation approaches that of human skin, 
which has been reported as 35 kPa for the dermis [36], and rat skin, which we measured 
to be 400 ± 150 kPa.  The injectable polyurethane networks are rubbery elastomers at 
physiological temperatures with glass transition temperatures (Tg) less than 10°C, and 
they sustain compressive strains exceeding 50% without mechanical failure [14]. The 
wound healing (Figure 3.4), cell proliferation (Figure 3.5), and matrix deposition (Figure 
3.7) data are consistent with the notion that the scaffold delays contraction and scarring 
due to the fact that its initial mechanical properties are approaching those of native skin.  
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Cutaneous wound repair goes through predictable stages, characterized by an initial acute 
inflammatory phase that leads to ingrowth of granulation tissue followed by a progressive 
transition to sustained matrix production and remodeling.  Rapid wound closure often 
leads to excessive matrix production and the very undesirable outcomes of scarring and 
wound contraction, which was not observed with these scaffolds.  Matrix production was 
visibly dampened and the alignment of collagen fibers more random compared to control 
wounds.  Thus, by resisting the contractile forces that are generated in the host tissue, the 
scaffolds promote cellular infiltration and remodeling rather than excessive matrix 
deposition and scarring.  
Excisional wounds treated with PUR scaffolds were significantly less contracted 
than blank wounds at day 7 as demonstrated by measures of wound gap (Figure 3.4C).  
While the cross-sectional area of granulation tissue was similar among all groups, 
unstented wounds tended to form a thickened eschar, although the differences were not 
significant (Figure 3.4B). These indicators suggest that the scaffolds stented the wounds 
at early time points, thus leading to a restorative rather than a scarring/contracting 
phenotype at later time points.  Although wounds treated with injectable scaffolds 
showed prolongation of the proliferative phase, the effects on myofibroblast 
accumulation and orientation are potentially advantageous features. Myofibroblasts 
normally generate unwanted contractile forces that promote wound contraction and 
fibrosis. The architectural disruption of myofibroblast alignment led to a more reticular 
arrangement of collagen fibers. Although the upper surface of the scaffolds was 
approximately flush with the surface of the skin, epidermal resurfacing of the wounds 
was delayed. While this response was likely due in part to the greater length of the 
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stented wounds, either the wound covering or the properties of the upper surface of the 
scaffold may benefit from further modification. 
At later time points in the study, the marked difference in the alignment of 
collagen fibers and cells within the composite scaffolds suggests that the transient 
presence of the scaffold disrupted the formation of a uniformly aligned extracellular 
matrix under elevated tension. Ideally the scaffold should degrade at a rate comparable to 
that of new tissue ingrowth.  While Figure 3.3 shows ~20% mass loss of the polyurethane 
after 24 weeks in vitro, we have recently shown that lysine-derived polyurethane 
scaffolds undergo oxidative degradation to soluble break-down products mediated by 
macrophages in vivo [17]. As a result, the scaffold was almost completely resorbed after 
4 weeks post-implantation in rat excisional wounds [17]. Biostable polyurethane foams 
have been developed as coverings to minimize fibrous encapsulation of breast implants 
[37, 38]. However, the polyurethane foams slowly degraded in vivo into small pieces 
after periods longer than 18 months post-implantation, thereby inducing fibrous 
encapsulation of the implant and an intense foreign-body response to the foam fragments. 
The delayed appearance of myofibroblasts in the injectable scaffolds was also consistent 
with an altered mechanical environment, particularly in light of the evidence that cell-
generated tension in the context of relatively stiff extracellular matrix can lead to the 
activation of latent TGF-ß, which promotes matrix accumulation and differentiation of 
the myofibroblast phenotype [39]. 
Although not tested in the present investigation, the injectable polyurethane 
scaffolds also have the potential to accelerate wound healing through the local delivery of 
biologics such as recombinant human platelet-derived growth factor (rhPDGF) [15] or 
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antibiotics [32, 40]. Delivery of rhPDGF-BB from polyurethane scaffolds implanted in 
excisional wounds in rats accelerated both ingrowth of new tissue as well as degradation 
of the scaffolds [15]. In another study, delivery of vancomycin from polyurethane 
scaffolds implanted in a contaminated femoral segmental defect in rats decreased 
bacterial counts in both bone and soft tissue [40].  Biologics can be added to the polyester 
triol component prior to mixing with the prepolymer, thereby facilitating clinical ease of 
use and customization at the point of care. 
 
Conclusions 
In this study, an injectable, biodegradable polyurethane scaffold supported 
cellular infiltration and ingrowth of new tissue in a rat excisional wound model. The two-
component polyurethanes exhibited working times and setting times ranging from 5 – 7 
and 15 – 19 minutes, respectively. A micron-sized polysaccharide powder, either 
hyaluronan or carboxymethylcellulose, added to the liquid polyurethane controlled 
excessive expansion after injection.  The cured scaffolds delayed wound contraction at 
early time points, with the favorable outcomes of enhanced cellular proliferation and 
reduced alignment of scar collagen.  The biocompatibility, ease of use, clinically relevant 
working and setting times, support of cellular infiltration, positive impact on matrix 
remodeling, and potential to deliver biologics at the point of care may present compelling 
opportunities for injectable polyurethanes as void fillers for healing of cutaneous tissue 
defects. 
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CHAPTER IV 
 
BIODEGRADABLE LYSINE-DERIVED POLYURETHANE SCAFFOLDS 
PROMOTE HEALING IN A PORCINE FULL-THICKNESS EXCISIONAL WOUND 
MODEL 
 
Introduction 
Reports estimate that 35 million cases of significant skin loss occur each year in 
the United States, of which 7 million become infected and chronic with prolonged times 
to wound closure [1]. Best estimates suggest that over 2 million Americans currently 
suffer from chronic ulcers, requiring treatment costs of approximately $8 billion per year 
[1]. Furthermore, in the acute wound category, over one million burns require hospital 
visits each year [2]. These cutaneous defects create a need for cost-effective wound care 
products that actually restore skin function. Autografts are the gold standard for treatment 
of large, acute, non-infected skin deficits, but they are a painful and precious resource to 
harvest, with high potential for unsightly donor site morbidity [1-3]. Natural and 
biological-based scaffolds that are currently available, such as Alloderm™, Integra™, 
Alloskin™ and Oasis™, are thin sheets that provide a temporary wound covering but are 
not ideal for filling deep tissue defects [4, 5].  Hydrogels have been used to deliver drugs 
and other biologics to wound sites; however, their small pore size and low porosity can 
result in delayed cellular infiltration and vascularization, and their low strength and 
stiffness provide limited mechanical support for tissue infiltration and remodeling [3, 6], 
hence not reflecting the robust viscoelastic properties that are needed  as a protective 
covering for underlying muscles, nerves and tendons.  
Polyurethane (PUR) is a biocompatible synthetic polymer that has been used in 
medical devices and tissue engineering applications [7]. Lysine-derived PUR scaffolds 
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(LTI) have been shown to be biocompatible and to degrade into nontoxic decomposition 
products [8, 9]. Furthermore, PUR scaffolds have potential for injectability and suitability 
as a delivery platform [10-17]. Chapter III reported that injectable and implantable PUR 
scaffolds supported cellular infiltration and extracellular matrix synthesis in rat excisional 
wounds [10]. However, rat skin differs from human skin both physiologically and 
anatomically. Both the dermis and epidermis are thinner in rats than in humans, the 
vascularity is much less in rats, and loose-skinned rats heal primarily through contraction 
rather than production of robust granulation tissue and epithelialization [18]. To achieve 
greater clinical relevance, the porcine wound model was chosen for the present study 
since pig and human skin have similar density and distribution of blood vessels, sweat 
glands, and hair follicles [18]. Furthermore, pigs and humans have similar epidermal 
thickness and heal primarily through re-epithelialization rather than contraction [18]. 
Previous studies have investigated the use of void-filling scaffolds in porcine 
wound models [19-22]. A study by Huang et al. treated full-thickness porcine wounds 
with a bilayer dressing comprising an internal gelatin sponge layer incorporating basic 
fibroblast growth factor-loaded microspheres protected by an elastomeric membrane [19].  
After 21 days, wounds treated with the dressing had smaller areas, thicker epidermis, and 
better collagen organization than control wounds treated with Vaseline gauze. Studies by 
Greenwood and Dearman investigated the use of biodegradable PUR foams as a 
temporizing matrix prior to skin graft surgery [20, 21]. Porcine excisional wounds treated 
with a PUR foam sealed with a microporous PUR membrane had no signs of infection 
and delayed contraction compared to wounds treated with Integra after 28 days. 
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However, wounds treated with unsealed foams exhibited significant contraction and had 
thick scar layers above the implants. 
The goal of the present study was to define cutaneous wound healing processes in 
the presence of a biocompatible void filler and to examine the positive or negative impact 
of two different modifications. We implanted single-layer PUR scaffolds that were 
synthesized from lysine triisocyanate and a polyester triol and tested for their potential to 
facilitate dermal wound healing in a full thickness porcine excisional wound model, 
without the use of protective membranes. Carboxymethylcellulose was added as a 
porogen to increase scaffold permeability and interconnectivity.  Plasma treatment was 
applied to decrease the hydrophobicity of the scaffold surface. Evaluation of the 
degradation properties of the scaffolds and their ability to support cellular infiltration and 
blood vessel formation showed favorable biomaterial performance. 
 
Methods 
Materials 
Glycolide and D,L-lactide were obtained from Polysciences (Warrington, PA). 
Glycerol and the sodium salt of carboxymethylcellulose (90 kDa) were purchased from 
Acros Organics (Morris Plains, NJ). TEGOAMIN33, a tertiary amine catalyst composed 
of 33 wt % triethylene diamine (TEDA) in dipropylene glycol, was received from 
Goldschmidt (Hopewell, VA). Lysine triisocyanate was obtained from Kyowa Hakko 
USA (New York), and stannous octoate catalyst was purchased from Nusil technology 
(Overland Park, KS). All other reagents were obtained from Sigma–Aldrich (St. Louis, 
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MO). Glycerol was dried at 10 mm Hg for 3 h at 80°C, and ɛ-caprolactone was dried over 
anhydrous magnesium sulfate prior to use. All other materials were used as received. 
 
PUR Scaffold Synthesis 
A polyester triol (900 Da) with a backbone comprising 60% caprolactone, 30% 
glycolide, and 10% lactide was synthesized by reacting a glycerol starter, cyclic ester 
monomers (ɛ-caprolactone, glycolide, and D,L-lactide), and stannous octoate catalyst 
under dry argon for 48 h at 140°C. The resulting polyester triol was vacuum-dried at 
80°C for 24 h.  
Lysine triisocyanate scaffolds (LTI) were synthesized by reactive liquid molding 
of the crosslinker with a hardener component comprising the polyester triol, 1.5 parts per 
hundred parts polyol (pphp) water, 1.5 pphp TEGOAMIN33 catalyst, and 4.0 pphp 
calcium stearate pore opener. LTI was added to the hardener and mixed for 30 sec in a 
Hauschild DAC 150 FVZ-K SpeedMixer™ (FlackTek, Inc., Landrum, SC). The resulting 
mixture then rose freely for 10–20 min and cured. The targeted index (the ratio of NCO 
to OH equivalents times 100) was 115.  
For synthesis of LTI + carboxymethylcellulose scaffolds (CMC), 
carboxymethylcellulose (15 wt%) was mixed with the hardener component for 30 sec 
prior to addition of LTI. After curing, the carboxymethylcellulose was leached by 
incubating for three days in water. For preparation of LTI + carboxymethycellulose + 
plasma scaffolds (Plasma), leached CMC scaffolds were exposed to oxygen plasma for 
60 sec using a Harrick Plasma PDC-001 Plasma Cleaner (Ithaca, NY). 
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Scaffold Physical and Mechanical Properties 
Scaffold densities and porosities were determined from mass and volume 
measurements of triplicate cylindrical foam cores. The pore size distribution was assessed 
by scanning electron microscopy (Hitachi S-4200 SEM, Finchampstead, UK) after gold 
sputter coating with a Cressington Sputter Coater (Vanderbilt Institute for Nanoscale 
Science and Engineering).  
Mechanical testing was performed using a TA Instruments Q800 Dynamic 
Mechanical Analyzer (DMA) in compression mode (New Castle, DE). Samples were 
soaked in water for three days prior to mechanical testing. Stress–strain curves were 
generated by compressing wet cylindrical 12 mm × 8 mm samples at 37°C at a rate of 
10% strain per min until they reached 50% strain. The Young's modulus was determined 
from the slope of the initial linear region of each stress–strain curve. 
Air permeability of LTI and CMC scaffolds was determined using the constant 
pressure gradient method. The air flow rate (Q) necessary to maintain a pressure gradient 
(P) of 0.12 kPa was measured, and the permeability (k) was calculated by applying 
Darcy’s law: 
Q =
kA
m
DP
L
         (4.1) 
where L is the scaffold thickness, A is the scaffold cross-sectional area, and  is the 
dynamic viscosity of air at room temperature. 
 
Contact Angle Measurements 
Polyurethane films were synthesized for contact angle measurement since the 
porous structure of the scaffolds precludes contact angle measurements on the scaffolds. 
  
65 
 
PUR films were synthesized by mixing polyester triol, 10 pphp TEGOAMIN33 catalyst, 
and LTI. The targeted index was 115. The static contact angle of a drop of water on the 
resulting films was measured using a Rame-Hart goniometer (Succasunna, NJ). 
 
Porcine Excisional Wound Study 
All surgical procedures were reviewed and approved by the local Institutional 
Animal Care and Use Committee. Recommendations from the NIH Guide for the Care 
and Use of Laboratory Animals (8
th
 Edition, 2011) were observed. The capacity of the 
scaffolds to facilitate healing in full-thickness cutaneous defects was evaluated in an 
excisional wound model (6.25 cm
2
 square wounds) in female Yorkshire pigs (50 lbs). 
Treatment groups included untreated wounds (negative control, n = 4) and LTI, CMC, 
and Plasma PUR scaffolds (n = 6). To reduce production of exudate, excisional wounds 
were created 24 h prior to scaffold implantation. This delay allowed us to advance 
beyond the period of hemostasis and thereby reduce the exudative characteristics of the 
wound bed.  Buprenex (an analgesic) and cefazolin (an antibiotic) were given at the time 
of surgery. For the remainder of the study, the analgesic fentanyl was applied in a 50 
mcg/hr transdermal patch that was replaced every three days, and 500 mg of the 
antibiotic cephalexin was given twice daily.  
Before surgery, scaffolds were trimmed into square pieces measuring 2.5 cm x 2.5 
cm x 0.3 cm. All scaffolds were sterilized using ethylene oxide. Plasma treatment was 
applied to Plasma scaffolds immediately prior to implantation. Scaffolds were loosely 
held in place by an X-shaped configuration of spanning sutures that extended from 
normal skin to normal skin. After scaffold implantation, each wound was dressed with 
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TELFA non-adherent dressing (Medline, Mundelein, IL), covered with Opsite adhesive 
film (Smith & Nephew, St. Petersburg, FL) beneath tube gauze, and secured with 
Vetwrap bandaging tape (3M, St. Paul, MN). Wounds were cleaned and dressings were 
changed every 2-3 days. Pigs were sacrificed and wounds were harvested at days 8 and 
15 after scaffold implantation.  
 
Tissue Analysis 
Wounds were fixed in neutral buffered formalin for 48 h, transferred into 70% 
ethanol for 48 h, embedded in paraffin, and sectioned at 5 μm and stained with Gomori’s 
trichrome. Reparative responses of tissues were examined and quantified using 
immunohistochemical markers and procedures that we have previously validated [23]. 
Actively proliferating cells were immunostained for Ki-67 antigen. After heat-mediated 
target retrieval in citrate buffer at pH 6.0 (DAKO, Carpenteria, CA), endogenous 
peroxidase activity was neutralized with 3% H2O2 for 40 minutes followed by blocking 
non-specific reactivity with a casein-based protein block (DAKO, Carpintera, CA) for 20 
minutes. Slides were incubated with rabbit anti-human Ki-67 (NovaCastra Laboratories 
Ltd., Newcastle, UK) diluted at 1:2,000 for 60 min. The rabbit Envision HRP System 
(DAKO) was used with DAB as substrate and the slides counterstained with 
hematoxylin. Macrophage infiltration into repairing tissues was assessed using MAC387 
antisera (AbD Serotec, Raleigh, NC). After antigen retrieval in 0.01 M Tris/HCL pH 10, 
quenching for peroxidase activity, and blocking of non-specific immunoreactivity, a 
monoclonal mouse anti-human antibody to a macrophage epitope (MAC387) was used at 
1:10,000 for 60 min. Fragmented DNA of apoptotic cells was visualized with the 
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DeadEnd Colorimetric TUNEL System (Promega Corporation, Madison, WI). The tissue 
sections were subjected to a second fixation in 4% paraformaldehyde, rinsed, and 
permeabilized with proteinase K for 5 minutes.  The sections then were treated with 
equilibration buffer (Promega) followed by biotinylated nucleotide incorporation into 
apoptotic cells using Terminal Deoxynucleotidyl Transferase (TdT). Endogenous 
peroxidase was neutralized by applying 0.3% hydrogen peroxide to the sections. 
Applications of streptavidin/HRP and DAB produced apoptotic-specific visible nuclear 
staining. Quantitative measurements were performed using Image-Pro Plus scientific 
image analysis software (Media Cybernetic, Inc., Silver Spring, MD.). Data are expressed 
as the total number of proliferating cells, immunolabeled macrophages, or apoptotic cells.  
Density of new capillaries in the wound bed was determined by immunostaining 
using antisera for Von Willebrand Factor. Sections underwent antigen retrieval using 5 
min of digestion with Proteinase K (DAKO, Carpinteria, CA). Following rinses and 
endogenous blockade with H2O2, sections were incubated at 25
0
 C in rabbit polyclonal 
antisera for Factor VIII-related antigen (Von Willebrand Factor; DAKO) for 30 minutes 
with a dilution of antibody at 1:900. Following this incubation in primary antisera, the 
sections were processed through the reagents supplied by rabbit Envision + System, HRP 
kit (DAKO). Data are expressed as area% of endothelial-lined areas within the wound.   
 
Statistical Analysis  
  One way analysis of variance (ANOVA) was used to evaluate the statistical 
significance of results. All p-values less than 0.05 were considered statistically 
significant. Data are presented as mean ± standard error unless otherwise indicated.  
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Results 
PUR Scaffold Physical and Mechanical Properties 
The physical and mechanical properties of PUR scaffolds were characterized in 
vitro (Table 4.1).  LTI and CMC scaffolds had similar density, porosity, pore size, and 
compressive modulus. However, CMC scaffolds had a 2.5-fold higher permeability than 
LTI scaffolds. Consistent with this analysis, SEM images in Figure 4.1 show that CMC 
scaffolds had similar pore size but higher interconnectivity than LTI scaffolds.  
 
Table 4.1. Physical and mechanical properties of PUR scaffolds. Data are shown as mean 
± standard deviation. Dagger denotes significant difference between LTI and CMC 
scaffolds (p < 0.05). 
  LTI CMC 
Density (kg/m3) 99.9 ± 15.3 109.8 ± 8.5 
Porosity (vol %) 91.8 ± 1.3 90.9 ± 0.7 
Pore size (mm) 370 ± 110 400 ± 110 
Permeability (m2) (1.9 ± 0.4)*10-11
 
† (4.9 ± 0.6)*10-11
 
† 
Compressive modulus (kPa) 18.2 ± 6.1 16.7 ± 2.9 
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To confirm that plasma treatment increased the hydrophilicity of the scaffold 
surface, the contact angle of PUR films was measured before and after plasma treatment. 
As shown in Figure 4.2, plasma treatment significantly decreased the contact angle from 
66° to 46° (p < 0.005). 
 
 
Figure 4.1. SEM images showing pore structure of PUR scaffolds. (A) LTI scaffold. 
(B) CMC scaffold. LTI and CMC scaffolds exhibit similar pore sizes (300 – 500 m). 
CMC scaffolds have more openings in pore walls than LTI scaffolds, resulting in 
higher permeability. Scale bar = 750 m. 
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Impact on Wound Dimensions (Wound Contractility) 
Measurements of wound dimensions harvested 8 and 15 days after scaffold 
implantation are shown in Figure 4.3. For all treatment groups, wound area decreased 
significantly from day 8 to day 15. Untreated wound areas were significantly greater than 
those of wounds treated with either LTI or Plasma scaffolds at day 8, but there were no 
significant differences in wound area among treatment groups by day 15 (Fig. 4.3A). 
There were no differences in epithelialization among the treatment groups at day 8, but 
untreated wounds were significantly more epithelialized than wounds treated with 
scaffolds by day 15 (Fig. 4.3B). Representative images of wounds at day 1 and day 15 are 
shown in Fig. 4.3C, and the degree of wound contraction was quantified in Fig. 4.3D. 
While wounds from the LTI, CMC, and untreated groups were significantly more 
 
Figure 4.2. Contact angle of LTI films before and after plasma treatment. Contact angle 
decreased from 65° to 45° after plasma treatment, providing evidence that plasma 
treatment increases surface hydrophilicity. Asterisk indicates significant difference (p < 
0.005). 
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contracted at day 15 than at day 8, wounds treated with scaffolds were significantly less 
contracted than untreated wounds at day 15. 
 
 
 
  
 
Figure 4.3. Histomorphometry of porcine wounds. (A) Wound cross-sectional area of 
LTI, CMC, Plasma, and untreated wounds (NT) measured from images of trichrome 
staining. Asterisks indicate significant difference, and daggers indicate significant 
difference from no treatment at day 8 (p < 0.05). The cross-sectional area of all 
treatment groups decreased significantly from day 8 to day 15. LTI and Plasma 
wounds were significantly smaller than untreated wounds at day 8. (B) Fraction 
reepithelialization measured from images of trichrome staining. Asterisks (p < 0.05) 
and double asterisks (p < 0.01) denote significant differences, and daggers indicate 
significant difference from no treatment at day 15. Epithelialization of all wounds 
increased from day 8 to day 15, and untreated wounds were more epithelialized than 
scaffold-treated wounds at day 15. (C) Representative images of wounds at day 1 and 
day 15. Untreated wounds exhibited greater contraction than scaffold-treated wounds. 
(D) Wound opening relative to initial size. Asterisks indicate significant difference, 
and daggers indicate significant difference from no treatment at day 15 (p < 0.05). 
LTI, CMC, and untreated wounds contracted significantly from day 8 to day 15. 
Untreated wounds had significantly greater contraction than all scaffold-treated 
wounds at day 15. 
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Impact on PUR Scaffold Degradation 
At day 8, wounds were immature and exhibited little collagen accumulation (Fig. 
4.4A), while day 15 wounds that were treated with scaffold showed replacement of the 
polymer by extracellular matrix (Fig. 4.4B). The progression and extent of PUR 
degradation, measured by fractional area, decreased significantly from day 8 to day 15 
for all scaffold treatment groups (Fig. 4.4C). There were no significant differences in 
area% PUR among the three PUR treatment groups at both time points, suggesting that 
the CMC and plasma treatments had an insignificant effect on the rate of PUR 
degradation. The gradient in trichrome green intensity between the upper (light green) 
and lower (dark green) regions within the scaffold confirmed that the scaffold-treated 
wounds have the same polarity of matrix reorganization as untreated wounds. 
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Figure 4.4. PUR scaffold degradation. (A) Representative images of trichrome staining 
of LTI scaffolds at day 8 at magnifications of 2X (left) and 20X (right). Scaffold 
fragments are marked by the letter S. (B) Representative images of trichrome staining of 
CMC scaffolds at day 15 at magnifications of 2x (left) and 20x (right). Fewer scaffold 
fragments are present at day 15 than at day 8. (C) Percentage of wound cross-sectional 
area occupied by PUR measured from images of trichrome staining. Asterisks indicate 
significant difference (p < 0.05). All scaffolds-treated wounds had significantly less 
polyurethane remaining at day 15 than at day 8, providing evidence that PUR scaffolds 
underwent biodegradation. 
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Impact on Cell Proliferation and Apoptosis 
For all treatment groups, the number of proliferating cells decreased significantly 
from day 8 to day 15 (Fig. 4.5 A).  This result suggests that all wounds were transitioning 
from the proliferative phase to the maturation phase by day 15.  At day 8, untreated 
wounds had more than three times as many Ki67
+
 cells as wounds treated with scaffolds 
(p < 0.02), suggesting that the presence of scaffold serves as a signal that dampens the 
proliferative response. Subtle differences in the proliferative response were detected 
among the three scaffold treated groups. The LTI treatment group had significantly more 
Ki67
+
 cells than the Plasma treatment group, which in turn had significantly more Ki67
+
 
cells than the CMC treatment group.  By day 15, untreated wounds had significantly 
fewer Ki67
+
 cells than CMC and Plasma treatment groups, suggesting that the formation 
of granulation tissue develops and resolves more quickly in the absence of scaffolds.  
TUNEL staining to assess the effect of scaffolds on apoptosis detected differential 
responses to treatment (Fig. 4.5B). At day 8, the Plasma treatment group had significantly 
more TUNEL
+
 cells than the LTI and CMC groups. The number of TUNEL
+
 cells 
increased significantly from day 8 to day 15 in wounds treated with LTI scaffolds. 
Wounds treated with Plasma scaffolds and untreated wounds had fewer TUNEL
+
 cells at 
day 15 than at day 8, which suggests that these wounds were moving more quickly into a 
resolution/remodeling phase of repair by day 15.  
Furthermore, the ratio of proliferation to apoptosis was quantified (Fig. 4.5C). 
The ratio of Ki67
+
 cells to TUNEL
+
 cells was calculated and adjusted assuming that Ki67 
is expressed for ~15 h in proliferating cells (the length of a fibroblast cell cycle [24]) and 
TUNEL is expressed for ~2 h during apoptosis [25]. At day 8, untreated wounds had a 
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significantly higher ratio than the LTI treatment group, which had a significantly higher 
ratio than the CMC and Plasma treatment groups. By day 15, there were no significant 
differences in proliferation/apoptosis ratio, which was slightly greater than one for all 
treatment groups. These results suggest that all wounds were moving into the remodeling 
phase by day 15.  
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Figure 4.5. Analysis of cell proliferation and apoptosis. (A) Ki67 immunostaining was 
used to analyze the presence of proliferating cells. Data are presented as number of 
Ki67
+
 cells per high power field (hpf). Asterisks indicate significant difference (p < 
0.05). Dagger indicates significant difference from CMC and Plasma at day 15 (p < 
0.02). The number of Ki67
+
 cells decreased significantly from day 8 to day 15 in all 
treatment groups. At day 8, there were significant differences among all treatment 
groups. At day 15, CMC and Plasma groups had significantly more proliferating cells 
than untreated wounds. (B) TUNEL immunostaining was used to analyze the presence of 
apoptosing cells. Data are presented as number of TUNEL
+
 cells per hpf. Asterisks 
indicate significant difference (p < 0.05). Dagger indicates significant difference from 
LTI and CMC at day 8 (p < 0.01). The number of TUNEL
+
 cells increased significantly 
from day 8 to day 15 in LTI scaffolds and decreased significantly from day 8 to day 15 
in Plasma scaffolds. At day 8, wounds treated with Plasma scaffolds had significantly 
more TUNEL
+
 cells than wounds treated with LTI and CMC scaffolds. (C) Ratio of 
proliferation to apoptosis. Dashed line represents a ratio of one. Asterisks indicate 
significant difference (p < 0.01), and dagger denotes significant difference from LTI and 
untreated wounds at day 8. By day 15, there were no significant differences in 
proliferation/apoptosis ratio among treatment groups. 
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Impact on Macrophage Recruitment and Persistence 
Macrophage numbers typically peak in the acute wound healing setting at around 
4-5 days [26]. Thus, it was anticipated that macrophage numbers would decline in the 
untreated wounds between day 8 and day 15 in the absence of any scaffold material 
(foreign body) or inflammatory stimulus. At day 8, there were no significant differences 
in number of MAC387
+
 macrophages among all treatment groups (Figure 4.6).  
However, the number of macrophages in wounds treated with CMC or Plasma scaffolds 
increased significantly from day 8 to day 15 while the number of macrophages decreased 
for the LTI and untreated groups. The increase in the number of macrophages from day 8 
to day 15 in the CMC and Plasma groups reflects the response to the presence of the 
scaffolds that contained carboxymethylcellulose.  
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Impact on Blood Vessel Formation 
Angiogenesis is a major component of granulation tissue progression. As shown 
in Figure 4.7, the density of factor VIII-positive blood vessels (area% occupied by blood 
vessels) increased significantly from day 8 to day 15 in LTI, Plasma, and untreated 
groups. Stated differently, the formation of granulation tissue was robust within all 
treatment groups and was a prominent feature during the window of time examined in 
this study. No significant differences in blood vessel percentage among the treatment 
groups were noted at either time point. These results show that treatment with the three 
different types of PUR scaffolds did not alter blood vessel formation during the wound 
healing process. 
 
 
Figure 4.6. Analysis of MAC387
+
 cells. MAC387 immunostaining was used to analyze 
the presence of macrophages. Data are presented as number of MAC387
+
 cells per hpf. 
Asterisks (p < 0.02) and dagger (p < 0.005) indicate significant difference. The number 
of MAC387
+
 cells increased significantly from day 8 to day 15 in Plasma scaffolds. At 
day 15, wounds treated with CMC and Plasma scaffolds had significantly more 
MAC397
+
 cells than untreated wounds. 
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Discussion 
PUR scaffolds were tested for their ability to safely and effectively support and 
modify the healing properties of full-thickness porcine excisional wounds in order to 
validate their clinical value. Two modifications were applied to the scaffolds to determine 
if scaffolds could be fine-tuned to increase the degree of cellular infiltration and 
attachment. Carboxymethylcellulose was added as a porogen to increase pore 
interconnectivity and thus facilitate cellular infiltration throughout the scaffold. Plasma 
treatment was applied to decrease the hydrophobicity of the scaffold surface and thereby 
provide a more hospitable substrate for cell attachment. In vitro characterization of the 
scaffolds showed that addition of carboxymethylcellulose increased the permeability of 
the scaffolds 2.5-fold, and plasma treatment decreased the contact angle by 20°.  The 
 
 
Figure 4.7. Blood vessel formation. Factor VIII immunostaining was used to analyze the 
presence of blood vessels. Data are presented as area% of blood vessels within the 
wound. Asterisks indicate significant difference (p < 0.05). The blood vessel density 
increased significantly from day 8 to day 15 in LTI, Plasma, and untreated wounds. 
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permeability of the scaffolds is comparable to that of rigid open-cell foams reported by 
Zhao et al. (10
-12
 – 10-10 m2) [27]. When implanted in porcine excisional wounds, PUR 
scaffolds stented the wounds, resulting in significantly less wound contraction than 
untreated wounds at day 15. This result is consistent with our previous study in a loose-
skinned, rodent model showing that PUR composite scaffolds stented rat excisional 
wounds at early time points, thereby diminishing the degree of  undesirable contraction 
and scarring [10].  All three versions of the scaffolds showed a statistically significant 
rate of biodegradation between the day 8 and day 15 that reduced — but did not prevent 
— wound contraction. Further optimization of the degradation rate of the PUR scaffold 
may help to achieve the long sought after aesthetic and functional goal: a lessening of 
undesirable wound contraction.   
In untreated wounds, the number of macrophages decreased from day 8 to day 15, 
consistent with wounds moving into resolution in the absence of scaffold material that — 
while transiently present — promotes a typical foreign body response [26]. As the 
scaffolds underwent infiltration, degradation and fragmentation between day 8 and day 
15, the number of macrophages only increased in the CMC and Plasma groups, 
suggesting that carboxymethylcellulose treatment influenced the innate immune 
response. Macrophage presence in the wounds that were treated with 
carboxymethylcellulose-containing scaffolds was significantly greater than in untreated 
wounds at day 15.  We have previously shown that PUR scaffolds undergo oxidative 
degradation mediated by macrophages [9]. The increase in macrophages in CMC and 
Plasma groups provides evidence that the scaffolds were being degraded by 
macrophages. It is possible that LTI scaffolds were slower to attract macrophages due to 
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their lower permeability and hydrophilicity than the other scaffold groups, leading to a 
slower rate of oxidative degradation at these relatively early time points.  
All treatment groups had significantly fewer Ki67
+
 cells at day 15 than at day 8, 
an indication that all wounds were moving from the proliferative phase to the remodeling 
phase by day 15 [26]. At day 15, the proliferation/apoptosis ratio was slightly greater than 
one for all treatment groups. Furthermore, the number of TUNEL
+
 cells and the blood 
vessel area% in untreated wounds were not significantly different from scaffold-treated 
groups at either time point. These data suggest that the PUR scaffolds do not adversely 
affect the wound healing process in porcine excisional wounds.  
There were few significant differences in wound healing among LTI, CMC, and 
Plasma scaffolds. By day 8, all three scaffolds exhibited good tissue infiltration, which 
suggests that the changes in interconnectivity and hydrophilicity of the scaffolds by 
addition of carboxymethylcellulose or plasma treatment did not significantly improve 
scaffold performance.  We have reported that injectable, lysine-derived PUR scaffolds 
reduced wound contraction in rat excisional wounds. However, porcine skin has an 
elastic modulus of 5.9 ± 1.5 MPa [28], which is 15 times greater than that of rat skin 
(0.40 ± 0.15 MPa) [10]. Another study has reported that a biodegradable PUR foam with 
a sealing membrane resulted in less contraction than Integra in a porcine excisional 
wound model while PUR foams without a sealing membrane did not reduce contraction 
[21], but the relative contributions of the foam and the membrane to space maintenance 
are not known. In the present study, single-layer PUR scaffolds prevented contraction 
without the use of protective membranes. In summary, PUR scaffolds implanted in 
porcine excisional wounds were biocompatible and supported tissue infiltration and 
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wound healing. Future work will involve testing injectable PUR scaffolds in porcine 
excisional wounds. 
 
 
Conclusions 
In conclusion, PUR scaffolds were biocompatible, biodegradable, and supported 
tissue infiltration in porcine excisional wounds. PUR scaffolds stented the wounds, 
lessening unwanted contraction at day 15. Consistent with previous studies showing 
macrophage-mediated degradation of PUR scaffolds, higher numbers of macrophages 
were present in scaffold-treated wounds compared to untreated wounds. Analysis of 
proliferating cells, apoptosing cells, and blood vessels suggests that the presence of 
scaffolds did not otherwise interfere with the wound healing process. 
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CHAPTER V 
 
INJECTABLE BIODEGRADABLE POLYURETHANE SCAFFOLDS SUPPORT 
TISSUE INFILTRATION AND DELAY WOUND CONTRACTION IN A PORCINE 
EXCISIONAL MODEL 
 
Introduction 
The number of people affected by chronic wounds is growing rapidly due to the 
aging of the population and a rising incidence of diseases such as diabetes and obesity [1-
4]. Reports estimate that $25 billion is spent annually on treatment for chronic wounds in 
the United States [1-3]. Furthermore, patients with acute wounds or scarring resulting 
from surgical or traumatic injuries require healthcare that costs $12 billion annually [1]. 
The morbidity, incidence, and cost of these cutaneous defects create a need for cost-
effective wound care products that restore tissue function. Injectable biomaterials that can 
conform to fill deep tissue defects, incorporate and deliver biologics at the point of care, 
offer patient-specific customization, and be applied with minimally invasive surgical 
techniques are a promising approach to skin wound healing [5]. However, successful 
injectable scaffolds must meet several requirements. The reactants and intermediates 
must be noncytotoxic, and the reaction exotherm must be minimal [5, 6]. The injectable 
biomaterial must be flowable for a sufficient time (the working time) so that it can be 
applied as a liquid, and it must cure within minutes (the setting time) to avoid long 
surgical procedures. In addition, porous scaffolds must have reproducible porosity, 
permeability, and pore size that are sufficient for cell migration, nutrient exchange, and 
tissue ingrowth [7]. 
Injectable hydrogels and smart biomaterials have been used as drug delivery 
systems in a variety of applications. A fluorocarbon-functionalized poly(ethylene glycol) 
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phase separation system was shown to deliver therapeutic proteins with diffusion-
controlled release kinetics [8], and a copolymer of N-isopropylacrylamide and 
propylacrylic acid has been developed for use as a delivery vehicle for angiogenic factors 
to sites of ischemia [9]. However, these biomaterials are not well-suited for tissue 
engineering applications due to their weak mechanical properties (low modulus and 
strength and high fragility). In contrast, in situ polymerizable scaffolds can achieve robust 
mechanical properties due to polymerization and crosslinking. Our group has used lysine-
derived polyurethane (PUR) scaffolds for skin wound healing and bone regeneration 
applications [10-15]. These scaffolds have been shown to be biocompatible and 
biodegradable, and they have tunable mechanical and degradation properties [16]. 
Moreover, they have potential for injectability and delivery of biologics [10, 11, 17]. In 
one study, injectable allograft bone/PUR composite scaffolds were shown to support 
tissue infiltration and new bone formation in femoral plug defects in rats [12]. In the rat 
excisional wound study described in Chapter III, injectable PUR scaffolds stented 
wounds, delayed wound contraction, and supported cellular infiltration and matrix 
remodeling [13]. 
In the present study, injectable PUR scaffolds were applied in a porcine full-
thickness excisional wound model. Due to the promising results from the small animal 
models, PUR scaffolds were tested in a large animal model with greater clinical 
relevance. The porcine wound model was used because pigs and humans have many 
anatomical and physiological similarities. Pigs and humans have comparable dermal and 
epidermal thickness and similar density and distribution of blood vessels, sweat glands, 
and hair follicles [18]. Pigs and humans heal primarily through epithelialization and 
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granulation tissue formation; in contrast, loose-skinned rodents heal mainly through 
wound contraction [18]. Previous studies on the use of scaffolds in porcine full-thickness 
wounds have involved pre-formed implants with multiple layers. A study by Huang et al. 
found that full-thickness porcine wounds treated with a bilayer dressing comprising an 
internal gelatin sponge layer incorporating basic fibroblast growth factor-loaded 
microspheres protected by an elastomeric membrane had smaller area, thicker epidermis, 
and better collagen organization than control wounds treated with Vaseline gauze [19]. 
Furthermore, Greenwood and Dearman showed that wounds treated with biodegradable 
PUR foams sealed with a microporous PUR membrane had no signs of infection and 
delayed contraction compared to wounds treated with Integra after 28 days [20, 21]. In 
Chapter IV, single-layer implantable polyurethane scaffolds were shown to delay 
contraction and facilitate healing in porcine excisional wounds. To our knowledge, 
injectable scaffolds have not been tested previously in a porcine cutaneous wound model. 
In this study, injectable PUR scaffolds were compared to pre-formed PUR implants in 
their ability to support cellular infiltration and facilitate wound healing. The physical, 
mechanical, and rheological properties of the scaffolds were characterized in vitro. In the 
porcine excisional wound study, PUR scaffold impact on wound contraction, 
epithelialization, cell proliferation and apoptosis, macrophage presence, and blood vessel 
formation was analyzed. 
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Methods 
Materials 
Glycolide and D,L-lactide were obtained from Polysciences (Warrington, PA). 
Glycerol was purchased from Acros Organics (Morris Plains, NJ). Lysine triisocyanate-
poly(ethylene glycol) (LTIPEG) prepolymer was obtained from Ricerca (Concord, OH). 
TEGOAMIN33, a tertiary amine catalyst composed of 33 wt % triethylene diamine 
(TEDA) in dipropylene glycol, was received from Goldschmidt (Hopewell, VA). Sucrose 
was obtained from Spectrum® (New Brunswick, NJ), and stannous octoate catalyst was 
purchased from Nusil technology (Overland Park, KS). All other reagents were obtained 
from Sigma–Aldrich (St. Louis, MO). Glycerol was dried at 10 mm Hg for 3 h at 80°C, 
and ɛ-caprolactone was dried over anhydrous magnesium sulfate prior to use. All other 
materials were used as received. 
 
PUR Scaffold Synthesis  
A polyester triol (900 Da) with a backbone comprising 60% caprolactone, 30% 
glycolide, and 10% lactide was synthesized by reacting a glycerol starter with the cyclic 
ester monomers (ɛ-caprolactone, glycolide, and D,L-lactide) in the presence of stannous 
octoate catalyst. After carrying out the reaction under dry argon for 48 h at 140°C, the 
resulting polyester triol was vacuum-dried at 80°C for 24 h. 
40% sucrose implants were synthesized by reactive liquid molding of the LTIPEG 
prepolymer with a hardener component and sucrose (300 – 500 m). The hardener 
comprised 100 parts polyester triol, 5 parts per hundred parts polyol (pphp) water, and 
5.5 pphp 30% TEGOAMIN catalyst in dipropylene glycol. The hardener was combined 
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with sucrose and mixed with a spatula for 30 sec. The prepolymer was then added and 
mixed with a spatula for 30 sec. The resulting mixture rose freely and cured. The targeted 
index (the ratio of NCO to OH equivalents times 100) was 115. After curing, the scaffold 
was cut into pieces of various sizes for the pig study or in vitro characterization.  
 
Physical and Mechanical Properties 
Scaffold densities and porosities were determined from mass and volume 
measurements of triplicate cylindrical foam cores. To determine physical properties after 
leaching, scaffolds were incubated in DPBS on a shaker for 72 h. Scaffolds were then 
blotted dry and vacuum-dried for 24 – 48 h. The pore size distribution was assessed by 
scanning electron microscopy (Hitachi S-4200 SEM, Finchampstead, UK) after gold 
sputter coating with a Cressington Sputter Coater (Vanderbilt Institute for Nanoscale 
Science and Engineering).  
Mechanical testing was performed using a TA Instruments Q800 Dynamic 
Mechanical Analyzer (DMA) in compression mode (New Castle, DE). Samples were 
leached in DPBS for three days prior to mechanical testing. Stress–strain curves were 
generated by compressing wet cylindrical 12 × 8 mm samples at 37°C at a rate of 10% 
strain per min until they reached 50% strain. The Young's modulus was determined from 
the slope of the initial linear region of each stress–strain curve. 
 
Permeability 
The permeability of PUR scaffolds foamed in different environments was 
investigated. The PUR reaction mixture was injected into empty Teflon containers (dry 
environment) or Teflon containers filled with water (wet environment to mimic surgery 
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conditions) and allowed to cure. Scaffolds were cut into 2 x 2 x 0.5 cm pieces. During 
scaffold formation, a film with lower porosity than the bulk material formed on the 
surface. Permeability was measured before and after removal of the surface film. To 
determine permeability after leaching, scaffolds were incubated in DPBS on a shaker for 
72 h. Scaffolds were then dried under vacuum for 24 – 48 h. Air permeability of PUR 
scaffolds was determined using the constant pressure gradient method. The air flow rate 
(Q) necessary to maintain a pressure gradient (P) of 0.12 kPa was measured, and the 
permeability (k) was calculated by applying Darcy’s law. 
Q =
kA
m
DP
L
         (5.1) 
where L is the scaffold thickness, A is the scaffold cross-sectional area, and  is the 
dynamic viscosity of air at room temperature. 
 
Rheological Properties 
The cure profile of 40% sucrose scaffolds was measured using a TA Instruments 
parallel plate AR 2000ex rheometer operating in dynamic mode with 25 mm disposable 
aluminum plates (New Castle, DE). After mixing the LTIPEG with the hardener and 
sucrose for 30 sec, the reaction mixture was loaded onto the bottom plate of the 
rheometer. An oscillation time sweep was run with a controlled strain of 1% and a 
frequency of 6.28 rad/s in order to obtain the cure profile. The storage modulus (G’) and 
loss modulus (G”) were determined as a function of time. The working time was 
determined to be the G-crossover point. To measure the tack-free time, the surface of the 
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foam was contacted with a spatula at regular intervals of one minute. The tack-free time 
was determined to be the time at which the foam did not stick to the spatula. 
 
Pig Study Surgery 
All surgical procedures were reviewed and approved by the local Institutional 
Animal Care and Use Committee. NIH Guide for the Care and Use of Laboratory 
Animals (8
th
 Edition, 2011) were observed. The capacity of the scaffolds to facilitate 
healing in full-thickness cutaneous defects was evaluated in an excisional wound model 
(9 cm
2
 square wounds) in female Yorkshire pigs (50 lbs). Treatment groups included 
untreated wounds (negative control) and 70% sucrose injectable, 40% sucrose injectable, 
and 40% sucrose implant scaffolds. The study design is displayed in Table 5.1. Due to the 
poor performance of 70% injectable scaffolds in the first study with two pigs sacrificed at 
days 9 and 13, this treatment group was removed from the second study with three pigs 
sacrificed at days 9, 13, and 30. Excisional wounds were created 24 h prior to scaffold 
implantation. This delay allowed us to advance beyond the period of hemostasis and 
thereby reduce the exudative characteristics of the wound bed. Buprenex (an analgesic) 
and cefazolin (an antibiotic) were given at the time of surgery. For the remainder of the 
study, the analgesic fentanyl was applied in a 50 mcg/hr transdermal patch that was 
replaced every three days, and 500 mg of the antibiotic cephalexin was given twice daily.  
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Table 5.1. Experimental design for porcine excisional wound study. 
Time 
Point 
Number of 
Pigs 
70% 
Injectable 
40% 
Injectable 
40% 
Implant 
No 
Treatment 
Day 9 2 n = 4 n = 9 n = 9 n = 9 
Day 13 2 n = 4 n = 9 n = 9 n = 9 
Day 30 1 n = 0 n = 5 n = 5 n = 5 
 
40% sucrose implants as well as reactants for 40% and 70% sucrose injectables 
were prepared prior to surgery. 40% sucrose scaffolds were cut into 3.5 x 3.5 x 0.2 cm 
implants, sterilized using ethylene oxide, and then leached in sterile DPBS for 72 h. For 
40% and 70% sucrose injectable scaffolds, reactants were sterilized prior to scaffold 
formation. Polyester triol, LTIPEG prepolymer, and TEGOAMIN catalyst were sterilized 
using gamma irradiation. Sucrose was sterilized with ethylene oxide exposure. Water was 
sterilized by filtration (0.2 m pore size). Immediately prior to surgery, the hardener 
component was added to sucrose and mixed for 30 sec with a spatula. The prepolymer 
was added and mixed for 30 sec. The resulting mixture (1 g) was then spread in a wound 
bed with a spatula and allowed to cure. Scaffolds were loosely held in place by an X-
shaped configuration of spanning sutures that extended from normal skin to normal skin. 
Each wound was dressed with TELFA non-adherent dressing (Medline, Mundelein, IL), 
covered with Opsite adhesive film (Smith & Nephew, St. Petersburg, FL) beneath tube 
gauze, and secured with Vetwrap bandaging tape (3M, St. Paul, MN). Wounds were 
cleaned and dressings were changed every 2-3 days. Pigs were sacrificed and wounds 
were harvested at days 9, 13, and 30 after scaffold implantation.  
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Tissue Analysis 
Wounds were fixed in neutral buffered formalin for 48 h, transferred into 70% 
ethanol for 48 h, embedded in paraffin, and sectioned at 5 μm and stained with Gomori’s 
trichrome.  Reparative responses of tissues were examined and quantified using 
immunohistochemical markers and procedures that we have previously validated [22]. 
Actively proliferating cells were immunostained for Ki-67 antigen. After heat-mediated 
target retrieval in citrate buffer at pH 6.0 (DAKO, Carpenteria, CA), endogenous 
peroxidase activity was neutralized with 3% H2O2 for 40 minutes followed by blocking 
non-specific reactivity with a casein-based protein block (DAKO, Carpintera, CA) for 20 
minutes. Slides were incubated with rabbit anti-human Ki-67 (NovaCastra Laboratories 
Ltd., Newcastle, UK) diluted at 1:2,000 for 60 min. The rabbit Envision HRP System 
(DAKO) was used with DAB as substrate and the slides counterstained with 
hematoxylin. Macrophage infiltration into repairing tissues was assessed using MAC387 
antisera (AbD Serotec, Raleigh, NC). After antigen retrieval in 0.01 M Tris/HCL pH 10, 
quenching for peroxidase activity, and blocking of non-specific immunoreactivity, a 
monoclonal mouse anti-human antibody to a macrophage epitope (MAC387) was used at 
1:10,000 for 60 min. Fragmented DNA of apoptotic cells was visualized with the 
DeadEnd Colorimetric TUNEL System (Promega Corporation, Madison, WI). The tissue 
sections were subjected to a second fixation in 4% paraformaldehyde, rinsed, and 
permeabilized with proteinase K for 5 minutes.  The sections then were treated with 
equilibration buffer (Promega) followed by biotinylated nucleotide incorporation into 
apoptotic cells using Terminal Deoxynucleotidyl Transferase (TdT). Endogenous 
peroxidase was neutralized by applying 0.3% hydrogen peroxide to the sections. 
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Applications of streptavidin/HRP and DAB produced apoptotic-specific visible nuclear 
staining. Quantitative measurements were performed using Image-Pro Plus scientific 
image analysis software (Media Cybernetic, Inc., Silver Spring, MD.). Data are expressed 
as the total number of proliferating cells, immunolabeled macrophages, or apoptotic cells.  
Density of new capillaries in the wound bed was determined by immunostaining 
using antisera for Von Willebrand Factor. Sections underwent antigen retrieval using 5 
min of digestion with Proteinase K (DAKO, Carpinteria, CA). Following rinses and 
endogenous blockade with H2O2, sections were incubated at 25˚C in rabbit polyclonal 
antisera for Factor VIII-related antigen (Von Willebrand Factor; DAKO) for 30 minutes 
with a dilution of antibody at 1:900. Following this incubation in primary antisera, the 
sections were processed through the reagents supplied by rabbit Envision + System, HRP 
kit (DAKO). Data are expressed as area% of endothelial-lined areas within the wound.   
 
Statistical Analysis  
  One way analysis of variance (ANOVA) was used to evaluate the statistical 
significance of results. All p-values less than 0.05 were considered statistically 
significant. Data are expressed as mean ± standard error unless otherwise indicated. 
 
Results 
Physical, Mechanical, and Rheological Properties of PUR Scaffolds 
Scaffold density, porosity, and pore size were measured before and after sucrose 
leaching (Table 5.2). As expected, leaching significantly decreased the density and 
increased the porosity of 40% and 70% sucrose scaffolds. The compressive modulus 
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decreased after leaching, but this difference was only significant for the 70% sucrose 
scaffolds. SEM imaging was performed to analyze pore morphology and sucrose bead 
distribution (Figure 5.1). SEM images show sucrose beads embedded in the walls of 40% 
(Fig. 5.1A) and 70% sucrose scaffolds (Fig. 5.1B). After leaching, sucrose was no longer 
visible (panels C and D). The rheological properties of 40% sucrose scaffolds are shown 
in Figure 5.2. The working time was considered to be the gel point, which was 
determined from the G-crossover point. The working time of the scaffolds was 4.8 ± 1.2 
min, and the tack-free time was 16 ± 3 min. 
 
Table 5.2. Physical and mechanical properties of 40% and 70% scaffolds before and after 
leaching. Data are expressed as mean ± standard deviation. Asterisks indicate significant 
difference before and after leaching (p < 0.01). 
 40% Sucrose 70% Sucrose 
Leaching – + – + 
Density (kg m
-3
) 490 ± 30 280 ± 20 * 660 ± 60 190 ± 10 * 
Porosity (%) 59 ± 3 77 ± 2 * 45 ± 5 84 ± 1 * 
Pore Size (m) 280 ± 80 290 ± 110 300 ± 140 250 ± 80 
Compressive Modulus (kPa) 70 ± 40 50 ± 20 150 ± 30 50 ± 10 * 
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Figure 5.1. SEM images of PUR scaffolds. Panels A and C show 40% sucrose scaffolds 
before (A) and after (C) leaching. Panels B and D show 70% sucrose scaffolds before 
(B) and after (D) leaching. Arrows indicate sucrose beads embedded in pore walls. Scale 
bar = 500 m. 
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Permeability of PUR Scaffolds 
The permeability of PUR scaffolds with a variety of treatments was evaluated 
using the constant pressure gradient method (Table 5.3). Some scaffolds were foamed in 
a wet environment to mimic the conditions of injection in the porcine excisional wound 
study. Since the surface of PUR scaffolds has lower porosity than the bulk material, the 
surface of some scaffolds was removed. Increasing the sucrose from 40% to 70%, 
leaching the scaffolds, foaming the scaffolds in a wet environment, and removing the 
surface film all increased the permeability of the scaffolds. All samples investigated had 
 
 
Figure 5.2. Rheological properties of PUR scaffolds. A) Representative cure profile of 
40% scaffold. Vertical dashed line indicates G-crossover point, which was used to 
determine the working time. B) Average working and tack-free times of 40% scaffolds. 
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permeability > 10
-10
 m
2
, which is comparable to the permeability of rigid open-cell foams 
reported elsewhere [23]. 
 
Table 5.3. Permeability of 40% and 70% sucrose scaffolds foamed in dry or wet 
environments with or without surface film. Leaching the scaffolds significantly increased 
their permeability (p < 0.01). Asterisks indicate significant difference from samples D, K, 
and L (p < 0.05). Daggers indicate significant difference from samples D and L (p < 
0.05). Double dagger indicates significant difference from sample L (p < 0.05).  
Sample Sucrose Leaching Environment Film 
Permeability 
(10
-10
 m
2
) 
Significance 
A 70% – Dry + 4.1 ± 1.8 † 
B 70% + Dry + 7.3 ± 1.6 ‡ 
C 70% – Wet + 9.4 ± 1.9 ‡ 
D 70% + Wet + 19.6 ± 3.2  
E 40% – Dry + 1.5 ± 0.2 * 
F 40% + Dry + 1.7 ± 0.1 * 
G 40% – Wet + 4.4 ± 0.5 † 
H 40% + Wet + 14.2 ± 0.6  
I 40% – Dry – 3.3 ± 1.5 * 
J 40% + Dry – 7.7 ± 2.2 ‡ 
K 40% – Wet – 19.0 ± 6.2  
L 40% + Wet – 28.9 ± 6.1  
 
Wound Dimensions 
Representative trichrome green images of porcine excisional wounds are shown in 
Figure 5.3. Collagen is stained green, cytoplasm is stained pink or red, and PUR scaffolds 
appear white because they do not take up the stain. At day 9, images with low (2x) and 
high (20x) magnification show cellular infiltration into the pores of PUR scaffolds in all 
scaffold treatment groups (Fig. 5.3A). All wounds appeared immature with little collagen 
accumulation. There were larger polyurethane fragments and less polyurethane present in 
  
99 
 
wound treated with 70% injectable scaffolds, indicating that these scaffolds did not 
infiltrate with tissue as well as the 40% scaffolds. At day 13, collagen production 
increased in all treatment groups (Fig. 5.3B). There was less polyurethane visible in 
wounds treated with 70% injectables than in wounds treated with 40% injectables or 
implants, providing further evidence that the 70% scaffolds did not infiltrate as well as 
the 40% scaffolds. All scaffold treatment groups had less PUR remaining at day 13 than 
at day 9. By day 30, only a few fragments of PUR remained in the scaffold treatment 
groups (Fig. 5.3C). Furthermore, collagen production increased and cellularity decreased 
in all treatment groups. 
 
  
100 
 
 
A          B 
       
C 
 
 
Figure 5.3. Representative images of trichrome green staining at days 9 (A), 13 (B), and 
30 (C) at magnifications of 2x (left) and 20x (right). Collagen is green or blue, 
cytoplasm is red or pink, and PUR scaffolds are unstained and appear white. 
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Wound measurements were obtained from images of trichrome staining and gross 
images (Figure 5.4). 40% implant scaffolds had significantly less contraction than 
untreated wounds at days 9, 13, and 30 (Fig. 5.4A). 40% injectable scaffolds had 
significantly less contraction than untreated wounds at day 9. Furthermore, the cross-
sectional area of untreated scaffolds decreased significantly from day 9 to day 13 while 
the cross-sectional area of wounds treated with 40% implant and injectable scaffolds did 
not decrease significantly until day 30 (Fig. 5.4B). These results provide evidence that 
PUR scaffolds prevented unwanted wound contraction at early time points. There were 
no significant differences in wound contraction or cross-sectional area between 40% 
implants and injectables at any of the time points, suggesting that injectable scaffolds are 
able to stent the wounds and delay contraction as well as implants. 
In addition, epithelialization and PUR scaffold degradation were evaluated using 
trichrome images. Wounds treated with scaffolds had slightly lower epithelialization than 
untreated wounds at day 13, but these differences were not significant (Fig. 5.4C). By day 
30, there were no differences in epithelialization among treatment groups. The 
progression of PUR degradation was evaluated by measuring fractional area of PUR 
within the wound (Fig. 5.4D). The fractional area of PUR decreased significantly from 
day 9 to day 13 in 40% injectable groups and from day 13 to day 30 in 40% implant 
groups. There were no significant differences among treatment groups at any of the time 
points, providing evidence that applying PUR scaffolds by injection instead of 
implantation did not adversely affect scaffold biodegradation and persistence. 
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Scaffold Impact on Cell Proliferation and Apoptosis 
The effects of PUR scaffold treatment on cell proliferation and apoptosis was 
investigated (Figure 5.5). Ki67 immunostaining was used to assess the level of cell 
proliferation at days 9 and 13 (Fig. 5.5A). At day 9, wounds treated with 70% and 40% 
 
 
Figure 5.4. Wound measurements from porcine full-thickness excisional wound study. 
(A) Wound opening measured from gross images. Asterisks indicate significant 
difference (p < 0.01). Daggers indicate significant difference from 70% injectable and 
no treatment at days 9 and 13 (p < 0.05). Double dagger indicates significant difference 
from no treatment at day 30 (p < 0.01). (B) Cross-sectional area of wounds measured 
from images of trichrome staining. Asterisks denote significant difference (p < 0.05). 
(C) Fraction reepithelialization. Asterisks indicate significant difference (p < 0.01). (D) 
Area fraction of PUR in the wound measured from images of trichrome staining. 
Asterisks indicate significant difference (p < 0.05). 
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injectable scaffolds had significantly more Ki67
+
 cells than untreated wounds. The 
number of Ki67
+
 cells decreased significantly from day 9 to day 13 in all treatment 
groups, and there were no differences in proliferating cells by day 13. Furthermore, 
apoptosis was evaluated using TUNEL immunostaining (Fig. 5.5B). All scaffold groups 
had slightly higher levels of apoptosis than untreated wounds, but this difference was 
only significant in wounds treated with 40% implants at day 9. There were no significant 
differences among scaffold treatment groups at either time point. In addition, the ratio of 
proliferation to apoptosis was quantified (Fig. 5.5C). The ratio of Ki67
+
 cells to TUNEL
+
 
cells was calculated and adjusted assuming that Ki67 is expressed for ~15 h in 
proliferating cells (the length of a fibroblast cell cycle [24]) and TUNEL is expressed for 
~2 h during apoptosis [25]. The proliferation/apoptosis ratio ranged from 5 – 15 for all 
treatment groups at day 9. By day 13, the ratio decreased to two for all treatment groups. 
These results indicate that the wounds were moving from the proliferating phase to the 
remodeling phase by day 13. There were no significant differences in 
proliferation/apoptosis ratio among treatment groups at either time point. 
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Scaffold Impact on Macrophage Presence 
Macrophage presence was evaluated using MAC387 immunostaining (Figure 
5.6). Wounds treated with 70% injectables or 40% implants had more than thrice as many 
MAC387
+
 macrophages as wounds treated with 40% injectables or untreated wounds, but 
this difference was only significant in wounds treated with 70% injectables. Our group 
 
 
Figure 5.5. Cell proliferation and apoptosis. (A) Quantification of Ki67 immunostaining 
at days 9 and 13. Asterisks denote significant difference (p < 0.0001). Dagger indicates 
significant difference from 70% injectable and 40% injectable at day 9 (p < 0.005). (B) 
Quantification of TUNEL immunostaining at days 9 and 13. Asterisk indicates 
significant difference (p < 0.005). (C) Ratio of proliferation to apoptosis. Dashed line 
represents ratio of one. Asterisks denote significant difference (p < 0.05). 
  
105 
 
has previously shown that PUR scaffolds undergo macrophage-mediated oxidative 
degradation [16], and the elevated macrophage presence in scaffold-treated wounds 
provides evidence that the scaffolds were being degraded by macrophages. Since 
macrophages numbers usually peak 4-5 days after wounding, it was expected that 
macrophage numbers would decrease between day 9 and day 13 [26]. Macrophage 
presence declined from day 9 to day 13 in all treatment groups, and there were no 
significant differences among treatment groups by day 13.  
 
 
 
Figure 5.6. Analysis of macrophage presence at days 9 and 13. Asterisks denote 
significant difference (p < 0.005). Daggers indicate significant difference from 70% 
injectable at day 9 (p < 0.005). 
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Scaffold Impact on Blood Vessel Formation 
Factor VIII immunostaining was used to assess blood vessel abundance at days 9 
and 13 (Figure 5.7). At day 9, all scaffold treatment groups had slightly higher blood 
vessel density (area% occupied by blood vessels) than untreated wounds, but these 
differences were not significant. At day 13, blood vessel density was significantly higher 
in wounds treated with 40% injectables than in wounds treated with 40% implants and 
untreated wounds. Blood vessel density decreased from day 9 to day 13 in all treatment 
groups, but this difference was only significant in wounds treated with 40% implants. 
These results suggest that the wounds were moving into the remodeling phase of healing 
by day 13. 
 
 
 
Figure 5.7. Analysis of blood vessel density at days 9 and 13. Asterisk indicates 
significant difference (p < 0.05). Dagger indicates significant difference from 40% 
implant and no treatment at day 13 (p < 0.05). 
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Discussion 
In this study, the capacity of injectable and implantable PUR scaffolds to facilitate 
wound healing in a porcine excisional model was investigated. The scaffolds were 
characterized in vitro to ensure that they met the requirements for injectable scaffolds. 
PUR scaffolds had working and setting times of 4.8 ± 1.2 min and 16 ± 3 min, 
respectively, which are appropriate for the clinical setting. After leaching sucrose from 
the scaffolds, they had similar density, porosity, and pore size to injectable PUR scaffolds 
used for skin wound healing in a previous study [13]. The permeability of the scaffolds 
was measured before and after leaching, with foaming in dry or wet environments, and 
before and after removal of the surface film. All scaffolds investigated had permeability > 
10
-10
 m
2
, which is greater than the permeability of rigid open-cell foams reported by Zhao 
et al. (10
-12
 – 10-10 m2) [23]. The high permeability and porosity, robust mechanical 
properties, and clinically relevant working and setting times of the scaffolds provided 
evidence that they would support cellular infiltration and stent wounds when injected in a 
porcine excisional model. 
 In the porcine excisional wound study, implantable and injectable 40% sucrose 
scaffolds stented the wounds at early time points, delaying unwanted wound contraction. 
Injectable and implantable scaffolds had significantly less wound contraction than 
untreated wounds at day 9. Furthermore, wounds treated with 40% sucrose implants or 
injectables did not significantly decrease in size until day 30 while untreated wound area 
decreased significantly from day 9 to day 13. Optimization of scaffold mechanical 
properties and degradation rate could further improve the stenting effect of the PUR 
  
108 
 
scaffolds. Although wounds treated with scaffolds were slightly less epithelialized than 
untreated wounds at day 9 and 13, this difference was not significant. 
In all scaffold treatment groups, polyurethane presence decreased over time with 
few fragments remaining by day 30. The number of MAC387
+
 macrophages was 
elevated in scaffold-treated wounds compared to untreated wounds at days 9 and 13, but 
this difference was only significant for 70% sucrose injectables and 40% sucrose 
implants at day 9. These results are consistent with oxidative degradation of PUR 
scaffolds mediated by macrophages [16]. The number of proliferating cells, ratio of 
proliferation to apoptosis, macrophage presence, and blood vessel density decreased from 
day 9 to day 13 in all treatment groups. Moreover, images of trichrome staining provide 
evidence that collagen accumulation increased from day 9 to day 13 in all treatment 
groups. These results suggest that the wounds were moving from the proliferative phase 
of healing to the remodeling phase by day 13. 
 Overall, there were few statistically significant differences between wounds 
treated with 40% implants and 40% injectables. Implants and injectables had similar rates 
of wound contraction, polyurethane biodegradation, and epithelialization. Implants had 
significantly higher macrophage presence at day 9 and lower blood vessel density at day 
13 than injectables. Otherwise, cell proliferation, apoptosis, macrophage presence, and 
blood vessel formation were comparable in the 40% implant and 40% injectable 
treatment groups. The histological analysis indicates that injectable PUR scaffolds do not 
adversely affect the wound healing process or scaffold persistence compared to 
implantable PUR scaffolds.   
  
109 
 
Other research on the use of void-filling scaffolds in porcine excisional wounds 
has involved implants with multiple layers. In one study, a wound dressing comprising an 
outer elastomeric membrane and an inner gelatin sponge layer incorporating basic 
fibroblast growth factor-loaded microspheres resulted in faster wound closure and better 
extracellular matrix organization than Vaseline gauze [19]. An investigation on the use of 
biodegradable PUR foams sealed with a microporous PUR membrane found that these 
bilayer scaffolds had no signs of infection and reduced contraction compared to Integra 
after 28 days [21]. To our knowledge, the use of injectable void-filling scaffolds in 
porcine cutaneous wounds has not been investigated prior to the present study. Previous 
research by our group on the use of injectable PUR scaffolds in rat excisional wounds 
(Chapter III) [13] and implantable PUR scaffolds in porcine excisional wounds (Chapter 
IV) has shown that PUR scaffolds are biocompatible, stent wounds to reduce wound 
contraction, and support cellular infiltration. The present study provides further evidence 
that implantable and injectable PUR scaffolds facilitate wound healing, support tissue 
infiltration and matrix production, and delay wound contraction in a clinically relevant 
animal model.  
 
Conclusions 
In summary, injectable PUR scaffolds with high permeability, robust mechanical 
properties, and working and setting times appropriate for the clinical setting were 
developed. Injectable and implantable PUR scaffolds had a stenting effect in porcine 
excisional wounds, resulting in the favorable outcome of delayed wound contraction. The 
patterns of cell proliferation, macrophage presence, and blood vessel formation from day 
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9 to day 13 were similar in all treatment groups. Macrophage numbers were slightly 
elevated in scaffold-treated wounds since the polyurethane scaffolds are degraded by a 
macrophage-mediated oxidative mechanism. These findings suggest that PUR scaffolds 
support tissue infiltration and wound healing in a porcine excisional wound model, and 
applying PUR scaffolds by injection rather than implantation does not adversely affect 
the wound healing process or scaffold biodegradation. This study focused on testing the 
biocompatibility of injectable PUR scaffolds in a porcine excisional model with high 
clinical relevance to human skin wounds. Injectable PUR scaffolds also have potential to 
incorporate and deliver biologics at the point of care, which is the focus of ongoing work. 
  
  
111 
 
References 
[1] Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin 
wounds: a major and snowballing threat to public health and the economy. Wound repair 
and regeneration : official publication of the Wound Healing Society [and] the European 
Tissue Repair Society 2009;17:763-71. 
[2] Zhao G, Usui ML, Lippman SI, James GA, Stewart PS, Fleckman P, et al. Biofilms 
and Inflammation in Chronic Wounds. Advances in wound care 2013;2:389-99. 
[3] Volk SW, Iqbal SA, Bayat A. Interactions of the Extracellular Matrix and Progenitor 
Cells in Cutaneous Wound Healing. Advances in wound care 2013;2:261-72. 
[4] Clark RAF, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. 
Journal of Investigative Dermatology 2007;127:1018-29. 
[5] Mikos AG, Kretlow JD, Klouda L. Injectable matrices and scaffolds for drug delivery 
in tissue engineering. Advanced drug delivery reviews 2007;59:263-73. 
[6] Belkoff SM, Deramond H, Wright NT. Temperature elevation caused by bone cement 
polymerization during vertebroplasty. Bone 1999;25:17s-21s. 
[7] Laurencin CT, Khan Y, Yaszemski MJ, Mikos AG. Tissue engineering of bone: 
Material and matrix considerations. Journal of Bone and Joint Surgery-American Volume 
2008;90A:36-42. 
[8] Tae G, Kornfield JA, Hubbell JA. Sustained release of human growth hormone from 
in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol). 
Biomaterials 2005;26:5259-66. 
[9] Garbern JC, Hoffman AS, Stayton PS. Injectable pH- and temperature-responsive 
poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for delivery of 
angiogenic growth factors. Biomacromolecules 2010;11:1833-9. 
[10] Guelcher SA, Li B, Davidson JM. The effect of the local delivery of platelet-derived 
growth factor from reactive two-component polyurethane scaffolds on the healing in rat 
skin excisional wounds. Biomaterials 2009;30:3486-94. 
[11] Guelcher SA, Li B, Brown KV, Wenke JC. Sustained release of vancomycin from 
polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental 
defect model. Journal of Controlled Release 2010;145:221-30. 
[12] Guelcher SA, Dumas JE, Zienkiewicz K, Tanner SA, Prieto EM, Bhattacharyya S. 
Synthesis and Characterization of an Injectable Allograft Bone/Polymer Composite Bone 
Void Filler with Tunable Mechanical Properties. Tissue Engineering Part A 
2010;16:2505-18. 
[13] Adolph EJ, Hafeman AE, Davidson JM, Nanney LB, Guelcher SA. Injectable 
Polyurethane Composite Scaffolds Delay Wound Contraction and Support Cellular 
Infiltration and Remodeling in Rat Excisional Wounds. Wound Repair and Regeneration 
2011;19:A9-A. 
[14] Dumas JE, BrownBaer PB, Prieto EM, Guda T, Hale RG, Wenke JC, et al. 
Injectable reactive biocomposites for bone healing in critical-size rabbit calvarial defects. 
Biomedical materials (Bristol, England) 2012;7:024112. 
[15] Guelcher SA, Dumas JE, Davis T, Holt GE, Yoshii T, Perrien DS, et al. Synthesis, 
characterization, and remodeling of weight-bearing allograft bone/polyurethane 
composites in the rabbit. Acta Biomaterialia 2010;6:2394-406. 
  
112 
 
[16] Guelcher SA, Hafeman AE, Zienkiewicz KJ, Zachman AL, Sung HJ, Nanney LB, et 
al. Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester 
urethane) scaffolds. Biomaterials 2011;32:419-29. 
[17] Nelson CE, Kim AJ, Adolph EJ, Gupta MK, Yu F, Hocking KM, et al. Tunable 
delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. 
Advanced materials (Deerfield Beach, Fla) 2014;26:607-14, 506. 
[18] Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human 
wound healing. Wound repair and regeneration : official publication of the Wound 
Healing Society [and] the European Tissue Repair Society 2001;9:66-76. 
[19] Huang S, Deng T, Wu H, Chen F, Jin Y. Wound dressings containing bFGF-
impregnated microspheres. Journal of Microencapsulation 2006;23:277-90. 
[20] Greenwood JE, Dearman BL. Split skin graft application over an integrating, 
biodegradable temporizing polymer matrix: immediate and delayed. Journal of burn care 
& research : official publication of the American Burn Association 2012;33:7-19. 
[21] Greenwood JE, Dearman BL. Comparison of a sealed, polymer foam biodegradable 
temporizing matrix against Integra(R) dermal regeneration template in a porcine wound 
model. Journal of burn care & research : official publication of the American Burn 
Association 2012;33:163-73. 
[22] Nanney LB, Woodrell CD, Greives MR, Cardwell NL, Pollins AC, Bancroft TA, et 
al. Calreticulin enhances porcine wound repair by diverse biological effects. The 
American journal of pathology 2008;173:610-30. 
[23] Zhao W, Pizzi A, Fierro V, Du G, Celzard A. Effect of composition and processing 
parameters on the characteristics of tannin-based rigid foams. Part I: Cell structure. 
Materials Chemistry and Physics 2010;122:175-82. 
[24] Kasinathan P, Knott JG, Moreira PN, Burnside AS, Jerry DJ, Robl JM. Effect of 
fibroblast donor cell age and cell cycle on development of bovine nuclear transfer 
embryos in vitro. Biology of reproduction 2001;64:1487-93. 
[25] Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in 
situ via specific labeling of nuclear DNA fragmentation. The Journal of cell biology 
1992;119:493-501. 
[26] Braiman-Wiksman L, Solomonik I, Spira R, Tennenbaum T. Novel insights into 
wound healing sequence of events. Toxicologic pathology 2007;35:767-79. 
 
  
  
113 
 
CHAPTER VI 
 
ENHANCED PERFORMANCE OF PLASMID DNA POLYPLEXES STABILIZED BY 
A COMBINATION OF CORE HYDROPHOBICITY AND SURFACE PEGYLATION 
 
 
Introduction 
Chapters III – V focused on the development of injectable and implantable 
polyurethane (PUR) scaffolds and their use in skin wound healing applications. The 
scaffolds were shown to be biocompatible and biodegradable in rat and porcine 
excisional wound models. The scaffolds also reduced contraction and supported tissue 
infiltration and matrix production in those wound models. However, PUR scaffolds alone 
are not enough to accelerate wound healing. PUR scaffolds have potential to deliver 
therapeutic proteins, drugs, and nucleic acids to enhance wound healing. This chapter 
discusses the development of a PUR delivery system for plasmid DNA (pDNA). 
Nonviral gene therapy is a promising approach for promoting tissue restoration 
and treating various genetic diseases. Plasmids can be produced efficiently and lacks the 
immunogenic risk associated with viral vectors. The endocytotic entry of pDNA is aided 
by condensation into stable nanoparticles. Ideally, the pDNA nanocarriers should be 
stable in physiological conditions (i.e., presence of proteins and salts) and should protect 
the plasmid cargo from nuclease degradation in the extracellular environment. After 
endocytosis, the vectors must escape the endo-lysosomal pathway into the cytoplasm, and 
the plasmid must be unpackaged and trafficked to the nucleus. A variety of synthetic 
polymer- and lipid-based carriers have been developed, but these transfection reagents 
have been optimized for in vitro use and face several challenges for in vivo transfection. 
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In order to be delivered from PUR scaffolds, pDNA must be stabilized during 
lyophilization and the PUR reaction.  
One strategy for nonviral gene delivery is electrostatic condensation of plasmids 
into nanoparticles using cationic polymers or lipids. Electrostatic interactions between 
positively charged amine groups on polymers such as polyethylenimine (PEI) or poly(2-
(dimethylamino)ethyl methacrylate) (PDMAEMA) and negatively charged phosphates on 
DNA result in the condensation of the pDNA into polyplexes (50 – 200 nm 
nanoparticles) [1, 2]. After entering cells through endocytosis, polyplexes made from 
amine-containing polymers with pKa in the range 5.0 – 7.4 buffer the acidification of 
endosomes. Proton and counterion influx increases, causing osmotic swelling and rupture 
of endosomes. This “proton sponge” effect enables release of pDNA into the cytoplasm 
[3, 4]. Although electrostatic condensation of pDNA has been effective for in vitro 
transfection, delivery of polyplexes from tissue-engineered scaffolds has been 
challenging due to polyplex aggregation [8, 9]. Studies by Segura et al. have shown that 
lyophilization of PEI-pDNA polyplexes with excipients such as sucrose decreased 
polyplex aggregation and improved transfection efficiency [10, 11]. However, 
approaches to improve the inherent stability of polyplexes and studies on the contribution 
of colloidal stability to transfection efficiency have not been extensively investigated. 
Block copolymers have been developed to improve colloidal stability, increase 
transfection efficiency, and decrease cytotoxicity of nonviral carriers. Complexation of 
pDNA with block copolymers comprising polycations and polyethylene glycol (PEG) 
enhanced steric stability of polyplexes by formation of a PEG corona [12-14]. Titration 
of hydrophobic content into the cationic, pDNA-condensing polymer block has also been 
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investigated as a strategy for reducing charge density, increasing stability, decreasing 
toxicity, and enhancing endosomal escape of polycations. For example, delivery of the 
pro-apoptotic TRAIL gene using terpolymers synthesized by enzyme-catalyzed 
copolymerization of lactone with dialkyl diester and amino diol significantly inhibited 
tumor growth in a xenograft model [15]. The high molecular weight and increased 
hydrophobicity were conjectured to compensate for the low charge density of the 
nanoparticles, resulting in low cytotoxicity and high transfection efficiency. Recently, we 
were the first to investigate a PEG-stabilized polyplex system in which siRNA cargo was 
loaded into the particle core, which contained a balance of BMA and DMAEMA, and 
yielded enhanced performance following intravenous injection in vivo [21]. Here, we 
extend this work and apply simple, controlled polymerization methods to synthesize 
polymers in a single step that can be used to form pDNA carriers that provide steric 
stabilization by incorporating a PEG corona as well as an optimal balance of cationic and 
hydrophobic content to allow improved stability, reduced toxicity, and endosomal escape. 
The current study also explores structure-property relationships governing the effects of 
poly(DMAEMA-co-BMA) composition and molecular weight on polyplex stabilization 
and performance.  
In this study, a library of poly(ethylene glycol-b-(dimethylaminoethyl 
methacrylate-co-butyl methacrylate)) [poly(EG-b-(DMAEMA-co-BMA))] polymers was 
synthesized using a one-step reversible-addition fragmentation chain transfer (RAFT) 
polymerization from a PEG-based macro-chain transfer agent (macro-CTA). These 
polymers were designed such that DMAEMA initiates nucleic acid electrostatic 
interactions and triggers formation of polyplexes that are further stabilized by the 
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hydrophobic interactions of the BMA in the polyplex core. The PEG corona was 
designed to shield the polyplex charge in the core and to provide enhanced steric 
stabilization while the poly(DMAEMA-co-BMA) block was designed to enhance 
colloidal stability and to achieve pH-dependent membrane disruption tuned to promote 
endosomal escape. The controlled nature of RAFT [22] was leveraged to synthesize a 
well-defined library of polymers containing a range of compositions with varied mol% 
BMA titrated into the cationic DMAEMA block. We also used controlled synthesis to 
make monodispersed polymers with varied molecular weights to enable study of the 
effect of molecular weight of the cationic block on performance of polymers with optimal 
[DMAEMA]/[BMA] ratios. The block copolymers were characterized for pDNA 
packaging efficiency, physicochemical properties of the polyplexes, colloidal stability, 
and in vitro transfection bioactivity before and after lyophilization.  The lead candidate 
was used to create pDNA polyplexes that were incorporated into PUR scaffolds and 
delivered to cells in vitro. 
 
Methods 
Materials 
Luciferase reporter plasmid (pPK-CMV-R3) and PromoFluor-500 fluorescent 
labeling kit were purchased from Promokine (Heidelberg, Germany). Live/dead 
viability/cytotoxicity kit, Opti-MEM reduced serum media, Dulbecco's phosphate 
buffered saline (DPBS), Dulbecco's Modified Eagle Medium (DMEM), fetal bovine 
serum (FBS), penicillin streptomycin, and 0.4% trypan blue stain were purchased from 
Invitrogen (Grand Island, NY). Pierce™ BCA Protein Assay Kit was obtained from 
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Thermo Fisher Scientific (Waltham, MA). NAP-5 desalting columns were purchased 
from GE. Lysine triisocyanate-poly(ethylene glycol) (LTIPEG) prepolymer was obtained 
from Ricerca (Concord, OH). TEGOAMIN33, a tertiary amine catalyst composed of 33 
wt% triethylene diamine (TEDA) in dipropylene glycol, was received from Goldschmidt 
(Hopewell, VA). MDA-MB-231 breast cancer cell line was obtained from ATCC 
(Manassas, VA). All other reagents were purchased from Sigma Aldrich (St. Louis, MO). 
 
Poly(EG-b-(DMAEMA-co-BMA)) Synthesis and Characterization 
RAFT polymerization was used to synthesize a library of diblock copolymers. 
The chain transfer agent (CTA) 4-Cyano-4-(ethylsulfanylthiocarbonyl) 
sulfanylvpentanoic acid was synthesized following standard procedures and was 
subsequently conjugated to 5 kDa mono-methoxy-PEG using DCC and DMAP, resulting 
in 91% substitution of the PEG [21, 23]. The polymerization reaction was carried out at 
70°C for 24 h using azobisisobutyronitrile as the initiator with a 5:1 [CTA]:[Initiator] 
molar ratio. A series of polymerizations were carried out with monomer feed ratios of 0, 
25, 40, 50, or 60 mol% BMA and 100, 75, 60, 50, or 40 mol% DMAEMA. For polymers 
with short block length, the degree of polymerization was 150, and the polymerization 
time was 6 h. For 0, 25, 40, and 60% BMA with long block length and 50% BMA with 
medium block length, the degree of polymerization was 150, and the polymerization time 
was 24 h. For 50% BMA with long block length, the degree of polymerization was 200, 
and the polymerization time was 24 h. All polymerizations were carried out with 40% 
wt/vol of monomer + CTA in dioxane. The reaction was stopped by exposing the 
polymerization solution to air, and the resulting diblock polymers were precipitated into 
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an excess of pentane. The isolated polymers were vacuum-dried, re-dissolved in water, 
further purified using PD10 columns, and lyophilized. Polymers were characterized for 
composition and molecular weight by 
1
H nuclear magnetic resonance spectroscopy 
(NMR, Bruker 400Mhz Spectrometer equipped with 9.4 Tesla Oxford magnet). Absolute 
molecular weight of the polymers was determined using DMF mobile phase gel 
permeation chromatography (GPC, Agilent Technologies, Santa Clara, CA, USA) with 
inline Agilent refractive index and Wyatt miniDAWN TREOS light scattering detectors 
(Wyatt Technology Corp., Santa Barabara, CA). 
 
Polymer-pDNA Polyplex Formation 
Prior to mixing, both pDNA and poly(EG-b-(DMAEMA-co-BMA)) polymers 
were diluted in 100 mM citric acid/sodium citrate buffer solution (pH 4).  Polyplexes 
were formed by mixing equal volumes of pDNA and polymer solutions by pipetting.  
After incubating the polyplexes 15 min at room temperature, sodium 
carbonate/bicarbonate buffer (pH 10.8) was added to bring the pH to 7.4. The 
concentration of pDNA in the final solution was 25 g/ml, and the concentration of the 
polymer solution was dependent on the desired amine/phosphate (N/P) ratio (1, 2, 5, 10, 
20, or 30). The N/P ratio was defined as the ratio of the total amines in the polymer to the 
total phosphates in pDNA. Some polyplexes were desalted by filtering through a GE 
NAP-5 column according to the manufacturer’s instructions (Fairfield, CT). Polyplexes 
were not desalted unless indicated. 
To make control polyplexes, PEI (25,000 Da, branched) and pDNA were 
separately diluted in equal volumes of phosphate buffer (pH 7.4). Polyplexes were 
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formed by mixing the PEI and pDNA solutions by pipetting. The mixture was incubated 
15 min before adding to cells. The concentration of pDNA in the final solution was 25 
g/ml, and the concentration of the polymer solution was dependent on the desired 
amine/phosphate (N/P) ratio (1, 2, 5, 10, 20, or 30). 
 
Polymer-pDNA Polyplex Lyophilization 
Polymer-pDNA polyplexes were formed as described above. Prior to 
lyophilization, trehalose or hydroxyprolyl -cyclodextrin (HPBCD) was added as a 
cryprotectant and excipient. The mass ratio of trehalose:polymer was 200, and the ratio of 
HPBCD:polymer ranged from 10 – 80.  Polyplexes were frozen at a rate of -1˚C/min until 
the temperature reached -45˚C. Polyplexes were lyophilized overnight with a vacuum of 
0.045 mbar and a collector temperature of -45˚C. For transfection and uptake 
experiments, polyplexes were reconstituted in water and incubated for 15 min before 
adding to cells. 
 
Agarose Gel Electrophoresis 
To determine the ability of the polymers to efficiently package pDNA, agarose 
gel electrophoresis was performed. Polymer-pDNA polyplexes were formed as described 
above. Samples containing 300 ng pDNA were loaded onto a 0.8% agarose gel and 
subjected to electrophoresis at 100 V for 45 min. Ethidium bromide was then added to the 
gel to visualize pDNA. 
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Dynamic Light Scattering (DLS) 
Polyplexes were formed as described above and diluted to a concentration of 1.5 
g/ml pDNA in DPBS or KCl solutions. Polyplex size was measured using a Zetasizer 
Nano ZS (Malvern Instruments, Worchestershire, UK). DLS was performed with a 
wavelength of 633 nm using a 4.0 mW Helium-Neon laser at a backscattering angle of 
173˚. Polyplex size was determined from the average of at least 10 runs of 10 seconds 
each. For the aggregation study, polyplexes were incubated at room temperature, and size 
was measured using DLS at various time points up to 72 h. For ζ-potential measurements, 
polyplexes were diluted in 1 mM KCl at pH 7 and the ζ-potential determined from the 
average of at least 10 runs using a universal dip cell. Data were fitted to diffusion-limited 
or reaction-limited models of colloidal aggregation. 
 
In Vitro Transfection 
MDA-MB-231 human breast cancer cells or immortalized murine dermal 
fibroblasts (IMDF) were plated in complete DMEM (10% FBS, 100 U/ml penicillin, and 
100 g/ml streptomycin) at a density of 20,000 cells/well in 96-well plates 24 hours prior 
to transfection. Immediately before transfection, media were aspirated and replaced with 
100 l Opti-MEM + 2% FBS or Opti-MEM without FBS. Polyplex solution containing 
150 ng pDNA was then added to each well. At 24 h after transfection, transfection media 
were aspirated and replaced with 100 l of 1 mg/ml luciferin in complete DMEM.  
Luminescence was measured using a Xenogen IVIS 200 bioluminescence imaging 
system (Perkin Elmer, Waltham, MA) after luciferin was added.  Relative luminescence 
in each well was quantified using Living Image
TM
 software. Cells were lysed using RIPA 
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buffer and total protein measured using the Pierce™ BCA Protein Assay Kit according to 
the manufacturer’s instructions. 
 
Cell Viability 
The cytotoxicity of polyplexes was determined using calcein AM staining to 
detect live cells. In vitro transfection experiments were carried out as described above. 24 
h after transfection, media were aspirated and replaced with 200 l of a solution of 1 
g/ml calcein AM in DPBS. After incubating 30 min at 37 ˚C, fluorescence intensity was 
measured using an FL600 microplate reader with an excitation wavelength of 485 nm and 
an emission wavelength of 530 nm (Bio-Tek Instruments, Winooski, Vermont).  
 
pH-dependent Red Blood Cell Hemolysis Assay 
To screen for endosomolytic activity, a red blood cell hemolysis assay was used 
to measure the pH-dependent membrane disruptive activity of the polyplexes [24].  
Polyplexes with N/P ratio of 10 were prepared as described above. Human red blood cells 
were incubated with polyplexes for one hour in buffers with pH 7.4, 6.8, 6.2, or 5.6 to 
mimic different stages in the endo-lysosomal pathway. After centrifugation to remove 
intact cells, the absorbance of the supernatant was measured at 405 nm to determine the 
amount of hemoglobin released. The absorbance of supernatant from untreated cells was 
subtracted, and the percent red blood cell disruption was normalized to positive control 
samples lysed with Triton X-100. 
 
 
  
122 
 
Confocal Microscopy 
Colocalization of plasmid and endosomes was analyzed using confocal 
microscopy. Plasmid DNA was fluorescently labeled using a PromoFluor-500 labeling 
kit according to the manufacturer’s instructions (PromoKine). MDA-MB-231 cells were 
plated in complete DMEM at a density of 10,000 cells/well in 8-well chamber slides 24 h 
prior to transfection.  Immediately before transfection, media were aspirated and replaced 
with Opti-MEM + 2% FBS.  Polyplex solution containing 150 ng pDNA was then added 
to each well. At 24 h after transfection, media were aspirated and replaced with complete 
DMEM + 75 nM LysoTracker Red probe + 1 g/ml Hoechst stain. After 30 min 
incubation, cells were imaged with a Zeiss LSM 710 fluorescent confocal microscope 
(Oberkochen, Germany) to determine distribution of plasmid and endosomes within the 
cells. ImageJ software was used to analyze colocalization of plasmid and endosomes. 
 
In Vitro Transfection on PUR Scaffolds 
Desalted 40L polyplexes were prepared as described above and lyophilized with 
HPBCD (10:1 HPBCD:40L). PUR scaffolds were synthesized by reacting a polyester 
triol (900 Da) with a backbone comprising 60% caprolactone, 30% glycolide, and 10% 
lactide, 2.7 parts per hundred parts polyol (pphp) TEGOAMIN33 catalyst, 10 pphp water, 
2 pphp calcium stearate, lyophilized polyplexes (2.5 or 5 wt% relative to scaffold mass), 
and LTIPEG prepolymer (index = 115). All reactants were sterilized prior to scaffold 
formation. After curing, scaffolds were cut into 8x2 mm pieces and placed in untreated 
24-well plates. 200,000 IMDF cells were seeded on each scaffold and incubated in 1 ml 
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Opti-MEM + 2% FBS. Every 24 h, media were replaced with Opti-MEM + 2% FBS + 1 
mg/ml luciferin, and luminescence was read on the IVIS imager as previously described. 
 
Statistical analysis 
One way analysis of variance (ANOVA) was used to evaluate the statistical 
significance of results. All p-values less than 0.05 were considered statistically 
significant. 
 
Results 
Poly(EG-b-(DMAEMA-co-BMA)) Characterization 
 A library of diblock copolymers with varying compositions and molecular 
weights were synthesized. Results of polymer characterization using GPC and 
1
H-NMR 
are shown in Table 6.1. The abbreviated names of the polymers indicate the mol% BMA 
in the DMAEMA-co-BMA block and the relative length of the DMAEMA-co-BMA 
block (short [S], medium [M], or long [L]). PEG block molecular weight was held 
constant at 5000 Da. 
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Table 6.1. Block lengths and composition of poly(EG-b-(DMAEMA-co-BMA)) 
polymers. 
Polymer 
Name 
PEG 
(Da) 
DMAEMA-co-
BMA (Da) 
% BMA in DMAEMA-
co-BMA block 
PDI 
0S 5000 13,743 0.00% 1.045 
0L 5000 17,035 0.00% 1.092 
25S 5000 13,128 24.50% 1.045 
25L 5000 18,747 23.80% 1.075 
40S 5000 12,428 39.3% 1.079 
40L 5000 20,765 39.6% 1.117 
50S 5000 13,683 48.5% 1.045 
50M 5000 18,041 48.3% 1.040 
50L 5000 22,857 49.7% 1.161 
60S 5000 8550 58.6% 1.127 
60L 5000 19,939 58.6% 1.081 
 
Fresh Polyplex Transfection 
The effects of BMA content (0 – 60% BMA) and poly(DMAEMA-co-BMA) 
block length (short or long) on transfection efficiency were assessed by delivering a 
luciferase reporter plasmid to MDA-MB-231 cells. As shown in Figure 6.1, transfection 
efficiency was maximized at 40% BMA, and polymers with 40 or 50 mol% BMA had 
significantly higher transfection than all other diblock copolymers. Furthermore, 
increasing the DMAEMA-co-BMA block length increased the transfection efficiency at 
each mol% BMA. 40L polyplexes had significantly higher transfection than PEI 
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polyplexes. Due to their superior transfection efficiency, polymers with 40 and 50 mol% 
BMA were the focus of subsequent experiments. 
 
 
 
Agarose Gel Electrophoresis 
Agarose gel electrophoresis was performed to assess the ability of the transfection 
reagents to package pDNA, as shown in Figure 6.2. Poly(EG-b-(DMAEMA-co-BMA))-
pDNA polyplexes with N/P ratios of 5, 10, and 20 did not migrate out of the loading 
wells, and no free pDNA was detected at any of the N/P ratios investigated (Figure 6.2A). 
40L polyplex formation was further investigated at lower N/P ratios (Figure 6.2B). Some 
free pDNA was detected at N/P ratios of 1 and 2 for 40L polyplexes and N/P ratio of 1 or 
PEI polyplexes. No free pDNA was visible at N/P ratios of 5 or above for 40L polyplexes 
 
Figure 6.1. Transfection efficiency of polymer-pDNA polyplexes. Luminescence 
produced by MDA-MB-231 cells transfected with fresh polyplexes containing 
luciferase pDNA (normalized to total protein). Asterisk indicates significant difference 
(p < 0.05). Data are plotted as mean ± standard deviation. 
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and 2 or above for PEI polyplexes. These results indicate that poly(EG-b-(DMAEMA-co-
BMA)) polymers efficiently encapsulate pDNA at N/P ratios of 5 or above. 
 
 
 
 
Figure 6.2. Agarose gel electrophoresis of polymer-pDNA polyplexes. Polyplexes 
were loaded onto a 0.8% agarose gel. Free pDNA and a DNA ladder were also 
included on the gel. (A) Poly(EG-b-(DMAEMA-co-BMA)) polyplexes with N/P 
ratios of 5, 10, or 20. pDNA is visible in the loading wells in the lanes containing 
polyplexes, and no free pDNA is visible in these lanes. (B) 40L and PEI polyplexes 
with varying N/P ratios. Free pDNA is visible lanes containing 40L polyplexes with 
N/P ratios of 1 and 2 and PEI polyplexes with N/P ratio of 1.  
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Polyplex Size and ζ-potential 
The size of polyplexes with N/P ratio of 10 was measured in DPBS before and 
after lyophilization (Figure 6.3A).  Before lyophilization, the diameter of poly(EG-b-
(DMAEMA-co-BMA)) polyplexes ranged from 130 – 180 nm.  BMA content and block 
length did not significantly affect initial polyplex size. After lyophilization, the size of 
PEI polyplexes and 50% BMA polyplexes increased significantly (p < 0.05), while the 
size of 40% BMA polyplexes did not significantly increase. In addition, the effect of N/P 
ratio on stability after lyophilization was investigated (data not shown). N/P ratio had no 
effect on polyplex size prior to lyophilization, but increasing the N/P ratio increased the 
stability of lyophilized polyplexes, leading to smaller increases in diameter after 
lyophilization. This trend was only significant for 50M polyplexes. 
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Since 40L was identified as the lead candidate for in vitro transfection and 
showed no significant change in polyplex size pre- versus post-lyophilization, it was the 
focus of subsequent investigations. As shown in Figure 6.4, the ζ-potential of 40L and 
PEI polyplexes measured in 1 mM KCl at pH 7 increased with N/P ratio. At N/P ratios ≥ 
5, the ζ-potential of 40L polyplexes approached 0 mV. Even at higher N/P of 20 and 30, 
the ζ-potential of 40L polyplexes was neutral due to shielding of the excess cationic 
charge in the polyplex core by the PEG corona. In contrast, the ζ-potential of PEI 
polyplexes increased up to an N/P ratio of 20, at which point it asymptotically 
approached +20 mV. 
 
 
Figure 6.3. Effect of lyophilization on the size of polymer-pDNA polyplexes 
measured by DLS. Polyplexes were diluted to a concentration of 1.5 g/ml pDNA in 
DPBS. Hydrodynamic diameter of polyplexes with N/P ratio of 10 before and after 
lyophilization and subsequent reconstitution. Asterisks indicate significant difference 
(p < 0.05). Data are plotted as means ± standard deviation. 
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Aggregation Studies and Modeling Analysis 
Due to the presence of the PEG corona and a combination of electrostatic and 
hydrophobic interactions to stabilize the core, the poly(EG-b-(DMAEMA-co-BMA)) 
polyplexes were expected to show increased colloidal stability compared to PEI 
polyplexes. The interaction potential between PEI polyplexes was calculated using 
DLVO theory by summing the short-range van der Waals attraction and the long-range 
electrostatic repulsion forces. In these calculations, no potential maximum was observed, 
thereby suggesting the absence of an energy barrier and consequent rapid (i.e., diffusion-
controlled) flocculation (stability ratio W ≈ 1). In contrast, poly(EG-b-(DMAEMA-co-
BMA)) polyplexes were stabilized by the terminally attached PEG corona, resulting in an 
 
Figure 6.4. -potential of polymer-pDNA complexes measured by DLS.-potential 
was measured in 1 mM KCl pH 7.0. -potential of 40L and PEI polyplexes increased 
with N/P ratio. -potential of 40L-pDNA polyplexes approached ~0 mV for N/P of 5 
or greater while -potential of PEI-pDNA polyplexes approached ~20 mV for N/P of 
20 or greater. Data are plotted as mean ± standard deviation. 
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interfacial layer ~6 nm thick. Thus, the relatively short-range van der Waals forces are 
screened by the long-range steric repulsion, resulting in a high stability ratio (W >> 1) 
and consequent slow (i.e., reaction-limited) flocculation. 
To quantify poly(EG-b-(DMAEMA-co-BMA)) polyplex stability, the aggregation 
kinetics were assessed in pH 7.4 DPBS at N/P ratios of 5 (Figure 6.5A) and 10 (Figure 
6.5B). The aggregation kinetics of PEI polyplexes are shown in Figure 6.5C. PEI 
polyplexes exhibited faster aggregation than poly(EG-b-(DMAEMA-co-BMA)) 
polyplexes, forming aggregates 1000 nm in diameter in less than 5 hours. For all 
polymers, polyplexes with N/P ratio of 5 were less stable than those with N/P ratio of 10. 
40L polyplexes with N/P ratio of 10 exhibited the greatest stability, remaining <200 nm 
in diameter after more than 60 hours in DPBS. 
Previous studies have shown that for slow flocculation, the floc diameter grows 
exponentially with time. Weitz described a reaction-limited colloidal aggregation model 
for systems with W >> 1 [25]: 
         (6.1) 
where Rh is a scaling parameter approximating the average hydrodynamic radius, ta is 
aggregation time, and t0 is an aggregation time constant that varies with initial particle 
concentration and single particle sticking probability. For systems with W ≈ 1, a power 
law model describing diffusion-limited aggregation can be applied: 
fd
h tR
1
~          (6.2) 
where df is the fractal dimension of the aggregates. As anticipated from the colloidal 
stability predictions, the reaction-limited model fit the data for poly(EG-b-(DMAEMA-
co-BMA)) polyplexes (Figures 6.5A and 6.5B; R
2
 = 0.85 – 0.98), while the diffusion-
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limited model fit the data for PEI polyplexes (Figure 6.5C; R
2
 = 0.95 – 0.98). Increasing 
the N/P ratio from 5 to 10 approximately doubled the aggregation time constants for 40L 
polyplexes.  
Polymer 40L (Figure 6.5D) and PEI (Figure 6.5E) polyplex stability was also 
investigated as a function of ionic strength by varying KCl concentration. As [KCl] 
increased, PEI polyplexes aggregated more rapidly, a behavior that was consistent with 
the notion that PEI polyplexes are stabilized by electrostatic repulsion. In contrast, [KCl] 
had no effect on aggregation rate of 40L polyplexes. 40L polyplexes did not aggregate 
substantially, remaining <200 nm in diameter after 72 h at all KCl concentrations 
investigated.  These observations suggested that 40L polyplexes are stabilized by steric 
interactions and not by electrostatic repulsion; hence, ionic strength does not affect their 
aggregation rate. In contrast, the diffusion-limited aggregation model fit the data for PEI 
polyplexes well (Figure 6.5F; R
2
 = 0.95 – 0.99), and PEI polyplex stability decreased 
with increasing [KCl]. 
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Figure 6.5. Aggregation kinetics of polyplexes in the presence of buffer salts. Panels 
A and B illustrate aggregation of polyplexes with N/P ratio of 5 (A) and 10 (B) in 
DPBS over time. Data for diblock copolymers were fit to the reaction-limited colloidal 
aggregation model. (C) Data for PEI in DPBS were fit to the diffusion-limited 
colloidal aggregation model. Panels D and E show effects of ionic strength of KCl on 
aggregation of 40L (D) and PEI (E) polyplexes. (F) Data for PEI in KCl were fit to the 
diffusion-limited colloidal aggregation model. Data are plotted as mean ± standard 
deviation. 
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In Vitro Transfection and Cytotoxicity of Lyophilized Polyplexes 
The ability of the lyophilized polyplexes to transfect MDA-MB-231 cells in vitro 
was assessed by delivering a luciferase reporter plasmid (Figure 6.6A). At N/P ratio of 5, 
40L polyplexes had significantly higher transfection than PEI. At N/P ratio of 10, all 
poly(EG-b-(DMAEMA-co-BMA)) polyplexes investigated had significantly higher 
transfection efficiency than PEI. At N/P ratio of 20, 40S, 40L, 50S, and 50M polyplexes 
produced significantly higher transfection than PEI. To determine cytotoxicity of fresh 
and lyophilized polyplexes, calcein AM staining was used to quantify number of live 
cells after transfection (Figure 6.6B). All wells treated with poly(EG-b-(DMAEMA-co-
BMA)) polyplexes had >70% viability relative to untreated wells. The viability of cells 
treated with poly(EG-b-(DMAEMA-co-BMA)) polyplexes was comparable to or higher 
than cells treated with PEI polyplexes.  
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pH-dependent Membrane Disruption and Endosomal Escape 
A red blood cell hemolysis assay was performed to determine pH-dependent 
membrane disruption by polyplexes with N/P ratio of 10. As shown in Figure 6.7A, all 
 
 
 
 
Figure 6.6. Transfection efficiency and cytotoxicity of lyophilized polymer-pDNA 
polyplexes. MDA-MB-231 cells were transfected with polymer-pDNA polyplexes 
lyophilized using trehalose as an excipient (200:1 trehalose:polymer). (A) 
Luminescence produced by cells transfected with lyophilized polyplexes normalized 
to total protein. Asterisks indicate significant increase in transfection compared to PEI 
(p < 0.05). (B) Cell viability after transfection with lyophilized polyplexes relative to 
untreated cells was assessed using calcein AM staining. Data are plotted as mean ± 
standard deviation. 
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polyplexes had <5% hemolysis at pH 7.4 (mimicking extracellular and cytosolic pH), 
which is important for minimizing polyplex cytotoxicity. As pH decreased, hemolytic 
behavior of the polyplexes increased significantly. All polyplexes produced 100% 
hemolysis (statistically equivalent to Triton X detergent) at pH 5.6 (mimicking late 
endosomes), suggesting that the polyplexes can achieve efficient endosomal escape.  
The ability of the diblock copolymers to aid in endosomal escape was further 
investigated using confocal microscopy. Images of cells transfected with 40L polyplexes 
(Figure 6.7B) were analyzed to quantify the colocalization of green (plasmid) and red 
(endosomes) fluorescent probes (Figure 6.7C). As the N/P ratio of 40L increased from 5 
to 20, the fraction of green colocalized with red decreased significantly (p < 0.05). These 
results provide evidence that in this setting, the active, pH-dependent membrane 
disruptive mechanism of 40L is concentration dependent and is similar in efficacy to the 
pure proton sponge mechanism of PEI. 
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In Vitro Transfection on PUR Scaffolds 
Although 40L-pDNA polyplexes achieved efficient transfection after 
lyophilization, a large amount of excipient was needed to stabilize the polyplexes (200:1 
trehalose:polymer). The excipient must be decreased in order to incorporate lyophilized 
  
 
 
 
 
Figure 6.7. Endosomal escape and pH-dependent membrane disruption. (A) pH-
dependent red blood cell hemolysis assay. All polyplexes investigated exhibited pH-
dependent membrane disruption, displaying minimal hemolysis at physiologic pH and 
switch-like transition into a membrane disruptive confirmation at endo-lysosomal pHs. 
Data are plotted as mean ± standard error. (B) Confocal microscopy images of MDA-
MB-231 cells transfected with 40L-pDNA polyplexes with N/P ratio of 10 showing 
distribution of plasmid (green), endosomes (red), and nuclei (blue). (C) Percentage of 
plasmid colocalized with Lysotracker dye. Data are plotted as mean ± standard error, 
and asterisk indicates statistically significant difference (p < 0.05). 
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polyplexes into tissue-engineered scaffolds with a high enough dose of pDNA to be 
effective. In this study, two strategies were applied to decrease the amount of excipient. 
First, polyplexes were desalted prior to lyophilization. Second, the excipient was changed 
to HPBCD, a -cyclodextrin derivative that has been shown to be effective in stabilizing 
PEGylated nanoparticles [26]. As shown in Figure 6.8A, desalting the polyplexes resulted 
in higher transfection both before and after lyophilization. Furthermore, efficient 
transfection was achieved with a ratio of HPBCD:40L as low as 10, which is 20-fold 
lower than the amount of trehalose required to stabilize the polyplexes. 
Desalted polyplexes were lyophilized with HPBCD with an excipient to polymer 
ratio of 10 and incorporated into PUR scaffolds with 2.5 or 5 wt% HPBCD relative to 
scaffold mass. As controls, polyplexes were injected into premade scaffolds immediately 
before cell seeding, adsorbed onto the scaffold surface at room temperature, or 
lyophilized onto the scaffold surface. Cells seeded on the scaffolds with 2.5% HPBCD 
had significantly higher transfection than cells seeded on scaffolds containing polyplexes 
that were injected into the scaffold pores or adsorbed or lyophilized on the scaffold 
surface for three days. This result provides evidence that incorporation of 40L-pDNA 
polyplexes in PUR scaffolds is a promising approach for stabilization and delivery of 
genes for therapeutic factors in local gene therapy applications. 
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Figure 6.8. Transfection of polyplexes delivered from PUR scaffolds. (A) IMDF cells 
were transfected with desalted polyplexes that were lyophilized using HPBCD as an 
excipient. Transfection was achieved with a ratio of HPBCD:40L as low as 10. Data 
are plotted as mean ± standard deviation. (B) Transfection of IMDF cells seeded on 
PUR scaffolds containing 5 g pDNA. Data are plotted as mean ± standard error. 
Asterisks indicate significant difference from all other treatments (p < 0.05). Scaffolds 
incorporating polyplexes as a lyophilized powder with 2.5% HPBCD resulted in 
significantly higher transfection than scaffolds containing polyplexes that were 
injected into the scaffold pores (Fresh) or adsorbed (Adsorb) or lyophilized (Lyo) on 
the scaffold surface. 
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Discussion 
Local gene therapy has applications for tissue restoration, wound healing, and 
treatment of disease. Previous research on delivery of naked or nanoparticulate pDNA 
incorporated into hydrogels and biomaterial scaffolds has produced transgene expression 
and tissue responses in vivo. However, these systems often suffer from low transfection 
efficiency, burst release of pDNA, or nanoparticle aggregation in physiologic conditions, 
necessitating delivery of high doses of pDNA. In this study, we designed pDNA 
polyplexes with high colloidal stability and enhanced cellular uptake and transfection 
efficiency compared to conventional PEI-pDNA polyplexes. The new polyplexes were 
composed of diblock polymers containing DMAEMA to electrostatically bind DNA, 
BMA to provide hydrophobic interactions and enhance polyplex core stability, and a 
PEG corona to shield charge and enhance steric stability. These polyplexes exhibited 
significantly less aggregation than PEI polyplexes after lyophilization or in the presence 
of high salt concentrations. In addition to being optimized to overcome extracellular 
barriers to polyplex stability, the poly(EG-b-(DMAEMA-co-BMA)) polyplexes were also 
designed to overcome intracellular endo-lysosomal delivery barriers through finely-tuned 
pH-dependent membrane disruptive activity. Several polyplex formulations had higher 
transfection efficiency than PEI complexes both before and after lyophilization. 
Furthermore, cells seeded on PUR scaffolds incorporating lyophilized polyplexes were 
efficiently transfected. These results point to the potential broad utility of diblock 
copolymer-pDNA polyplexes for tissue, intravenous, or local gene delivery when 
incorporated into tissue engineering scaffolds. 
  
141 
 
Despite being considered a gold standard for nonviral gene delivery, PEI has 
several disadvantageous properties. PEI polyplexes have been shown to have poor 
stability at high concentrations, in the presence of salt and serum, and during 
lyophilization [10, 11, 27]. Excipients can reduce aggregation through increased viscosity 
[10], but sucrose and agarose excipients add to the overall complexity of the formulation 
and may have adverse biological effects or alter the curing or mechanical properties of 
the delivery vehicle. It has been reported that plasma proteins adsorb to PEI-pDNA 
polyplexes, resulting in rapid aggregation that can be reduced by polyplex PEGylation 
[28]. In the present study, DLS measurements revealed that PEI polyplexes aggregated 
rapidly during lyophilization. Consistent with the notion that PEI polyplexes are 
electrostatically stabilized, their aggregation rate increased with increasing salt 
concentration due to screening of the electrostatic repulsion forces. While PEI polyplexes 
aggregated slowly in 0.1 M KCl, PEI polyplexes aggregated rapidly in 0.3 M and 0.5 M 
KCl and also in DPBS, a buffer that mimics physiologic conditions.  
In contrast to PEI, the best performing diblock copolymer-pDNA polyplexes (40L 
with N/P = 10) was stable after lyophilization and at high salt concentrations. Consistent 
with the notion that the polyplexes were sterically stabilized, the electrolyte concentration 
did not affect the polyplex aggregation rate. To more quantitatively assess the kinetics of 
aggregation of nanoparticles in DPBS, the particle size time-course data (Figure 6.4) 
were fit to colloidal aggregation models [25]. Diblock copolymer polyplex aggregation 
was reaction-limited while PEI polyplex aggregation was diffusion-controlled, providing 
evidence that diblock copolymers have greater stability than PEI. The diblock copolymer 
polyplexes are stabilized sterically by the PEG corona as well as by DMAEMA-pDNA 
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electrostatic interactions and BMA hydrophobicity in the core. Thus, they can be readily 
tuned by varying the BMA content to optimize polyplex stability. Due to their high 
colloidal stability, poly(EG-b-(DMAEMA-co-BMA))-pDNA required a small amount of 
excipient during lyophilization. Polyplexes lyophilized with an excipient:polymer ratio of 
10 achieved efficient transfection when delivered from PUR scaffolds in vitro. 
Previous studies suggest that PEGylation increases stability but decreases 
transfection efficiency. In the present study, several poly(EG-b-(DMAEMA-co-BMA)) 
polyplexes had better transfection efficiency in serum than PEI before and after 
lyophilization despite having neutral -potential. The best performing diblock copolymer-
pDNA polyplex, 40L with N/P = 10, had greater luminescence production than PEI both 
before and after lyophilization. This observation is consistent with a previous study 
reporting that dextran-PEI complexes had moderately lower transfection efficiency than 
PEI in serum-free medium at 4 h, but in the presence of serum at longer time points (48 
h), significantly higher transfection efficiencies were observed for dextran-PEI 
complexes compared to PEI [29]. Another study has reported that PEI transfection 
decreases 2-20 fold in the presence of 10% serum compared to serum-free media [30]. 
Taken together with these previous studies, our data suggest that sterically stabilized 
polyplexes (i.e., 40L and dextran-PEI) have a slower initial rate of uptake in vitro due to 
lower ζ-potential, but their increased steric stability in the presence of salts and serum 
provides them with superior long-term performance under physiologically relevant 
conditions. 
Polymer-pDNA nanoparticles used for local gene delivery from tissue 
engineering scaffolds must not only be effectively stabilized against colloidal aggregation 
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but also support efficient endosomal escape in order to achieve high levels of 
transfection. PEGylation and titration of hydrophobic content into polycations are known 
to have several beneficial effects on nonviral gene therapy [17]. Triblock copolymers 
composed of PEG, hydrophobic poly(n-butyl acrylate) (PnBA), and cationic DMAEMA 
have been reported to form polyplexes with DNA that exhibit improved stability against 
aggregation and reduced interactions with negatively charged serum components [31]. 
While NMR spectroscopy measurements revealed that the PEG corona shielded the 
charged DMAEMA-DNA polyplex, incorporation of the hydrophobic PnBA 
homopolymer block decreased transfection efficiency, which was conjectured to occur 
due to decreased intracellular release of pDNA from the polyplexes.  
Poly(EG-b-(DMAEMA-co-BMA)) polymers have been shown to be effective for 
packaging of siRNA for intravenous delivery [21] but had not been tested yet for 
formation and stabilization of pDNA polyplexes that mediate endosomal escape through 
an active, pH-dependent membrane disruption mechanism. Previous studies have 
reported that active membrane disruption mechanisms can be used to enhance endosome 
escape and transfection efficiency relative to relying solely on proton sponge osmotic 
disruption of endosomes (i.e., as achieved using PEI or homopolymers of DMAEMA). 
For example, the membrane-porating peptide melittin has been shown to aid in endosome 
escape and increase transfection efficiency of PEI- and lysine-based polyplexes [32, 33]. 
In the present study, the composition and molecular weight of the DMAEMA-co-BMA 
block were tuned to achieve an optimal balance of pH-responsiveness and hydrophobic 
interactions in order to form colloidally stable nanoparticles that increase endosomal 
escape and transfection efficiency. 
  
144 
 
Conclusions 
Poly(EG-b-(DMAEMA-co-BMA) diblock copolymers were synthesized and 
tested for stability, endosomal escape, and transfection efficiency of pDNA. The 
polymers formed pDNA polyplexes that exhibited increased colloidal stability after 
lyophilization and in the presence of salt relative to PEI-pDNA polyplexes, with polymer 
40L exhibiting optimal performance. Poly(EG-b-(DMAEMA-co-BMA))-pDNA 
polyplexes had greater transfection efficiency than PEI-pDNA polyplexes and achieved 
pH-dependent membrane disruption leading to improved endosomal escape. Polyplexes 
incorporated into and delivered from PUR scaffolds transfected cells in vitro. The 
enhanced colloidal stability and transfection efficiency of the lyophilized diblock 
copolymer-pDNA polyplexes underscores their potential utility for numerous 
applications including local nonviral gene delivery from 3D scaffolds, which is the focus 
of ongoing studies.   
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CHAPTER VII 
 
CONCLUSIONS 
 
In conclusion, research on the development of injectable polyurethane (PUR) 
scaffolds with delivery of biologics was described in this dissertation. The main results of 
this work provide evidence that injectable PUR scaffolds support wound healing in 
animal models and can be used to deliver plasmid DNA encoding genes for regenerative 
factors. Overall, this research suggests that an injectable PUR delivery system for 
plasmid DNA has high potential for use in wound healing applications. 
Previous research on PUR scaffolds has demonstrated that they are biocompatible 
and support healing in skin and bone defects in several small animal models [1-5]. In 
Chapter III, injectable PUR biocomposite scaffolds were developed for use in skin wound 
healing applications [6]. These scaffolds were shown to support cellular infiltration and 
extracellular matrix remodeling in a rat excisional wound model. Injectable scaffolds can 
conform to irregular wounds, are easy to use at the point of care, and offer options for 
patient-specific customization [7]. However, injectable biomaterials must have 
noncytotoxic reactants and intermediates, low reaction exotherms, and working and 
settting times on the order of minutes to be useful in a clinical setting [8]. In this study, 
injectable PUR scaffolds exhibited a minimal reaction exotherm and clinically relevant 
working and setting times. A polysaccharide filler, either carboxymethylcellulose or 
hyaluronic acid, was added to the reactive polyurethane mixture to control excessive 
expansion after injection. Due to their compressive mechanical properties, which 
approach those of native skin, the PUR scaffolds stented the wounds at early time points 
and delayed wound contraction. The stenting effect of the scaffolds resulted in the 
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positive outcomes of enhanced cellular proliferation and reduced collagen alignment and 
the negative outcome of delayed epithelialization. The scaffolds did not have significant 
effects on the level of apoptosis at any time point, suggesting that the polyurethane was 
biocompatible and non-cytotoxic. These results present compelling opportunities for the 
use of injectable polyurethanes as void fillers for healing of cutaneous tissue defects. 
Due to the promising results from the use of injectable scaffolds in a small animal 
model, PUR scaffolds were investigated in a large animal model to more closely 
approximate human wounds. Chapter IV discussed the testing of implantable PUR 
scaffolds in a porcine excisional model. The porcine model was chosen because pig skin 
is anatomically and physiologically similar to human skin [9]. Two modifications were 
applied to implantable lysine-derived PUR scaffolds (LTI) to improve cellular infiltration 
and attachment: carboxymethylcellulose was added as a porogen to increase permeability 
and interconnectivity (CMC), and plasma treatment was applied to decrease the 
hydrophobicity of the scaffold surface (Plasma). Addition of carboxymethylcellulose 
increased the permeability of the scaffolds 2.5-fold, and plasma treatment decreased the 
contact angle by 20°. The permeability of the scaffolds was comparable to that of rigid 
open-cell foams reported elsewhere (10
-12
 – 10-10 m2) [10]. Consistent with the rat 
excisional wound study described in Chapter III, PUR scaffolds stented porcine 
excisional wounds and resulted in significantly less contraction than untreated wounds at 
day 15. All three versions of the scaffolds supported tissue infiltration and showed 
significant biodegradation between day 8 and day 15. In untreated wounds, the number of 
MAC387
+
 macrophages decreased from day 8 to day 15, consistent with wounds moving 
into resolution in the absence of scaffold material that  promotes a typical foreign body 
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response [11]. As the scaffolds underwent degradation between day 8 and day 15, the 
number of macrophages increased in the CMC and Plasma groups, suggesting that 
carboxymethylcellulose treatment influenced the innate immune response. This transient 
increase in macrophages in scaffold treatment groups is consistent with an oxidative 
degradation mechanism mediated by macrophages [12]. All treatment groups had 
significantly fewer Ki67
+
 cells at day 15 than at day 8, an indication that all wounds were 
moving from the proliferative phase of wound healing to the remodeling phase by day 15 
[11]. Furthermore, the number of TUNEL
+
 cells and the blood vessel area density in 
scaffold-treated wounds were not significantly different from untreated wounds at either 
time point. These data suggest that the PUR scaffolds did not adversely affect the wound 
healing process in porcine excisional wounds. To our knowledge, this is the first study 
demonstrating that single-layer void-filling scaffolds support wound healing in a porcine 
excisional model. 
Since implantable PUR scaffolds achieved promising results in a porcine model, 
injectable PUR scaffolds were compared to implants in their ability to support cellular 
infiltration and facilitate wound healing in a porcine excisional model. Sucrose was 
added to the scaffolds as a porogen to prevent excessive foaming by absorbing moisture 
in the wound environment. The physical, mechanical, and rheological properties of the 
scaffolds were characterized in vitro. After leaching sucrose from the scaffolds, porosity 
and permeability increased, and density and compressive modulus decreased. The 
working and setting times of the scaffolds (4.8 ± 1.2 min and 16 ± 3 min, respectively) 
were appropriate for the clinical setting. In the porcine excisional wound study, implants 
had significantly less contraction than untreated wounds at days 9, 13, and 30, and 
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injectable scaffolds had significantly less contraction than untreated wounds at day 9. 
There were no significant differences between implants and injectables in wound 
contraction or cross-sectional area at any of the time points, suggesting that injectable 
scaffolds stented the wounds and delayed contraction as well as implants. Both the 
number of Ki67
+
 cells and the proliferation/apoptosis ratio decreased from day 9 to day 
13 in all treatment groups, and there were no significant differences in apoptosis among 
scaffold treatment groups. Implants had more macrophages than injectables at day 9, but 
macrophage presence declined from day 9 to day 13 in all treatment groups. Blood vessel 
density also decreased from day 9 to day 13 in all treatment groups. The patterns of 
proliferation, apoptosis, macrophage presence, and blood vessel formation provide 
evidence that the wounds were moving into the remodeling phase of healing by day 13. 
This study suggests that applying PUR scaffolds by injection rather than implantation did 
not adversely affect the wound healing process and that both injectable and implantable 
PUR scaffolds were biocompatible and reduced wound contraction in a porcine 
excisional model. Injectable scaffolds have not been tested previously in porcine 
excisional wounds. This research lays the groundwork for the use of injectable PUR 
scaffolds in tissue engineering applications to provide mechanical support and deliver 
biologics at the point of care. 
Chapter VI described the development of a PUR plasmid delivery system for local 
gene therapy applications. This delivery system also has potential for use as a screening 
tool to test the performance of regenerative factors in animal models. Since many 
traditional transfection reagents such as polyethylenimine (PEI) suffer from instability 
[13, 14], a library of novel poly(ethylene glycol-b-(dimethylaminoethyl methacrylate-co-
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butyl methacrylate)) polymers was developed to stabilize plasmid DNA (pDNA) during 
lyophilization and incorporation into PUR scaffolds. These polymers were designed such 
that dimethylaminoethyl methacrylate initiates electrostatic interactions with pDNA to 
trigger formation of polyplexes that are further stabilized by hydrophobic interactions of 
the butyl methacrylate in the core and steric shielding by the PEG corona. The butyl 
methacrylate content was tuned to achieve pH-dependent membrane disruption to 
promote endosomal escape. In this study, several diblock copolymers were shown to have 
higher stability and transfection efficiency than PEI before and after lyophilization. The 
diblock copolymer polyplexes had high stability ratios in physiologic conditions, leading 
to slow reaction-limited aggregation. In contrast, PEI polyplexes had a low stability ratio 
and fast diffusion-limited aggregation. The best performing diblock copolymer, 40L, had 
significantly higher transfection than PEI after lyophilization at N/P ratios of 5, 10, and 
20. 40L polyplexes that were incorporated into PUR scaffolds as a lyophilized powder 
achieved higher transfection than polyplexes injected into the scaffold pores for up to 
three days after cell seeding. These results suggest that PUR scaffolds incorporating 
diblock copolymer-pDNA polyplexes as a lyophilized powder have high potential for use 
in local gene therapy applications. Injectable PUR scaffolds can deliver therapeutic 
pDNA at the point of care. Furthermore, a PUR delivery system for pDNA can be used as 
a screening tool to test the ability of newly discovered regenerative factors to enhance 
wound healing in animal models. In summary, the findings described in this dissertation 
indicate that an injectable PUR delivery system for plasmid DNA is a promising 
approach to healing skin wounds. 
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CHAPTER VIII 
 
SUGGESTIONS FOR FUTURE WORK 
 
  
The results of this dissertation have laid the groundwork for the use of injectable 
polyurethane (PUR) scaffolds with delivery of plasmid DNA (pDNA) for wound healing 
applications. This chapter presents suggestions for future studies on optimizing injectable 
PUR scaffolds and developing a PUR plasmid delivery system. 
 
Improve rate of epithelialization 
 The studies on the use of injectable and implantable PUR scaffolds in rat and pig 
cutaneous wound models described in Chapters III – V provide evidence that wounds 
treated with PUR scaffolds have delayed re-epithelialization compared to untreated 
wounds. Although this delay is transient with no significant differences in 
epithelialization after 30 days, slow wound closure creates problems such as an increased 
probability of infection. To accelerate the rate of epithelialization, natural extracellular 
matrix (ECM) components such as fibrin, collagen, and hyaluronic acid can be applied as 
a gel or film to the top surface of the PUR scaffold. Fibrin is a major component of the 
blood clot that forms on the surface of a wound, collagen is the most common structural 
protein in the ECM, and hyaluronic acid is a glycosaminoglycan found in the ECM. 
Keratinocytes in the epidermis are more likely to attach to these natural biomaterials than 
to the more hydrophobic polyurethane. A rat excisional wound model should be used 
initially to test the effects of a variety of surface treatments on epithelialization in wounds 
treated with implantable or injectable PUR scaffolds. After the most effective treatments 
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have been identified in the small animal model, they should be applied to implantable and 
injectable PUR scaffolds in a porcine excisional wound model.  
 
Use PUR scaffolds in an impaired porcine wound model  
In Chapters IV and V, implantable and injectable PUR scaffolds were shown to be 
biocompatible and support tissue infiltration in porcine excisional wounds. However, 
with the exception of stenting wounds to reduce unwanted contraction, the scaffolds did 
not enhance healing. Untreated wound were fully epithelialized by day 30 after surgery. 
Testing the use of PUR scaffolds in an impaired healing model will better elucidate the 
capacity of the scaffolds to improve wound healing. One option for creating chronic 
wound conditions is using an ischemic flap model to restrict blood supply to the wound 
[1, 2]. Full-thickness excisional wounds developed in the middle of bipedicle flaps results 
in reduced epithelialization, delayed macrophage presence, and lower blood vessel 
density compared to non-ischemic wounds [1]. Another option for creating an impaired 
wound model is inducing diabetes in pigs using streptozotocin injections, but diabetes 
induction requires more time and higher cost than the ischemic flap model [3, 4]. A study 
comparing 40% sucrose implants, 40% sucrose injectables, and untreated wounds at days 
8, 15, and 30 would require three pigs total with 12 wounds per pig (n = 4). Scaffold 
impact on epithelialization, wound contraction, cell proliferation and apoptosis, 
macrophage presence, and blood vessel formation should be assessed. 
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Optimize release kinetics of pDNA from PUR scaffolds in vitro 
 In Chaper VI, diblock copolymer-plasmid DNA polyplexes achieved transfection 
after release from PUR scaffolds in vitro for up to three days. Differences in transfection 
efficiency were observed when the wt% of solids (polyplexes + excipient) within the 
PUR scaffolds was increased from 2.5 to 5 wt%. Since transfection decreased over time 
and was higher for the 2.5 wt% scaffolds, it is likely that most of the polyplexes were 
delivered in a burst release within 1-2 days. In applications involving local delivery of 
therapeutic growth factors, a sustained release for several days after wound healing is 
desired. Decreasing the excipient wt% within PUR scaffolds has been shown to reduce 
the burst release and increase the sustained release of biologics [5, 6]. Therefore, the 
delivery of polyplexes from PUR scaffolds should be tested with lower excipient wt%. A 
range of excipient concentrations should be investigated (0.5 – 5 wt%). The release 
kinetics of polyplexes can be measured in vitro by labeling pDNA with a PromoFluor-
500 fluorescent dye according to the manufacturer’s instructions (Promokine, Heidelberg, 
Germany). PUR scaffolds incorporating polyplexes made with fluorescently labeled 
pDNA can be incubated in phosphate-buffered saline. The fluorescence in the releasate 
can be measured with an FL600 microplate reader (Bio-Tek Instruments, Winooski, 
Vermont), and the fluorescence in the scaffolds can be measured with a Xenogen IVIS 
imaging system (Perkin Elmer, Waltham, MA). The power law model or Weibull model 
can be used to characterize the polyplex release profile [5, 6]. After the release kinetics 
have been optimized, the transfection of cells seeded on PUR scaffolds incorporating 
pDNA polyplexes can be measured as described in Chapter VI. 
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Deliver pDNA from PUR scaffolds in vivo  
Once the release kinetics and transfection efficiency of polyplexes delivered from 
PUR scaffolds have been optimized in vitro, the PUR plasmid delivery system can be 
tested in vivo. Scaffolds can be implanted subcutaneously in mice or rats, and transfection 
can be monitored by measuring luminescence with the IVIS imager. A wide range of 
pDNA doses has been used in previous studies investigating delivery of pDNA in vivo [7-
10], so the dose will likely need to be optimized. A dose response experiment comparing 
PUR scaffolds incorporating 2-3 different doses of pDNA can be performed. Blank PUR 
scaffolds without pDNA should be included as a negative control. Polyplexes injected 
into the muscle of the hind limb can be included as a positive control. 
After transfection of luciferase pDNA delivered from PUR scaffolds is confirmed, 
delivery of pDNA encoding genes for therapeutic proteins can be investigated. One 
regenerative factor that has potential to enhance wound healing is secreted Frizzled-
related protein-2 (sFRP2). Young et al. discovered that sFRP2 is overexpressed in 
mesenchymal stem cells of MRL mice, a strain with remarkable healing capabilities [11, 
12]. They have shown that sFRP2 inhibits the Wnt signaling pathway, leading to 
increased MSC proliferation and engraftment and decreased apoptosis, senescence, and 
differentiation to osteogenic and chondrogenic lineages in a subcutaneous wound model 
in mice [11, 12]. Another study by the Young group showed that daily injections of 
pyrvinium, a small-molecule Wnt inhibitor, in murine subcutaneous wounds resulted in 
enhanced granulation tissue formation, cell proliferation, and vascularization compared to 
wounds without pyrvinium treatment [13].  For delivery of sFRP2 pDNA, a small animal 
model should be used initially to test proof of concept. An excisional wound model in 
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diabetic rats would enable investigation of the effects of sFRP2 delivery in an impaired 
healing model. This model can be used to optimize the sFRP2 pDNA dose and release 
kinetics for future studies. Finally, an injectable PUR delivery system for sFRP2 pDNA 
can be investigated in a porcine excisional wound model. The effects of sFRP2 delivery 
from PUR scaffolds on stem cell recruitment, ECM production and organization, cell 
proliferation and apoptosis, and vascularization can be determined. 
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APPENDIX 
 
EXPERIMENTAL PROTOCOLS 
 
 
General PUR Scaffold Synthesis 
Principle: 
Procedure for making polyurethane scaffolds for skin wound healing projects. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, 
labcoat, goggles, etc.) 
 
Reagents: 
 Polyester triol 
 Isocyanate (LTI, LTIPEG, HDIt, etc) 
 Turkey red oil 
 Calcium stearate 
 TEGOAMIN catalyst 
 
Materials and Equipment: 
 Water 
 Mixing cups 
 Spatulas 
 Mixer 
 Kimwipes 
 Pipettes 
 Pipette tips 
 Balance 
 
Procedure: 
1. If delivering biologic such as protein or nucleic acid, lyophilize in mixing cup 
overnight 
a. Note: if lyophilized solids are clumpy, break up with spatula 
2. Combine polyol, catalyst(s), water, calcium stearate, and turkey red oil in mixing 
cup 
3. Mix in mixer at high speed (3400 rpm) for 30 sec  
a. Note: increase time to 1 min for high molecular weight (>900) polyols 
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4. Add porogen (salt, sugar, CMC) if applicable and mix 30 sec 
5. Add isocyanate and mix 30 sec 
a. Note: start timer when mixing begins 
6. Let scaffold rise freely in open mixing cup 
 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (blue cardboard box) 
2. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
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Developing or Modifying PUR Scaffold Formulation 
Principle: 
Procedure for changing the formulation of polyurethane scaffolds for skin wound healing 
projects if scaffolds are not forming correctly. Typical problems that are encountered are 
listed below followed by suggestions for solving them. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, 
labcoat, goggles, etc.) 
 
Reagents: 
 Polyester triol 
 Isocyanate (LTI, LTIPEG, HDIt, etc) 
 Turkey red oil 
 Calcium stearate 
 TEGOAMIN catalyst 
 
Materials and Equipment: 
 Water 
 Mixing cups 
 Spatulas 
 Mixer 
 Kimwipes 
 Pipettes 
 Pipette tips 
 Balance 
 
Procedure: 
1. High polyol molecular weight 
a. Increase catalyst pphp 
b. Increase water pphp 
2. Low polyol molecular weight 
a. Decrease catalyst pphp 
b. Decrease water pphp 
c. Decrease turkey red oil (these foams have a greater tendency to shrink) 
3. Mechanical properties are too low 
a. Add or increase gelling catalyst (COSCAT or iron catalyst) 
b. Decrease porosity (see below)  
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4. Porosity/pore size is too high 
a. Decrease water 
b. Increase turkey red oil 
c. Decrease blowing catalyst (DMAEE or TEGOAMIN33) 
5. Porosity/pore size is too low 
a. Increase water 
b. Decrease turkey red oil 
c. Increase blowing catalyst (DMAEE or TEGOAMIN33) 
6. Interconnectivity is too low 
a. Increase calcium stearate 
b. Increase water 
c. Decrease turkey red oil 
d. Increase blowing catalyst (DMAEE or TEGOAMIN33) 
e. Add or increase leachable porogen (salt, sugar, CMC) 
7. Results are not reproducible 
a. Check humidity 
b. If possible make scaffolds on same day 
8. Foams shrink/collapse after some time (minutes to days) 
a. Decrease or eliminate turkey red oil 
b. Increase water 
9. Incomplete or slow gelling reaction 
a. Increase catalyst 
b. Add or increase  gelling catalyst (COSCAT or iron catalyst) 
10. When adding filler, scaffold does not solidy or does not form pores 
a. Decrease filler concentration 
b. Use granular form of filler (larger particles: >100 um) rather than fine 
powder 
11. Filler aggregates or is not evenly distributed throughout scaffold 
a. Break up filler into smaller pieces before adding to scaffold 
b. Instead of mixing in mechanical mixer, mix by hand with spatula and put 
in mixer briefly (~15 sec) to concentrate PUR mixture at bottom 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (blue cardboard box) 
2. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
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Pig Study Protocol 
Principle: 
Protocol for preparing implantable and injectable PUR scaffolds for use in pig skin 
wound healing studies. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, 
labcoat, goggles, etc.) 
 
Reagents: 
 Polyester triol (T6C3G1L900) 
 LTIPEG 
 TEGOAMIN catalyst 
 Sucrose (300-500 um) 
 
Materials and Equipment: 
 Water 
 Mixing cups 
 Spatulas 
 Syringes 
 Mixer 
 Kimwipes 
 Pipettes 
 Pipette tips 
 Balance 
 Manilla folder 
 Razor blades 
 Meat slices 
 DPBS 
 
Procedure: 
 
Implants 
1. Make implants at least 5 days before surgery 
2. Make 3.5x3.5x7 cm box out of manila folder 
3. Combine T6C3G1L900 polyol, TEGOAMIN33 catalyst (5.46 pphp), and water (5 
pphp) in mixing cup 
4. Mix in mixer at high speed (3400 rpm) for 30 sec  
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5. Add sugar beads (300-500 um) at desired concentration (40% or 70%) and mix by 
hand with spatula for 30 sec 
6. Add Ricerca LTIPEG (index = 115) to mixing cup and mix by hand with spatula 
for 30 sec 
7. Use spatula to transfer PUR mixture to manila folder box (this must be done 
quickly – working time is ~5 min) 
8. Allow scaffold to cure overnight 
9. Cut scaffold into 2-3 mm thick slices using meat slicer 
10. Cut 3x3 cm squares using razor blade 
a. Note: these can be slightly bigger than wound size to allow for 
adjustments at the surgery 
11. Sterilize implants using ethylene oxide 
12. Soak in DPBS for 3 days prior to surgery (keep in sterile environment) 
13. Immediately before surgery, blot with Kimwipes and place in wounds 
 
Injectables 
 
14. Sterilize liquids with gamma irradiation, sucrose beads with ethylene oxide, and 
syringes and mixing cups in autoclave 
15. Combine T6C3G1L900 polyol and TEGOAMIN33 catalyst (5.46 pphp) in mixing 
cup 
16. Mix in mixer at high speed (3400 rpm) for 30 sec  
17. Aliquot enough polyol+TEDA for 1 g batches (or desired batch size) in sterile 
syringes 
18. Aliquot LTIPEG for 1 g batches (or desired batch size) in sterile syringes 
19. Aliquot sucrose for 1 g batches (or desired batch size) in sterile mixing cups 
20. On day of surgery, add polyol+TEDA to mixing cup with sucrose beads 
21. Pipette in water (5 pphp) and mix for 30 sec with spatula 
22. Add LTIPEG syringe and mix 30 sec 
23. Spread onto wound with spatula 
 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (blue cardboard box) 
2. Collect all sharps (razor blades, needles) and dispose in sharps container (red 
plastic box) 
3. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
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Histological Analysis Procedures 
Principle: 
Protocol for taking images of tissue sections, analyzing immunostaining, and performing 
histomorphometry. 
 
Taking images 
1. Check filter, condenser, shutter, and brightness settings on microscope 
2. Use Infinity Analyze 
3. Use “Area WB” (white balance) under “Capture Control” (select empty area on 
slide) 
4. Adjust exposure, gain, gamma, light source, saturation, hue, brightness, and 
contrast in the “Imaging control” panel 
5. Record these settings for future use to improve image consistency 
6. Capture image (camera icon) 
7. Save as .bmp to use in Metamorph 
 
Metamorph analysis (histology and histomorphometry) 
Applying a threshold 
1. Go to Measure > Threshold image 
2. Draw a region around area with desired color 
3. Click “Add to threshold” in “Threshold Image” window 
4. Save threshold for use in other images with same stain/threshold color 
 
Counting cells/objects 
1. Load or create a threshold 
2. Set threshold state to “Inclusive” 
3. Go to Measure > Integrated Morphometry Analysis 
4. Adjust filter sizes as desired (note: if limits are not automatically adjusted in 
results, uncheck and check “Filter” box) 
5. Click “Measure” and go to “Summary” tab for results 
 
Measure wound area 
1. Draw a “trace region” around desired area 
2. Measure granulation tissue area (pink and/or  light green) and possibly scaffold 
area – white) 
3. Do not include fibrin clot (dark red) above wound or fat (white) or muscle 
(reddish brown) below wound 
4. Go to Measure > Region Measurements 
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5. Select/enable “Area” in “Configure” tab 
6. Area will be listed in “Measurements” tab 
 
Measure wound length 
1. Use trichrome images 
2. Draw 3-4 “single lines” horizontally across wound 
3. Use mature collagen (dark green) as limits  
4. Go to Measure > Region Measurements 
5. Select/enable “Distance” in “Configure” tab 
6. Distance will be listed in “Measurements” tab 
 
Measure wound thickness 
1. Use trichrome images 
2. Draw 8-10 “single lines” vertically across wound 
3. Measure granulation tissue thickness – do not include fibrin clot (dark red) above 
wound or fat (white) or muscle (reddish brown) below wound 
4. Go to Measure > Region Measurements 
5. Select/enable “Distance” in “Configure” tab 
6. Distance will be listed in “Measurements” tab 
 
Measure reepithelialization 
1. Use trichrome images 
2. Draw “traced lines” horizontally across top surface of wound 
3. Use separate lines for portions of the surface with and without epithelium 
4. Use mature collagen (dark green) as limits  
5. Go to Measure > Region Measurements 
6. Select/enable “Distance” in “Configure” tab 
7. Distance will be listed in “Measurements” tab 
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In vitro Transfection Experiment Protocol 
Principle: 
Steps for performing in vitro transfection experiments. This protocol can be used to optimize 
transfection efficiency or compare transfection reagents. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Disinfect surfaces of Biosafety Cabinet with ethanol 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Biosafety cabinet 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, labcoat, 
goggles, etc.) 
 
Reagents: 
 Poly(ethylene glycol)-b-(dimethylaminoethyl methacrylate-co-butyl 
methacrylate) 
 Polyethylenimine (PEI) 
 Lipofectamine2000 
 Plasmid DNA (ex: pPK-Luc-R3) 
 
Materials and Equipment: 
 PEG-b-(DMAEMA-co-BMA) 
 Polyethylenimine 
 Lipofectamine2000 
 Plasmid DNA (ex: pPK-Luc-R3) 
 Ethanol 
 Citrate buffer (pH 4) 
 Carbonate buffer (pH 10.8) 
 2 ml Eppendorf tubes 
 15 ml centrifuge tubes 
 50 ml centrifuge tubes 
 Costar 96 well plate (black walls, clear bottom) 
 D-luciferin potassium salt 
 OPTIMEM 
 DPBS 
 DMEM 
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Procedure: 
 
Day 1 
 
1. Plate cells in 100 ul complete media in 96-well plate (see Cell Splitting protocols) 
- IMDF:  10,000 cells/well  
- MDA-MB-231: 20,000 cells/well 
 
Day 2 
 
2. Make polymer-DNA complexes in pH 4 citric acid/sodium citrate buffer  
- Calculate concentrations of plasmid and polymer needed in dilutions 
based on desired N/P ratio and amount of DNA added per well     
i. Note: I typically use a final DNA concentration of 25 ng/ml and 
determine the polymer concentration from the N/P ratio 
- Add polymer dilutions to plasmid dilutions in equal volumes and mix 
gently with pipette 
- Incubate complexes at room temperature for 15 min 
- Add pH 10.8 carbonate buffer to raise pH to 7.4 
- Aspirate media in designated wells and add 100 µL transfection media 
(ex: complete DMEM, serum-free DMEM, OPTI-MEM, OPTI-MEM + 
2% FBS)  
i. Note: serum-free media achieves highest transfection, but serum-
containing media is more similar to in vivo environment 
- Add complex solution containing 150-300 ng DNA to cells in 96-well 
plate 
 
3. Make Lipofectamine 2000 positive control 
- Make plasmid dilution in OPTI-MEM 
- Make Lipofectamine 2000 dilution in OPTI-MEM (2.5-5 ul lipo/ug DNA) 
- Add lipo dilution to plasmid dilution and mix well 
- Incubate complexes at room temperature for 20 min 
- Aspirate media in designated wells and add 100 µL OPTI-MEM 
- Add lipo complexes to designated wells 
 
4. Make PEI positive control 
- Calculate concentrations of plasmid and polymer needed in dilutions 
based on desired N/P ratio and amount of DNA added per well     
- Dilute PEI and plasmid in equal volumes of water 
- Add PEI dilution to plasmid dilution drop wise while vortexing 
- Aspirate media and add 100 µL PEI complexes to designated wells 
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Day 3 
 
5. 24 h after transfection, aspirate transfection media and replace with complete 
media 
- Note: this time can be adjusted 
6. Add 20 µL of 5 mg/mL luciferin to each well 
7. Read luminescence signal on IVIS imager in VUIIS (wait 10 min after adding 
luciferin) 
- Read time of 5-30 sec depending on intensity 
- Field of view C 
- Use 8x12 grid to quantify signal 
8. Immediately after reading luminescence, perform BCA assay following 
manufacturer’s instructions (use RIPA buffer to lyse cells) 
Clean-up:  
3. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
4. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
5. Aspirate all liquid waste into the  liquid waste container  
6. Disinfect surfaces of biosafety cabinet with ethanol 
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PUR Scaffold Synthesis for Plasmid Delivery 
Principle: 
Protocol for making PUR scaffolds incorporating plasmid for delivery in vitro or in vivo. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, 
labcoat, goggles, etc.) 
 
Reagents: 
 Polyester triol (T6C3G1L900) 
 LTIPEG 
 TEGOAMIN catalyst 
 Calcium stearate 
 Poly(ethylene glycol)-b-(dimethylaminoethyl methacrylate-co-butyl 
methacrylate) 
 Plasmid DNA 
 
Materials and Equipment: 
 Water 
 Mixing cups 
 Spatulas 
 Mixer 
 Kimwipes 
 Pipettes 
 Pipette tips 
 0.2 um filter 
 Balance 
 
1. Sterilize all materials (autoclave mixing cups and spatulas; sterilize calcium 
stearate with ethylene oxide; filter water with 0.2 um filter; and sterilize polyol, 
LTIPEG, and TEGOAMIN33 by gamma irradiation) 
2. Lyophilize pDNA polyplexes in mixing cup overnight 
3. Break lyophilized solids up with spatula (so they will be well dispersed 
throughout scaffold) 
4. Prepare polyol mix by combining T6C3G1L900 polyol, TEGOAMIN33 catalyst 
(2.73 pphp), water (10 pphp), and calcium stearate (2 pphp) in separate mixing 
cup 
5. Mix in mixer at high speed (3400 rpm) for 30 sec  
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6. Add Ricerca LTIPEG (index = 115) to mixing cup containing polyplexes 
7. Mix in mixer at high speed (3400 rpm) for 30 sec  
a. If solids are not well dispersed, break up with spatula 
8. Add polyol mix to LTIPEG and polyplexes 
9. Mix in mixer at high speed (3400 rpm) for 30 sec  
10. Let scaffold rise freely in open mixing cup in sterile hood 
 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
2. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
3. Aspirate all liquid waste into the  liquid waste container  
4. Disinfect surfaces of biosafety cabinet with ethanol 
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Transfection on PUR Scaffolds In Vitro 
Principle: 
Steps for determining transfection of plasmid DNA incorporated into PUR scaffolds in vitro. 
Cells are seeded on the scaffolds, and luminescence is measured daily. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Disinfect surfaces of Biosafety Cabinet with ethanol 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Biosafety cabinet 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, labcoat, 
goggles, etc.) 
 
Reagents: 
 Poly(ethylene glycol)-b-(dimethylaminoethyl methacrylate-co-butyl 
methacrylate) 
 Plasmid DNA (pDNA) 
 Hydroxyprolyl beta-cyclodextrin (HPBCD) 
 Polyurethane 
 
Materials and Equipment: 
 PEG-b-(DMAEMA-co-BMA) 
 Plasmid DNA (ex: pPK-Luc-R3) 
 Hydroxyprolyl beta-cyclodextrin (HPBCD) 
 PUR scaffolds 
 Ethanol 
 Citrate buffer (pH 4) 
 Carbonate buffer (pH 10.8) 
 2 ml Eppendorf tubes 
 15 ml centrifuge tubes 
 50 ml centrifuge tubes 
 Non-tissue culture treated 24-well plates 
 D-luciferin potassium salt 
 OPTIMEM 
 DPBS 
 DMEM 
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Procedure: 
 
Making polyplexes and incorporating into scaffolds 
 
1. Make a 10 mg/ml solution of 40% long (40L) PEG-b-(DMAEMA-co-BMA) in 
citrate buffer (pH 4) 
- Dissolve polymer in 100% ethanol with a concentration of 100 mg/ml 
- Slowly add citrate buffer until concentration reaches 10 mg/ml 
- Filter polymer solution with a 0.2 m sterile filter 
2. Make a 1 mg/ml solution of pDNA in citrate buffer (pH 4) 
3. Add 40L solution to pDNA solution to achieve N/P = 10 (or desired ratio) and 
mix by pipetting 
4. After incubating 15 min at room temp, add carbonate buffer (pH 10.8) to bring pH 
to 7.4 
5. Desalt by filtering with GE Sephadex G-25 Nap-5 columns 
- Note: Larger columns may be required depending on sample volume. 
NAP-5 columns have maximum sample volume of 0.5 ml. 
6. Transfer desalted polyplexes to 2 mL Eppendorf tubes (9 mm diameter) or 1 mL 
cylindrical Fisher vials (6 mm diameter) 
- If polyplex solution does not fit in vial, use higher polymer and pDNA 
concentration in steps 1 and 2. Precipitate may form in polyplex solution 
at high concentrations. 
7. Add sterile 10 mg/ml HPBCD to achieve desired HPBCD:40L ratio 
8. Freeze at -1 C/min in -80 C freezer (use pink freezing container or Nalgene 
container with isopropyl alcohol) 
9. Lyophilize overnight and incorporate into PUR scaffold as lyophilized powder 
(see protocol for making PUR scaffolds for detailed instructions) 
- Note: make scaffolds in sterile hood with sterile materials. Polyplex 
activity is decreased by ethylene oxide exposure, so all components must 
be sterile prior to scaffold incorporation. 
10. After curing, cut scaffolds into pieces with 1-2 mm thickness using razor blades 
11. Measure total scaffold mass and mass of each piece to estimate amount of 
plasmid in each piece 
12. Place PUR scaffold pieces in untreated 24-well plate (one piece per well) 
13. Store in refrigerator until cell seeding 
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Seeding cells on PUR scaffolds 
 
14. Begin splitting IMDF cells following instructions IMDF Cell Splitting protocol 
15. After aspirating trypsin, disperse cells in 1 mL OPTI-MEM + 2% FBS (instead of 
5 mL complete media) 
16. Make 1:10 dilution of cells to add to hemocytometer and count cells as described 
in cell splitting protocol 
17. Dilute cells to a concentration of 4,000,000 cells/mL 
18. Add cells to PUR scaffolds in untreated 24-well plate 
- For 6 mm diameter scaffolds, add 25 ul (100,000 cells) 
- For 9 mm diameter scaffolds, add 50 ul (200,000 cells) 
19. Place plate in 37 C incubator for 30 min 
20. Add 1 ml OPTI-MEM + 2% FBS to each well 
21. If possible, place plate on shaker in incubator 
 
Measuring luminescence 
 
22. Every 24 h, aspirate transfection media and replace fresh OPTIMEM + 2% FBS + 
1 mg/ml luciferin 
23. Read luminescence signal on IVIS imager in VUIIS (wait 10 min after adding 
luciferin) 
- Read time of 0.5-2 min depending on intensity 
- Field of view C 
- Use 4x6 grid to quantify signal 
 
Clean-up:  
7. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
8. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
9. Aspirate all liquid waste into the  liquid waste container  
10. Disinfect surfaces of biosafety cabinet with ethanol 
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Transfection on PUR Scaffolds In Vivo 
Principle: 
Steps for incorporating plasmid DNA into PUR scaffolds and measuring luminescence produced 
in animals (mice or rats) containing PUR implants. 
 
Before starting:  
 Read and understand the MSDS of the reagents listed below 
 Disinfect surfaces of Biosafety Cabinet with ethanol 
 Personal Protective and Safety Equipment required:  
o Disposable nitrile gloves 
o Biosafety cabinet 
o Appropriate attire according to the Chemical Hygiene Plan (shoes, labcoat, 
goggles, etc.) 
 
Reagents: 
 Poly(ethylene glycol)-b-(dimethylaminoethyl methacrylate-co-butyl 
methacrylate) 
 Plasmid DNA (pDNA) 
 Hydroxyprolyl beta-cyclodextrin (HPBCD) 
 Polyurethane 
 
Materials and Equipment: 
 PEG-b-(DMAEMA-co-BMA) 
 Plasmid DNA (ex: pPK-Luc-R3) 
 Hydroxyprolyl beta-cyclodextrin (HPBCD) 
 PUR scaffolds 
 Ethanol 
 Citrate buffer (pH 4) 
 Carbonate buffer (pH 10.8) 
 2 ml Eppendorf tubes 
 D-luciferin potassium salt 
 DPBS 
 1 ml insulin syringes (sterile) 
 Nalgene tubing and connector 
 60 ml syringe 
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Procedure: 
 
Making polyplexes and incorporating into scaffolds 
1. Make a 10 mg/ml solution of 40% long (40L) PEG-b-(DMAEMA-co-BMA) in 
citrate buffer (pH 4) 
- Dissolve polymer in 100% ethanol with a concentration of 100 mg/ml 
- Slowly add citrate buffer until concentration reaches 10 mg/ml 
- Filter polymer solution with a 0.2 m sterile filter 
2. Make a 1 mg/ml solution of pDNA in citrate buffer (pH 4) 
3. Add 40L solution to pDNA solution to achieve N/P = 10 (or desired ratio) and 
mix by pipetting 
4. After incubating 15 min at room temp, add carbonate buffer (pH 10.8) to bring pH 
to 7.4 
5. Desalt by filtering with GE Sephadex G-25 Nap-5 columns 
- Note: Larger columns may be required depending on sample volume. 
NAP-5 columns have maximum sample volume of 0.5 ml. 
6. Transfer desalted polyplexes to 2 mL Eppendorf tubes (9 mm diameter – for rat 
study) or 1 mL cylindrical Fisher vials (6 mm diameter – for mouse study) 
- If polyplex solution does not fit in vial, use higher polymer and pDNA 
concentration in steps 1 and 2. Precipitate may form in polyplex solution 
at high concentrations. 
7. Add sterile 10 mg/ml HPBCD to achieve desired HPBCD:40L ratio 
8. Freeze at -1 C/min in -80 C freezer (use pink freezing container or Nalgene 
container with isopropyl alcohol) 
9. Lyophilize overnight and incorporate into PUR scaffold as lyophilized powder 
(see protocol for making PUR scaffolds for detailed instructions) 
- Note: make scaffolds in sterile hood with sterile materials. Polyplex 
activity is decreased by ethylene oxide exposure, so all components must 
be sterile prior to scaffold incorporation. 
10. After curing, cut scaffolds into pieces with 1-2 mm thickness using razor blades 
11. Measure total scaffold mass and mass of each piece to estimate amount of 
plasmid in each piece 
12. Store in refrigerator until surgery 
13. Implant in subcutaneous pockets or excisional wounds 
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Measuring luminescence 
 
14. Measure luminescence using IVIS imager in VUIIS at defined time points 
15. Make solution of 15 mg/ml luciferin in DPBS (enough to inject 10 ul/g animal) 
16. Anesthetize animals using isoflurane setting of 1.5-2 and oxygen flow rate of 2 
- Note: image up to 5 mice or 1 rat at a time 
17. Place animal in IVIS with mouth connected to isoflurane 
- Note: make sure both valves from isoflurane dispenser to IVIS are open 
and any unused openings in IVIS are plugged 
- Note: rat mouths are too big for openings available in IVIS. Connect a 
Nalgene connector (one side 7/16”, on side 5/16”) with flexible tubing 
(5/16”). Connect the other end of the tubing to the opening of a 60 ml 
syringe. Cut the syringe at the 20 ml mark, and place the rat’s mouth in the 
syringe. Tubing length and position will need to be adjusted to get rat in 
field of view. 
18. Inject luciferin solution i.p. using 1 mL insulin syringe 
19. If desired, tape animals’ legs down to get better view of scaffolds 
20. Read luminescence signal on IVIS (wait 5 min after adding luciferin) 
- Read time of 1-5 min depending on intensity 
- Adjust field of view so all scaffolds are in view 
- Use individual circles to quantify signal 
 
Clean-up:  
11. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
12. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
13. Aspirate all liquid waste into the  liquid waste container  
14. Disinfect surfaces of biosafety cabinet with ethanol 
15. Disinfect IVIS and anesthesia box 
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Splitting Immortalized Murine Dermal Fibroblasts (IMDF) 
Principle: 
Steps for splitting IMDF cells, plating flasks and well plates, and freezing cells. 
 
Before starting:  
1. Aliquot the required amount of media (MEM or DMEM, 10% FBS, 1% pen-
strep) 
2. Warm up the DPBS, 0.25% trypsin and media to 37C using the water bath 
3. Check cells using the inverted microscope 
o Healthy cells are spindle shaped and branched 
o If cells are rounded, change media or check water in incubator 
o If media is cloudy, cells are contaminated – add bleach and dispose 
4. Get out pipettes (10 and 5 ml) 
5. If you are freezing cells: prepare a 2 ml freezing tube (screw top with O-ring) 
and the freezing media (10% DMSO in FBS) 
 
Materials and Equipment: 
 Complete media 
 DPBS 
 Trypsin 
 5 and 10 ml pipettes 
 Hemocytometer 
 Inverted microscope 
 Centrifuge 
 Incubator 
 
Procedure: 
 
1. Aspirate old media – discard 
2. Add 5-10 mL PBS and rock softly 
3. Aspirate PBS 
4. Add 1-2 mL trypsin and rock to make sure that its covering all the surface 
a. Incubate at room temp for 1-2 min 
b. While waiting- set up centrifuge 
c. Tap flask sideways to promote detachment of cells 
5. Verify that cells are detached  
a. Use the inverted microscope to check morphology – the cells should 
be round and moving when the flask is tilted 
b. Look at the flask from underneath and rock it – the cells should be 
seen moving (cloudy) 
6.  Add 3-4 mL media, mix well 
a. Pipette up the mixture and use it to wash the surface of the flask. This 
will help remove the cells that are still attached. Repeat this several 
times. 
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7. Transfer to a 15 ml centrifuge tube 
8. Centrifuge at 500 rpm for 5 min 
a. While waiting- set up hemocytometer (small coverslip on top- S.G.) 
9. Aspirate all supernatant - discard 
 
TO FREEZE: 
10. Add DMSO media (~2 mL) – [10% DMSO in FBS] 
11. Release cells from tube, suspend 
12. Transfer into 2 mL freezing tube 
13. Freeze at -80C (leave in freezer overnight) 
14. Transfer to vapor phase of nitrogen storage tank (current cells stored in box 4-2) 
 
TO PLATE: 
15. Add 5 mL fresh complete media 
16. Thoroughly resuspend cell pellet by pipetting up/down 
17. Inject 10 uL cell suspension into hemocytometer 
18. Count # of cells in 1 mm squares (top, bottom, left, right) 
a. Cells/mL = (average # of cells per square)*(10^4) 
19. Seed appropriate density into individual flasks and/or well plates (required cell #/(# of 
cells/mL)) 
b. 1:10 split will reach confluency in 3-4 days 
20. Fill flasks to 12 mL complete media (total) 
 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
2. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
3. Aspirate all liquid waste into the  liquid waste container  
4. Disinfect surfaces of biosafety cabinet with ethanol 
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Splitting MDA-MB-231 Cells 
Principle: 
Steps for splitting MDA-MB-231 cells, plating flasks and well plates, and freezing cells. 
 
Before starting:  
1. Aliquot the required amount of media (MEM or DMEM, 10% FBS, 1% pen-
strep) 
2. Warm up the DPBS, 0.25% trypsin and media to 37C using the water bath 
3. Check cells using the inverted microscope 
o Healthy cells are spindle shaped or triangular (smaller than fibroblasts 
and MC3T3) 
o If cells are rounded, change media or check water in incubator 
o If media is cloudy, cells are contaminated – add bleach and dispose 
4. Get out pipettes (10 and 5 ml) 
5. If you are freezing cells: prepare 2 ml freezing tubes (screw top with O-ring) 
and the freezing media (70% DMEM, 20% FBS, 10% DMSO) 
 
Materials and Equipment: 
 Complete media 
 DPBS 
 Trypsin 
 5 and 10 ml pipettes 
 Hemocytometer 
 Inverted microscope 
 Centrifuge 
 Incubator 
 
Procedure: 
 
1. Aspirate old media – discard 
2. Add 5-10 mL PBS and rock softly 
3. Aspirate PBS 
4. Add 2 mL trypsin and rock to make sure that its covering all the surface 
a. Incubate at 37C for 3-5 min 
b. While waiting- set up centrifuge 
c. Tap flask sideways to promote detachment of cells 
5. Verify that cells are detached  
a. Use the inverted microscope to check morphology – the cells should be round 
and moving when the flask is tilted 
b. Look at the flask from underneath and rock it – the cells should be seen 
moving (cloudy) 
6.  Add 3 mL media, mix well 
a. Pipette up the mixture and use it to wash the surface of the flask. This will 
help remove the cells that are still attached. Repeat this a couple of times. 
  
182 
 
7. Transfer to a 15 ml centrifuge tube 
8. Centrifuge at 1000 rpm for 5 min 
a. While waiting- set up hemocytometer (small coverslip on top- S.G.) 
9. Aspirate all supernatant - discard 
 
TO FREEZE: 
10. Add DMSO media (~2 mL) – [70% DMEM, 20% FBS, 10% DMSO] 
11. Transfer into 2 mL freezing tubes 
12. Freeze at -80C (leave in freezer overnight) 
13. Transfer to vapor phase of nitrogen storage tank (current cells stored in box 4-2) 
 
TO PLATE: 
14. Add 5 mL fresh complete media 
15. Thoroughly resuspend cell pellet by pipetting up/down 
16. Inject 10 uL cell suspension into hemocytometer 
17. Count # of cells in 1 mm squares (top, bottom, left, right) 
c. Cells/mL = (average # of cells per square)*(10^4) 
18. Seed appropriate density into individual flasks and/or well plates (required cell #/(# of 
cells/mL)) 
d. 1:10 split will reach confluency in 3-4 days 
19. Fill flasks to 12 mL complete media (total) 
 
Clean-up:  
1. Collect all glass waste (pipettes, vials, or broken glass) and dispose in the broken 
glass container (red box) 
2. Collect all solid waste and dispose in the biohazard waste container (red trash 
can) 
3. Aspirate all liquid waste into the  liquid waste container  
4. Disinfect surfaces of biosafety cabinet with ethanol 
 
